




Investigating the effect of the KSHV vIRF2 and 




LAURA NAMBIKAI HINDLE 
 
A thesis submitted to  
The University of Birmingham  
for the degree of  















The School of Cancer Sciences 
College of Medical and Dental 
Sciences 

















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 









The type I IFN response forms part of the innate immune system, which is the first line 
of defence against invading viruses. Kaposi’s sarcoma-associated herpesvirus, a 
gamma herpesvirus, encodes a number of genes that down regulate the type I IFN 
response. These include four viral interferon regulatory factors (vIRFs). vIRFs 1, 2 
and 3 have been shown to inhibit type I IFN signalling previously, whereas vIRF4 was, 
until now, not thought to inhibit this pathway. The aim of this study was to determine 
the mechanism by which vIRF2 inhibits type I IFN signalling and to characterise the 
effects of the vIRF4 protein on this system. Cell lines were engineered to express 
inducible vIRF2 or vIRF4 proteins that both demonstrated significant inhibition of JAK-
STAT signalling via ISRE-luc reporter assays.  Electrophoretic mobility shift assays 
showed that vIRF2 and vIRF4 could significantly reduce ISGF3:ISRE complex 
formation. Stable isotope labelling of amino acids in cell culture coupled to LC-
MS/MS was employed to facilitate the identification of the vIRF2 and vIRF4 
interactomes. USP7 and CBP were identified as binding partners for both viral 
proteins and their contribution to inhibition of JAK-STAT signalling was explored.  
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1.1. Overview of introduction 
This thesis aims to identify if and how the Kaposi’s sarcoma-associated 
herpesvirus (KSHV) encoded viral interferon regulator factor 2 (vIRF2) and vIRF4 
proteins regulate the immune system. Specifically, the type I interferon (IFN) 
signalling pathways will be examined. This introduction covers the relevant 
background to these studies. Initially, information regarding KSHV will be detailed, 
followed by an overview of the type I IFN signalling system. Finally current 
knowledge of KSHV-encoded vIRFs will be described.  
 
1.2. KSHV 
The first part of this introduction provides an overview of KSHV, its discovery, 
related diseases and its lifecycle. 
 
1.2.1. Classification 
The Herpesviridae family belongs to the order Herpesvirale, of which there are 
three families. The Malacoherpesviridae family contains viruses which infect 
molluscs, the Alloherpesviridae family contains fish and amphibian viruses and the 
Herpesviridae family contains viruses which infect humans and animals. The 
Herpesviridae family is further divided into three subfamilies; Alpha (α), Beta (β) 
and Gamma (γ) herpesvirinae (reviewed in Davidson et al, (2009)). The two 
human γ-herpesviruses are Epstein–Barr virus (EBV or HHV 4) which is a member 
of the Lymphocryptoviridae and KSHV, a member of the Rhadinoviridae. Rhesus 
rhadinovirus (RRV) is closely related to KSHV (Alexander et al., 2000), and the 
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genomic organization between KSHV and RRV is essentially co-linear (Searles et 
al., 1999). As such, RRV has been used as an animal model for KSHV. See 
Figure 1.1 for a diagram of how KSHV fits into the Herpesvirales order.  
 
 
Figure 1.1: A brief overview of where KSHV fits into the Herpesvirale order. 
The human herpesviruses are shown in their respective sub-families (Based on 
Davison et al (2009)). KSHV is a γ-2 herpesvirus. HSV1 = Herpes simplex virus 1. 
HSV-2 = Herpes simplex virus 2. VZV = Varicella zoster virus. CMV = 
Cytomegalovirus. HHV6 = Human herpesvirus. RRV = Rhesus Rhadinovirus (non-
human virus). There are many more herpesviruses which are not shown, as they 
infect other non-human species.  
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1.2.2. Discovery 
A virus was suspected to be the cause of Kaposi’s sarcoma (KS), which led to 
research of KS tissues to identify the putative virus. In 1972, herpesvirus-like 
particles were identified in analyses of KS biopsies by electron microscopy 
(Giraldo et al., 1972). However, these were thought to be that of cytomegalovirus 
(CMV). It was not until 1994, that a new herpesvirus was identified from KS 
tissues. Yuan Chang and Patrick Moore used representational difference analysis 
to identify DNA sequences which were present in KS lesions but absent in control 
samples from the same patient. They identified sequences which were 
homologous, but distinct from γ-herpesvirus genes, and named this new virus 
KSHV (Chang et al., 1994). KSHV was the second human herpesvirus identified 
which showed oncogenic potential, with EBV being the first.  
 
1.2.3. Diseases associated with KSHV 
In 2009, KSHV was formally defined as the causative agent of KS and Primary 
Effusion Lymphoma (PEL), and was said to be associated with Multicentric 
Castleman’s Disease (MCD) (Bouvard et al., 2009). 
 
1.2.3.1. Kaposi’s sarcoma 
KS was originally described by Moriz Kaposi more than a century ago (Kaposi, 
1872). Then, it was a rare pigmented growth most commonly found in elderly men 
in the mediteranian. However, during the AIDS epidemic of the 1980s there was 
an increase of KS in AIDS patients and this malignancy became known as an 
AIDS-defining illness. There are currently four forms of KS, each prevalent in 
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certain areas of the globe, occurring among different demographic groups. All 
forms of KS are associated with KSHV infection.  
 
Classical KS was the form identified by Kaposi. It is typically seen in elderly 
Mediterranean patients, or those of Arabic or Jewish decent. 
 
 AIDS-associated KS, sometimes referred to as epidemic KS, was described 
during the 1980s and is very aggressive. The incidence of AIDS-KS has 
decreased in the western world due to highly active antiretroviral therapy (HAART) 
to treat Human immunodeficiency virus (HIV) infection (Franceschi et al., 2008), 
but in some developing countries, particularly those in sub-Saharan Africa, the 
incidence of KS continues to grow.  
 
Endemic KS occurs in people living in Equatorial Africa. KSHV infection is much 
more common in Africa than in other parts of the world, so the risk of KS is higher. 
Endemic KS used to be the most common type of KS in Africa but as HIV infection 
increased AIDS-KS became more common.  
 
Iatrogenic KS presents following organ transplantation, due to the administration 
of immunosuppressant drugs. However, the reactivation of the immune system 
through removal of immunosuppressant drugs or lowering the dose can cause KS 
to regress spontaneously (reviewed in Szajerka and Jablecki, (2007) and 
Restrepo and Ocaziones, (2011)).  
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1.2.3.2. Primary Effusion Lymphoma 
PEL is an aggressive, non-Hodgkin’s lymphoma that is usually fatal. It arises in 
immunocompromised individuals, and as such is often associated with HIV 
infection. The majority of cases arise in body cavities such as the pleural, 
pericardial, and peritoneal spaces. In most cases, the lymphoma cells are also 
infected with EBV, but EBV negative PELs have been described (reviewed in 
Verma and Robertson (2003)). The role of EBV in PEL remains unclear (Chen et 
al., 2007).  
 
1.2.3.3. Multicentric Castleman’s Disease 
MCD is rare lymphoproliferative disorder characterized by non-cancerous growths 
in a microenvironment of excess interleukin 6 (IL-6). Lesions develop at multiple 
sites and are polyclonal. KSHV is found in almost all HIV positive cases and in 
about 40% of HIV negative cases (Soulier et al., 1995) 
 
1.2.4. Structure of the KSHV virion 
All herpesviruses share a similar structure, comprising four elements; the core, the 
capsid, the tegument and the envelope (Figure 1.2). The capsid, tegument and 
envelop proteins can be visualised by electron microscopy, and in the past this 
was used to define membership of the Herpesviridae family. Nowadays, genomic 
analyses are the means by which such assignments are made (reviewed in 
McGeoch et al, (2006)).  The core contains a single linear double stranded DNA 
(dsDNA) genome which is surrounded, and protected by an icosahedral capsid. 
The KSHV capsid consists of 162 surface capsomeres, made from the major 
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capsid protein. The capsid is held together and stabilised with triplexes made from 
triplex-1 protein (TRI-1/ORF62) and triplex-2 protein (TRI-2/ORF26) (Wu et al., 
2000). Surrounding the capsid is a protein-filled tegument. The tegument was 
previously considered amorphous, but it is now thought to be more organised due 
to interactions between the tegument proteins and also between tegument 
proteins and either envelop proteins or capsid proteins. The KSHV proteins found 
in the tegument are involved in many stages of the viral life cycle, such assembly 
and transportation of viral particles and immune evasion processes (reviewed in 
Sathish et al, (2012)). The outer layer of the virus particle is the envelope, 
comprised of numerous glycoproteins which are thought to mediate KSHV entry 
(see section 1.2.6). 
 
 
Figure 1.2: The structure of KSHV. 
The simplified structure of a KSHV virion is illustrated. The Inner core is 
surrounded by the capsid. Surrounding the capsid are the inner and outer 
teguments and these are enclosed by the envelope.   
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1.2.5. The KSHV genome 
The KSHV genome organisation is similar to that of other gammaherpesviruses, 
especially Herpesvirus saimiri (HVS), retroperitoneal fibromatosis associated 
herpesvirus (RFHV) and EBV, its closest human relative (Chang et al., 1994, 
Russo et al., 1996, Neipel et al., 1998, Rose et al., 2003). KSHV exhibits collinear 
homology between these viruses, and contains a long unique region (LUR) 
flanked by terminal repeat (TR) sequences (Russo et al., 1996). The size of the 
genome is between 165-170kb, and this variation is due to differences in the 
number of TR between KSHV isolates. The LUR is about 138-140.5kb (Wen 
2009). The KSHV genome contains 86 genes of which at least 22 are potentially 
immunomodulatory (Rezaee et al., 2006). When KSHV was first sequenced, its 
closest homologue was HVS, with at least 66 of its open reading frames (ORFs) 
being homologous to HVS. These KSHV genes were named after the HVS genes 
and have the prefix ‘ORF’ (Russo et al., 1996). Genes unique to KSHV were 
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Figure 1.3: The genome arrangement of KSHV.  
The genome consists of a unique region flanked at each end by terminal repeats. 
Coloured regions indicate protein coding regions. Red regions are genes inherited 
from α, β and γ herpesvirinae. Pink regions are genes inherited from β and γ 
herpesvirinae. Blue regions are immunomodulatory genes. Gene names are 
shown below while names of important proteins mentioned in this thesis are 
shown above. This figure is reproduced from (Rezaee et al., 2006)  
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1.2.6. KSHV entry 
An overview of the proposed KSHV entry process is illustrated in Figure 1.4. 
KSHV encodes a number of glycoproteins which are conserved among 
herpesviruses (gB, gH, gL, gM and gN) along with unique glycoproteins (ORF4, 
gpK8.1A, gpK8.1b, K1, K14 and K15) (Russo et al., 1996, Neipel et al., 1998). 
These proteins enable KSHV to interact with a multitude of cellular receptors. 
KSHV entry is incompletely understood, but is likely a very complex process 
involving multiple host cell surface factors which vary in different cell types.  
 
Like many herpesviruses, KSHV binds heparan sulphate (HS). It is thought that 
KSHV binds HS to increase the local concentration of virions on the surface of the 
cells, enhancing opportunities for KSHV to bind to other cellular receptors which 
lead to cell entry. Thus HS is classed as an attachment factor. KSHV binds HS 
predominantly through gB, gH, ORF4 and gpK8.1A. The importance of HS as an 
attachment factor can be see in the removal of this receptor, using heparinases, 
which decrease KSHV infectivity (Birkmann et al., 2001, Wang et al., 2001). 
 
The binding of KSHV to dendritic cell-specific intercellular adhesion molecule 
grabbing non-integrin (DC-SIGN) has been shown in myeloid dendritic cells (DCs) 
and macrophages. Blocking DC-SIGN with anti-DC-SIGN antibodies inhibits 
KSHV binding and infection (Rappocciolo et al., 2006), but it is not known how 
KSHV interacts with this cellular protein.  
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Recently, it has been shown that the gH and gL glycoproteins of KSHV bind to the 
epinephrine-A2 (EpHA2) receptor. Han et al, (2012) showed that EpHA2 co-
precipitated with gH-gL and KSHV virions, and overexpression of EpHA2 led to an 
increase in KSHV infection. Blocking EpHA2 with antibodies or siRNA against 
EpHA2 decreased infection and treatment of KSHV with soluble EpHA2 also 
decreased infection. The authors also found that binding of gH-gL to EpHA2 
caused phosphorylation of this receptor and resulted in endocytosis (Hahn et al., 
2012). Thus, EpHA2 is thought to bind to KSHV and mediate its entry via 
endocytosis.   
 
The 12-transmembrane transporter protein xCT was identified as being important 
in KSHV entry. xCT is a light chain component of the CD98 glycoprotein complex. 
Ectopic expression of xCT rendered non-susceptible adherent target cells to 
become susceptible to KSHV infection (Kaleeba and Berger, 2006). However, the 
role of xCT in KSHV entry is unclear as Veettil et al, (2008) showed that xCT does 
not affect KSHV binding or entry. They used RT-PCR to measure viral DNA levels 
at different time points post KSHV infection. They found that incubation with anti-
xCT antibodies did not decrease viral binding or entry, but rather decreased KSHV 
gene expression following entry. Therefore, binding of KSHV to xCT was proposed 
to activate signalling cascades leading to an increase in viral gene expression 
(Veettil et al., 2008).  
 
KSHV has been found to associate with integrins which have roles in KSHV 
binding and entry. Akula et al, (2002) identified the cellular integrin α3β1 as a 
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potential entry receptor for KSHV. When cellular integrins were blocked with 
antibodies, or KSHV virions were incubated with soluble integrins, a decrease in 
infection of KSHV was observed. The gB glycoprotein was proposed to interact 
with α3β1, as anti-gB antibodies immunoprecipitated virus-α3β1complexes (Akula 
2002). Integrin α5β3 is also proposed to be important for KSHV entry into cells.  
α5β3 was shown to bind to KSHV virions by confocal microscopy, and α5β3 
function-blocking antibodies inhibited KSHV infection by 70 to 80% (Garrigues et 
al., 2008). Veettil et al, (2008) found that α3β1, α5β3 and α5β5 play roles in KSHV 
infection of adherent cells. Pre-incubation of soluble α3β1, α5β3 or α5β5 reduced 
KSHV infection, and incubation of these integrins in combination reduced infection 
further, suggesting that they act together. xCT was also found to associate with 
these integrins and the theory that KSHV causes the formation of a multi 
molecular complex containing α3β1, α5β3 and α5β5 and CD98/xCT was proposed 
(Veettil et al., 2008). 
 
When KSHV binds to host cell receptors, it activates a range of signalling 
pathways, which are thought to mediate its uptake into cells. As mentioned 
previously, EphA2 phosphorylation, induced by KSHV binding can lead to 
endocytosis (Hahn et al., 2012). It has recently been shown that KSHV induces 
the interaction of integrins with EphA2 and the adapter protein c-Cbl. C-Cbl can 
then ubiquitinate EphA2, leading to endocytosis (Dutta et al., 2013). Integrin 
signalling is also thought to be important in KSHV uptake into the host cell. Ligand 
binding to integrins activates focal adhesion kinase (FAK), which is a key activator 
of cell signalling pathways. Using RT-PCR, to measure internalised viral DNA, 
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Krishnan et al, (2006) showed that a cell line lacking FAK resulted in a 70% 
reduction in the internalization of viral DNA compared to a control, indicating that 
FAK is involved in KSHV entry. Activation of FAK leads to induction of 
downstream Src and PI3-Kinases, which are thought to trigger the endocytosis of 
virions (reviewed in Chandran (2010) and Chakraborty et al, (2012).  
 
Using electron microscopy KSHV virions in endocytic vesicles have been 
observed along with the fusion of the virus envelope with the vesicle following 
infection (Akula et al., 2003, Raghu et al., 2009). As mentioned above, KSHV 
binding to integrins and EphA2 activates signalling cascades which results in 
endocytosis. However, the precise mechanism of endocytosis seems to vary 
between cell types. For example, in human foreskin fibroblasts (HFF) cells, 
inhibition of clathrin-coated pits (using chlorpromazine) inhibited KSHV entry, 
whereas inhibition of endocytosis mediated by caveolae or dissociation of lipid 
rafts did not (Akula et al., 2003). This suggests that KSHV enters HFFs via 
clathrin-coated pits. However, chlorpromazine had no effect on KSHV entry in 
human dermal microvascular endothelial (HMVEC-d) cells or human umbilical vein 
endothelial (HUVEC) cells. In these cells, inhibitors of macropinocytosis and actin 
polymerization decreased virus entry instead (Raghu et al., 2009), suggesting 
macropinocytosis is the means by which KSHV enters HMVEC-d and HUVEC 
cells. 
 
It is believed that KSHV reaches the nucleus using the microtubule network. 
Naranatt et al, (2005) found that KSHV capsids colocalised with microtubules and 
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the inactivation of Rho GTPases reduced the delivery of viral DNA to the nucleus. 
Conversely, nuclear delivery of viral DNA increased in cells expressing a 
constitutively active RhoA mutant (Naranatt et al., 2005). It was therefore 
proposed that KSHV induces Rho-GTPases to modulate microtubule stability 
which allows reorganization of microtubules occurs, enabling capsid transport to 
the nucleus (reviewed in Chandran (2010) and Chakraborty et al, (2012)). 
 
Figure 1.4: KSHV entry into host cells.  
KSHV binds to HS, which enables interaction of the virus with other receptors. 
These include integrins α3β1, α5β3 and α5β5 and the EphA2 receptor. Integrins 
activate FAK and this leads to endocytosis. EphA2 can interact with the c-Cbl 
proteins which ubiquitinates EphA2 which also results in endocytosis.  Following 
KSHV entry by endocytosis, the endocytic vesicle then releases the KSHV capsid, 
which moves to the nucleus along the microtubule network. At the nucleus, the 
KSHV DNA is released. Figure based on (Chandran, 2010).  
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1.2.7. KSHV lifecycle overview 
Like other herpesviruses, upon entry into the nucleus, the KSHV genome can 
enter one of two phases, the latent or the lytic life cycles. In the latent state the 
virus genome is maintained as an episome and only a small sub-set of the KSHV 
genes are expressed which are essential to its survival in the host. No new virus 
particles are produced during this phase. The lytic phase involves replication of 
the genome and production of new virus particles.  
 
1.2.8. Maintenance of latency 
During latency, the KSHV genome is maintained in the nucleus of the host as a 
circular episome. Only a very small sub-set of genes are expressed but the 
genome is propagated between daughter cells. In KS, PEL and MCD, the Latency 
associated nuclear antigen (LANA), viral cyclin (v-cyclin), v–Flice-inhibitory protein 
(v-FLIP), Kaposins A, B, and C and microRNAs are expressed (Cai et al., 2005, 
Greene et al., 2007). In PEL and MCD, the vIRF3 and viral Interleukin 6 (vIL6) 
genes are also expressed. Recently ORF-K1 has also been assigned as a latency 
protein (Chandriani and Ganem, 2010). Following primary infection, latency is 
typically established (Bechtel et al., 2003). To maintain this latent state, some of 
the latent genes have functions which promote latency and inhibit transition to the 
lytic cycle. Their products are discusses in this context in the following paragraphs. 
 
1.2.8.1. LANA 
LANA is encoded by ORF73. LANA is highly expressed in KSHV-infected cells 
and its detection is hence used to determine cells which are KSHV positive (Gao 
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et al., 1996). LANA associates with the KSHV TRs and also with the host 
chromosome. These associations tether the KSHV DNA to chromosomes during 
mitosis and enable the episomes to segregate with daughter cells (Cotter and 
Robertson, 1999, Ballestas et al., 1999).  The interaction of LANA with the TR of 
KSHV has also been shown to be sufficient for episomal DNA replication (Fejer et 
al., 2003). Therefore, during latent replication LANA functions to replicate the 
DNA, maintain the viral episomes and then segregate these into daughter cells, 
thus maintaining the infection of cells (reviewed in Ye et al, (2011), Greene et al, 
(2007)). Another important function of LANA is to maintain latency, and it achieves 
this by also downregulating the expression of the lytic switch protein, replication 
transcriptional activator (RTA). RTA regulates the switch to lytic replication (see 
section 1.2.9). LANA can downregulate the promoter activity of RTA, and thus 
inhibit its expression (Lan et al., 2004). LANA can also bind to the recombination 
signal sequence-binding protein Jκ (RBPJκ), which acts either as a repressor or 
activator of transcription, depending on the proteins it is bound to. The LANA-
RBPJκ complex binds to the RBPJκ cognate DNA sequence within the RTA 
promoter and inhibits its transcription (Lan et al., 2005). LANA is therefore a key 




v-FLIP is encoded by ORF71 (K13) and is involved in promoting latency though a 
number of mechanisms. Firstly, it prevents death receptor signalling, by inhibiting 
caspase activation, which therefore inhibits apoptosis and thus promotes cell 
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survival (Djerbi et al., 1999). It also promotes NFkB signalling, which was found to 
be important in decreasing lytic reactivation (Grossmann and Ganem, 2008). 
Finally, it inhibits the expression of RTA, which is a key promoter of lytic 
reactivation (Ye et al., 2008).  
 
1.2.8.3. V-Cyclin  
Viral cyclin, encoded by ORF72 is structurally similar to cellular cyclin D. v-cyclin 
can bind to and activate CDK6 kinase. The v-cyclin-CDK6 complex overcomes cell 
cycle arrest, induced by cdk-inhibitors, and causes cell cycle progression and cell 
transformation that may contribute to KS formation (Swanton et al., 1997). The v-
cyclin-CDK6 kinase complex also phosphorylates nucleophosmin, stabilising the 
LANA-nucleophosmin interaction. Nucleophosmin (NPM) is a nuclear 
phosphoprotein and a histone chaperone which has been implicated in 
transcription control. The interaction between nucleophosmin and LANA enables 
the silencing of KSHV lytic genes (Sarek et al., 2010).  
 
1.2.9. Lytic reactivation 
Lytic cycle results in replication of the viral genome and assembly of new viral 
particles which are released from the cells. RTA, encoded by ORF50, is a lytic 
switch protein for KSHV viral reactivation from latency which is both necessary 
and sufficient to trigger this programme (Lukac et al., 1998, Sun et al., 1998). 
Activation of RTA expression is thought to involve epigenetic changes, as 
methylation of the RTA promoter is responsible for its repression. Additionally, the 
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association of regulators of acetylation, such as HDACs, are thought to have a 
role in RTA activation (reviewed in Greene et al, (2007)). RTA can bind some 
KSHV promoters directly and initiate their transcription, and these are known as 
RBPJκ-independent promoters. RTA can also induce transcription through the 
RBPJκ protein, which recruits additional co-activators of transcription (Guito and 
Lukac, 2012). RTA expression triggers the expression of KSHV genes in a 
temporal manner beginning with the immediate early (IE) genes, followed by early 
(E) genes and finally late (L) genes.  
 
1.3. Viruses and cancer 
In 2008, 16% of all cancers were attributable to infectious agents. In developing 
countries, this frequency rises to almost 23% (de Martel, 2012). The majority of 
these oncogenic agents are viruses. KSHV is one such virus out of a total of 7 
currently known human oncogenic viruses (summarised in Table 1.1).  
 
Table 1.1: The seven human oncogenic viruses and the major malignancies 
with which they are associated. 
Virus Malignant disease 
Epstein–Barr virus 
Burkitt’s lymphoma; Nasopharyngeal 
carcinoma; Hodgkin lymphoma 
Hepatitis B virus Liver cancer 
Human papillomavirus Cervical cancer 
Human T-cell leukaemia virus type 1 Adult T-cell leukaemia 
Hepatitis C virus Liver cancer 
Kaposi’s sarcoma-associated 
herpesvirus 
Kaposi’s sarcoma; Primary effusion 
lymphoma 
Merkel cell polyomavirus* Merkel cell carcinoma 
*A causal association between Merkel cell polyomavirus and Merkel cell 
carcinoma has yet to be formally established.  
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1.4. The innate immune system 
The aims of this thesis are to investigate how the KSHV-encoded vIRF2 and 
vIRF4 proteins regulate the innate immune system. The next part of this 
introduction will therefore outline the innate immune system. It will focus on how 
viral components are detected by cells, and in turn how the cell brings about an 
antiviral response. Examples of how viral proteins downregulate the innate 
immune system will also be provided.   
 
1.4.1. Overview of innate immune signalling 
The innate immune system is the first line of defence against invading organisms. 
The main role of this system is to detect pathogens and to bring about a response 
which removes them from the host cell and the host. The innate immune system 
detects microorganisms through proteins called pattern recognition receptors 
(PRRs). PRRs recognise either common features of pathogens known as 
pathogen-associated molecular patterns (PAMPs) or danger-associated molecular 
patterns (DAMPs) which are endogenous molecules released from dying cells. 
Different PRRs react with speciﬁc PAMPs and in the case of viruses, viral RNA or 
DNA can be detected by a variety of PRRs including toll like receptors (TLRs) and 
cytosolic receptors sensing RNA or DNA. These will be detailed in the following 
sections. After the detection of PAMPs, signalling cascades are evoked, which 
lead to the production of type I IFNs. There are three types of IFN; I, II, and III. In 
humans type I IFNs include IFNα and IFNβ (which are the focus of much of this 
thesis) as well as IFNω, IFNε and IFNκ. Type II IFN consists of IFNγ only (Pestka 
et al., 2004) and it is produced by T-cells and natural killer cells in order to activate 
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cells of the immune system. Type III IFNs consist of IFN-λ1, -λ 2, and -λ 3 (also 
called interleukin-29 [IL-29], IL-28A, and IL-28B, respectively) (Kotenko et al., 
2003). Following production of type I IFNs, a second signalling cascade is 
triggered, which is referred to in this thesis as the JAK-STAT signalling pathway. 
This pathway leads to the production of proteins which have antiviral effects.  
 
1.4.2. The IFN production pathway 
The detection of viral components by a variety of mechanisms leads to the 
activation of signalling pathways. These result in the production of type I IFNs and 
pro-inflammatory cytokines. These pathways will be discussed in the following, 
and throughout this thesis these pathways will be collectively known as the IFN 
production pathway.  
 
1.4.3. TLRs 
TLRs are the best characterised PRRs, and they are evolutionarily conserved.  
TLRs were first identified in Drosophila melanogaster (Lemaitre et al., 1996) and 
there are currently 10 known human TLRs. They are located in different areas of 
the cell, to enable the recognition of different PAMPs (see Table 1.2). TLRs have 
three main domains, the extracellular domain, which is responsible for ligand 
binding, the transmembrane domain, and the cytoplasmic Toll-IL-1 receptor (TIR) 
domain which interacts with adapter proteins to activate signalling cascades. The 
myeloid differentiation factor 88 (MyD88) is a key protein recruited to activated 
TLRs and it is used by all but TLR3 in downstream signalling (reviewed in 
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Takeuchi and Akira, (2010)). Activation of such pathways results in the production 
of pro-inflammatory cytokines. TLRs 3, 7 and 9 are important sensors of viral 
PAMPs and their downstream signalling pathways also result in the production of 
type I IFNs. These TLRs are located in endosomes, and they detect viral nucleic 
acids. The specific signalling pathways are discussed in more detail below.   
 
Table 1.2: PRRs: Location and ligands 
Receptor Location Ligands detected 
TLR1 Plasma membrane Lipoproteins 
TLR2 Plasma membrane Lipoproteins 
TLR3 Endosome dsRNA 
TLR4 Plasma membrane LPS 
TLR5 Plasma membrane Flagellin 
TLR6 Plasma membrane Lipoproteins 
TLR7 Endosome ssRNA 
TLR8 Endosome ssRNA 
TLR9 Endosome Un-methylated CpG 
TLR10 Endosome/Plasma membrane Unknown 
RIG-I Cytosol dsRNA 
mda-5 Cytosol dsRNA 
STING Cytosol Activated by other sensors 
DAI Cytosol dsDNA 
RNA Pol III Cytosol dsDNA 
IFI16 Cytosol/Nucleus DsDNA 
cGAS Cytosol dsDNA 
  
1.4.3.1. TLR3 signalling 
TLR3 senses dsRNA and signals via a MyD88-independent route (Alexopoulou et 
al., 2001).  dsRNA is a key feature of infection by many viruses. Positive stranded 
RNA viruses, dsRNA viruses and DNA viruses have been shown to produce 
dsRNA following infection of cells (Weber et al., 2006) and hence, the immune 
system has evolved to detect these viral signatures. A synthetic form of dsRNA, 
polyinosinic-polycytidylic acid (poly(I:C)) is an efficient inducer of the IFN response 
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and is commonly used to study IFN induction (Fuld et al., 2006, Areste et al., 
2009). 
 
When dsRNA binds to TLR3, it activates a signalling cascade which results in the 
production of pro-inflammatory cytokines and type I IFNs. Activated TLR3 recruits 
the adaptor protein TIR-domain-containing adapter-inducing interferon-β (TRIF) 
via its TIR domain (Yamamoto et al., 2002). TRIF can then recruit both TNF 
receptor associated factor 3 (TRAF3) and TRAF6. These two proteins allow 
signalling to diverge into two pathways, one which activates IRF3, and the other 
which activates NFκB. 
 
Recruitment of TRAF3 causes activation of TANK-binding kinase 1 (TBK-1) and 
IκB kinase. These activated kinases lead to phosphorylation and dimerization of  
Interferon regulatory factor 3 (IRF3) (Matsumoto and Seya, 2008) allowing it to 
translocate to the nucleus and activate the transcription of type I IFNs as part of 
the IFNβ enhanceosome (Honda et al., 2006).  
 
TRIF can also associate with TRAF6 (Sato et al., 2003) and this association leads 
to phosphorylation and activation of the IκB kinase (IKK) complex which enables 
the translocation of NFκB into the nucleus. NFκB is normally found in the 
cytoplasm. It is retained here due to its interaction with the inhibitor molecule IκB. 
IκB is phosphorylated by activated IKK which leads to its ubiquitination and 
degradation, allowing NFκB nuclear translocation. Activated NFκB can induce the 
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production of pro-inflammatory cytokines and type I IFN genes (reviewed in 
Hayden and Ghosh (2004) and Takeuchi and Akira (2010)) (see Figure 1.5).  
 
1.4.3.2. TLR7 signalling 
TLR7 recognizes single stranded RNA (ssRNA) (Diebold et al., 2004) as well as 
small purine compounds (imidazoquinolines) (Hemmi et al., 2002). TLR7 signalling 
involves the MyD88 adapter protein. Activation of TLR7 recruits MyD88, which 
then recruits IL-1R-associated kinase (IRAK4). IRAK4 activates other IRAK family 
members, IRAK1 and IRAK2 which interact with TRAF6 (Takeuchi and Akira, 
2010, Randall and Goodbourn, 2008). As described for TLR3 signalling, TRAF6 
leads to the activation of NFkB and production of pro-inflammatory cytokines. 
 
A complex consisting of MyD88, TRAF6, IRAK-1 and IRAK-4 binds directly to 
IRF7 which leads to the phosphorylation of IRF7 (Kawai et al., 2004). 
Phosphorylated IRF7 can then translocate to the nucleus where it activates the 
transcription of type I IFNs (see Figure 1.5) (Takeuchi and Akira, 2010, Randall 
and Goodbourn, 2008).  
 
1.4.3.3. TLR9 signalling 
TLR9 detects unmethylated DNA. This is in contrast to human DNA, which is 
heavily methylated, and thus the detection of unmethylated DNA by TLR9 enables 
distinction between self and pathogen (Randall and Goodbourn, 2008). Once 
activated, TLR9 signals as described for TLR7 (see Figure 1.5). 
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Figure 1.5: TLR signalling in response to viral nucleic acids.  
TLRs 3, 7 and 9 are found in endosomes. Detection of ligands triggers signalling 
cascades. TLR3 recognises dsRNA and signals via a MyD88-independent 
pathway, inducing production of IFNs and pro-inflammatory cytokines. TLR7 
recognises ssRNA and TLR9 recognises CpG-unmethylated DNA. Both TLR7 and 
TLR9 signal via MyD88-dependent pathways, inducing production of IFNs and 
pro-inflammatory cytokines.  
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1.4.4. Cytoplasmic RNA sensors 
Two key cytoplasmic sensors of RNA are retinoic acid inducible gene I (RIG-I) and 
melanoma differentiation-associated gene 5 (MDA5). These receptors are 
members of the RIG-I-like receptor (RLR) family and recognize dsRNA. RIG-I was 
identified by Yoneyama et al, (2004) as a regulator for dsRNA-induced signalling. 
RIG-I has a caspase recruitment domain (CARD) which can induce IRF3 and 
NFκB signalling resulting in the production of type I IFNs (Yoneyama et al., 2004). 
MDA5 was identified by Andrejeva et al, (2004) when they found that the V 
proteins of paramyxoviruses bound to it and repressed IFNβ promoter activity 
(Andrejeva et al., 2004). Examination of MDA5 revealed that it contained a CARD 
and overexpression of this protein activated the IFNβ promoter in the presence of 
dsRNA (Andrejeva et al., 2004).  
 
The CARDs of RIG-I and MDA5 trigger signalling cascades by recruiting a CARD-
containing adaptor protein called IFN-β-promoter stimulator 1 (IPS-1) (also known 
as CARD adaptor inducing IFN-β (Cardif) or virus-induced signalling adaptor 
(VISA) or mitochondrial antiviral signalling protein (MAVS)) (Kawai et al., 2005, 
Seth et al., 2005, Xu et al., 2005, Gale and Foy, 2005), from now on referred to as 
IPS-1. This protein is found at mitochondrial membranes. The resulting signalling 
cascades are thought to proceed in a similar manner to TLR3 signalling through 
TRAF3 and TRAF6, and thus activate the production of type I IFNs and pro-
inflammatory cytokines (Randall and Goodbourn, 2008). This pathway is illustrated 
in Figure 1.6.  
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1.4.5. DNA sensors 
In recent years, many DNA sensors have been identified, and the following will 
outline some of these sensors. The stimulator of interferon genes (STING) is an 
important signalling protein which activates type I IFN genes in response to 
cytosolic DNA (Burdette and Vance, 2013). STING does not bind DNA directly, 
instead other DNA sensors have been identified which sense DNA, and then 
activate STING (see below and Figure 1.6). The C-terminal domain of STING 
provides a scaffold and recruits IRF3 in close proximity to TBK1, leading to TBK1-
dependent phosphorylation of IRF3 (Tanaka and Chen, 2012) and thus activation 
of type I IFN genes. 
 
Unterholzner et al, (2010) identified IFI16 as a DNA sensor which acts through 
STING. IFI16 binds dsDNA and recruits STING to induce signalling which causes 
production of type I IFNs (Unterholzner et al., 2010). IFI16 can be found 
cytoplasmically and in the nucleus, giving rise to the idea that DNA sensors could 
be found in the nucleus also.  
 
Recently, Wu et al, (2013) identified that cyclic-GMP-AMP (cGAMP) could activate 
IFN production in response to cytosolic DNA. They found that cGAMP could bind 
to STING leading to activation of IRF3. Sun et al, (2013) then identified that 
cGAMP synthase (cGAS), which binds to DNA, could induce the synthesis of 
cGAMP from ATP and GTP. These results combined with those of Wu et al, 
(2013), indicate that cGAS is a cytosolic DNA sensor that binds to DNA and 
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synthesises the production of cGAMP. cGAMP then activates type I IFN genes via 
STING.   
 
Ablasser et al., (2009) and Chiu et al, (2009) identified RNA polymerase III as a 
cytoplasmic DNA sensor. RNA polymerase III shown to use DNA as a template, to 
make 5’triphosphoate RNAs, which would then activate RIG-I and activate the 
production of type I IFNs as described in section 1.4.4. Ishikawa and Barber 
(2008) showed that RIG-I can associate with STING and thereby activate IFN 
promoter activation (Ablasser et al., 2009, Chiu et al., 2009). Hence the 
transcription of DNA to RNA by RNA polymerase III allows the utilisation of RIG-I 
and STING to activate type I IFN production.  
 
Takaoka et al (2007) identified the DNA-dependent activator of IFN-regulatory 
factors (DAI) protein as a cytoplasmic sensor of DNA. It was found to bind to DNA 
and activate IRF3, leading to an increase in type I IFN genes in response to DNA 
stimulation. Increasing the significance of this observation, DeFilippis et al, (2010) 
showed that DAI is essential for activation of type I IFN genes following CMV 
infections. It remains to be seen if DAI functions through STING. 
 
Figure 1.6 illustrates how the DNA sensors described above feed into signalling 
pathways which activate the production of type I IFNs. 
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Figure 1.6: Cytoplasmic sensors of nucleic acids.  
RNA is sensed by RIG-I and MDA5, which signal via IPS-1 to activated IRF3. DNA 
can be converted to RNA by RNA polymerase III, and this RNA can then activate 
RIG-I. DNA can also be sensed by IFI16, cGAS and DAI, and these sensors 
activate IRF3 via STING.  
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1.4.6. The IFNβ enhanceosome 
The transactivation of the IFNβ promoter is understood in detail and involves the 
formation of the IFNβ enhanceosome. This process will be briefly outlined. The 
IFNβ promoter element contains four positive regulatory domains (PRD) I, II, III 
and IV, which are nucleosome-free. Transcription factors are able to bind these 
regions specifically. The IRF proteins bind to PRD I and III, NFκB binds to PRD II, 
and AP-1 (a heterodimer composed of activating transcription factor 2 (ATF2) and 
c-Jun) binds to PRD IV. Together these are known as the IFNβ enhanceosome. 
The IFNβ enhanceosome can recruit histone acetyltransferases (HATs) including 
the general control of amino acid synthesis 5 (GCN5) and CREB binding protein 
(CBP). The transcriptional start site for the IFNβ promoter is blocked by the 
presence of the nucleosome, but acetylation of histones within this nucleosome by 
GCN5 and CBP lead to its displacement. Transcription factor II D (TFIID) and RNA 
polymerase II can then be recruited to the start site of the IFNβ promoter, leading 
to transcription initiation (Panne, 2008, Honda et al., 2006) 
 
1.4.7. Viral evasion of the IFN production pathways 
Since the TLR and cytoplasmic nucleic acid sensing pathways allow the detection 
of viral components in order to bring about antiviral effects, it is not surprising that 
viruses have evolved to evade and augment these signalling systems. There are 
so many ways in which viruses can do this, and a few examples will be described 
briefly in the following. Figure 1.7 illustrates these mechanisms.  
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TRIF is a key component of the MyD88-independent signalling as it brings about 
the activation of IRF3 and NFκB. The hepatitis C virus (HCV) encoded NS3/4A 
protease cleaves the TRIF protein, inhibiting IRF3 and NFκB signalling (Li et al., 
2005a).  
 
IRF3 activates the transcription of type I IFNs, many of the signalling pathways 
described above result in the activation of IRF3, and thus it is an important protein. 
The KSHV-encoded vIRF2 protein targets IRF3, and this mechanism is discussed 
in section 1.5.2. Another example of a virus protein targeting IRF3 is the rotavirus 
NSP1 protein. NSP1 inhibits IFNβ promoter activation by binding to IRF3 and 
causing its degradation via the proteasome (Barro and Patton, 2005).   
 
Cytoplasmic sensing of RNA is important in the detection of RNA viruses. As 
described in section 1.4.4, RIG-I is a cytoplasmic sensor of dsRNA which activates 
signalling via its CARD domain through the mitochondrion-located IPS-1 protein. 
Human Respiratory Syncytial Virus (HRSV) encodes the non-structural protein 2 
(NS2), which can inhibit RIG-I mediated signalling. NS2 binds to the CARD 
domain of RIG-I and prevents the interaction with IPS-1 which turn represses the 
production of Type I IFNs (Ling et al., 2009).  IPS-1 is a vital signalling component 
in RIG-I and MDA5 activated signalling following dsRNA detection. Hence, viruses 
also target this protein. One example is the HCV NS3/4A protein that cleaves IPS-
1, resulting in its dislocation from the mitochondria. This dislocation blocks IFNβ 
induction (Li et al., 2005b).  
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The HCV encoded NS4B protein, identified as an inhibitor of the IFNβ promoter, 
functions by down-regulating DNA sensing pathways. Through 
immunoprecipitation studies, NS4B was shown to bind to STING, blocking its 
interaction with TBK-1, thus inhibiting downstream signalling pathways (Ding et al., 
2013). 
 
Finally, the IFNβ enhanceosome enables the transcription of IFNβ, and again is 
targeted by viral proteins. The KSHV-encoded LANA protein inhibits the 
production of IFNβ by disrupting the formation of the IFNβ enhanceosome. LANA 
can bind to the PRD I and III, and compete with IRF3 for these binding sites. In the 
presence of LANA, IRF3 binding to the IFNβ promoter was reduced (Cloutier and 
Flamand, 2010).  
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Figure 1.7: Viral inhibition of the IFN production pathway. 
An Illustration of how viral proteins, mentioned in section 1.4.7, can target 
components of the IFN production pathway. This figure shows selected signalling 
components of the IFN production pathway. For more detailed signalling pathways 
see Figure 1.5 and Figure 1.6. The TLR3 activation pathway is shown as the 
NS3/4A protein, encoded by HCV targets TRIF, and KSHV-encoded vIRF2 cause 
IRF3 degradation. The RIG-I cytoplasmic sensor of RNA is inhibited by the HRSV 
encoded NS2 protein and IPS1 is cleaved by NS3/4A. The regulator of DNA 
sensors, STING is targeted by the HCV encoded NS4B protein. Finally, formation 
of the IFNβ enhanceosome is targeted by LANA.  
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1.4.8. JAK-STAT signalling 
The pathways described in the previous sections above are collectively known 
throughout this thesis as the IFN production pathway. This signalling pathway 
results in the production of IFNα/β, which are secreted from cells. These cytokines 
bind to receptors on the surface of cells and activate the JAK-STAT signalling 
pathway. This signalling pathway results in activation of interferon stimulated 
response element (ISRE)-containing promoters, which are present in most IFN 
stimulated genes (ISGs). ISGs encode proteins which have antiviral effects. Thus, 
the antiviral effect of the type I IFNs are exerted by the induction of ISGs. This 
thesis examined the JAK-STAT signalling pathway, and therefore it will be 
described in detail in the following.  
 
The JAK-STAT signalling pathway is activated by binding of IFNα/β to IFNα 
receptors 1 and 2 (IFNAR1 and IFNAR2) (Novick et al., 1994, Darnell et al., 1994). 
These receptors are transmembrane proteins which are located separately prior to 
IFN stimulation. The cytoplasmic tail of IFNAR1 is associated with tyrosine kinase 
2 (Tyk2) and the IFNAR2 subunit is associated with the tyrosine kinase JAK1. 
Upon binding of IFNα/β, the receptors dimerize, which causes a conformational 
change (Darnell et al., 1994). Tyk2 phosphorylates tyrosine 466 on IFNAR1 
(Colamonici et al., 1994) which serves as a docking site for Signal Transducer and 
Activator of Transcription (STAT) 2 via its Src Homology 2 (SH2) domain, which is 
subsequently phosphorylated (Yan et al., 1996). Phosphorylated STAT2 recruits 
STAT1, which then becomes phosphorylated by JAK1 (Leung et al., 1995, Randall 
and Goodbourn, 2008). STAT1 and STAT2 can now associate with IRF9 to form 
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the interferon-stimulated gene factor 3 (ISGF3) complex (Fu et al., 1990, Randall 
and Goodbourn, 2008). Phosphorylated STAT1-STAT2 dimers form a nuclear 
localisation sequence (NLS which causes the translocation of this complex into the 
nucleus. As well as phosphorylation, acetylation is important in the formation and 
function of ISGF3. Tang et al, (2007) showed that in response to type I IFN 
stimulation, CBP is recruited to the IFNAR2 and acetylates it. This creates a 
docking site for IRF9 which is then acetylated. Receptor bound STAT1 and STAT2 
are also acetylated by CBP. The acetylation of IRF9 and STAT2 is critical for 
ISGF3 function (Randall and Goodbourn, 2008, Tang et al., 2007). Figure 1.8 
illustrates this pathway.   
 
In the nucleus the ISGF3 complex binds to ISRE sequences in the promoters of 
ISGs. The consensus ISRE sequence is AGTTTCNNTTTCNC/T (Darenell 1994), 
where ‘N’ is any nucleotide. IRF9 participates in binding to ISRE and the STAT1 
and STAT2 proteins stabilise the association (Kessler et al., 1990). Both STAT1 
and STAT2 associate with HATs CBP/p300 (Bhattacharya et al., 1996, Zhang et 
al., 1996) that are thought to be important in the transcription of ISGs following 
ISGF3 binding to ISREs. CBP/p300 have the ability to acetylate histones which 
makes DNA more accessible to transcriptional activators. The STAT2-CBP 
association occurs at the C-terminal domain of STAT2 (Bhattacharya et al., 1996), 
which is essential for transactivation of ISGs (Qureshi et al., 1996). Both the C- 
and N- terminal domains of STAT1 bind to CBP/p300 (Zhang et al., 1996). STAT2 
also interacts with the general control non-depressible 5 (GCN5), another HAT 
transcriptional co-activator which promotes transcriptional activation. Interaction of 
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STAT2 with HATs results in localised acetylation of histones (Paulson et al., 
2002).  STAT2 also associates with the Brahma-related gene 1 (BRG1) protein, 
which is a key component of the ATP-dependent chromatin-remodelling complex. 
BRG1 can enhance the IFN-α-induced expression of certain ISGs (Huang et al., 
2002). Further work in this area is necessary to identify how these HATs and 
associated factors contribute to ISGs transactivation. 
 
1.4.9. Viral evasion of JAK-STAT signalling 
Viruses target all stages of JAK-STAT signalling, from the IFNARs to the formation 
of the ISGF3 complex. Similar to section 1.4.7, some examples of viruses which 
evade the JAK-STAT signalling pathway will now be provided, focusing on the 
ISGF3 complex. Figure 1.8 illustrates these mechanisms. 
 
STAT1 is part of the ISGF3 complex and is necessary for induction of ISGs. As 
such, STAT1 is a viral target. The C proteins of Sendai virus can interact with 
STAT1 to prevent JAK-STAT signalling. The larger C proteins cause proteasome-
mediated degradation of STAT1 (Garcin et al., 2002). Additionally the P protein 
encoded by Nipah virus can sequester inactive STAT1 in the cytoplasm to prevent 
its nuclear translocation (Ciancanelli et al., 2009). 
 
STAT2 is another member of the ISGF3 complex, and is again targeted by 
viruses. Dengue Virus (DENV) infection causes the degradation of STAT2, which 
enables it to limit type I IFN signalling transduction decreasing ISG expression 
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(Jones et al., 2005). The NS5 protein of DENV prevents the phosphorylation of 
STAT2 and consequently, IFNα mediated signalling (Mazzon et al., 2009). 
Similarly, the expression of HRSV NS1 and NS2 proteins cause the degradation of 
STAT2 (Lo et al., 2005).  
 
IRF9, the third member of the ISGF3 complex is targeted by the E7 protein 
encoded by the human papillomavirus (HPV) 16. The E7 protein can inhibit the 
activation of ISGs following IFNα stimulation and is thought to do so by preventing 
the translocation of IRF9 into the nucleus (Barnard and McMillan, 1999). 
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Figure 1.8: The JAK-STAT signalling pathway, and viral proteins which 
inhibit it.  
Activation of the IFN receptors causes dimerization and activation of the JAK-
STAT signalling pathway. STAT1, STAT2 and IRF9 are recruited to the IFN 
receptors, and are phosphorylated and acetylated. The resultant ISGF3 complex 
translocates to the nucleus and binds to the ISRE consensus sequences 
transactivating ISGs. Viral proteins which downregulate JAK-STAT signalling, by 
targeting components of this pathway, are indicated. The C proteins of Sendai 
virus lead to the degradation of STAT, while The P protein of Nipah virus inhibits 
STAT1 translocation. The NS1 and NS2 proteins encoded by HRSV cause STAT2 
degradation and DENV NS5 protein inhibits STAT2 phosphorylation. Finally, the 




CHAPTER1  Introduction 
~ 38 ~ 
  
1.4.10. Activation of antiviral genes and their effects 
The activation of the JAK-STAT signalling pathway up-regulates the expression of 
many genes which bring about an antiviral state. The following sections will detail 
some of these genes and the effects of the proteins they encode. Examples of 
viruses which target these proteins will also be included. 
 
1.4.10.1. Protein kinase R 
The dsRNA-dependent protein kinase (PKR) is up-regulated by type I IFNs. PKR 
is a serine threonine kinase which has many roles in the antiviral defence 
mechanism of the host. This protein normally exists in an inactive form as a 
monomer. PKR binds to dsRNA with its N-terminal dsRNA-binding motifs, and this 
leads to dimerization of two PKR monomers. These are then autophosphorylated, 
which leads to the formation of an active PKR dimer (Garcia et al., 2006). 
Eukaryotic initiation factor 2 (eIF2α) is phosphorylated by active PKR, which 
prevents the recycling of this factor leading to a halt in translation initiation within 
the cell (Randall and Goodbourn, 2008). This inhibitis the translation of viral (and 
cellular) mRNAs, and is thus an antiviral effect. 
 
The vIRF2 protein downregulates the antiviral effect of IFN as it can rescue 
translation of vesicular stomatitis virus (VSV) mRNA translation (Burysek and 
Pitha, 2001). These same authors also showed that vIRF2 binds to PKR and can 
inhibit the phosphorylation of eIF2α, hence evading antiviral effects induced by 
IFN stimulated PKR. However, it must be noted that these studies were performed 
only on the first exon of vIRF2, and not the full length protein. 
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1.4.10.2. Mx 
The Mx proteins, comprised of MxA and MxB in humans, are large GTPases and 
their expression is dependent on type I IFN stimulation. Mx is very important in 
controlling the infections of RNA viruses. For example, mice with Mx are less 
susceptible to influenza infection than those without (Haller et al., 1980). In mice, 
Mx inhibited viral RNA synthesis of Measles virus (Schneider-Schaulies et al., 
1994). Mx can recognise nucleocapsid proteins in the cytoplasm and restrict their 
movement into the nucleus, which prevents the virus from replicating. Both the 
central interacting domain and the C-terminal domain of Mx proteins are required 
to recognise target viral structures (Kochs and Haller, 1999).   
 
Hepatitis B virus (HBV) precore or core protein can interact with the MxA promoter 
to prevent MxA gene expression, highlighting a mechanism of viral evasion from 
ISGs (Fernandez et al., 2003).  
 
1.4.10.3. ISG15 
ISG15 is induced by IFNs. It functions in a similar manner to ubiquitin, as it can be 
joined covalently to many cellular proteins via its C-terminal LRLRGG motif which 
is referred to ISGylation. The mechanism of how it exerts its antiviral effects 
remains unknown, but ISGylation does not lead to degradation of the target 
protein, rather its activation or inactivation (Sadler and Williams, 2008). Many 
proteins which are ISGylated are involved in the IFN signalling, for example JAK1, 
STAT1, RIG-I, MxA, PKR and RNaseL (Zhao 2005). The importance of ISG15 is 
highlighted in IFNAR knockout mice, as they were protected against Sindbis virus-
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induced lethality when ISG15 was expressed (Lenschow et al., 2005). ISGylation 
of IRF3 has also been shown to prevent proteolysis of IRF3 mediated by viruses, 
increasing production of type I IFNs (Lu et al., 2006).   
 
1.4.10.4. 2’5’ Oligoadenylate synthetase  and RNAse L 
Oligoadenylate synthetase (OAS) and RNase L are induced by type I IFNs. They 
are involved in a pathway activated by dsRNA, which results in the degradation of 
viral and cellular RNAs, leading to a block in viral infections (Silverman, 2007). 
Like PKR, OAS is natively inactive and dsRNA stimulates its activation. Active 
OAS uses ATP to produce 2’5’-linked oligoadenylates, which bind to the 
endoribonuclease RNase L, and cause inactive RNase L monomers to form active 
dimers (Dong and Silverman, 1995). These dimers can cleave both viral and 
cellular mRNA, inhibiting viral replication and protein synthesis (Silverman, 2007). 
Furthermore, these cleaved mRNAs can then be detected by MDA5 and RIG-I 
leading to the production of type I IFNs (see section 1.4.4).  
 
Murine Coronavirus NS2 protein can cleave 2’5’-oligoadenylate, preventing RNase 
L activation. This block on RNA degradation is thus a mechanism by which a virus 
evades the ISGs effects (Zhao et al., 2012).  
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1.5. KSHV-encoded vIRFs 
An introduction to the KSHV-encoded vIRFs will now be provided, and will focus 
on their effects on IFN signalling.  
 
The vIRF genes are found in a cluster within the KSHV genome between ORFs 57 
and 58. They are encoded by ORFs K9 (vIRF1), K11/11.1 (vIRF2), K10.5/10.6 
(vIRF3), and K10 (vIRF4) (see Figure 1.3) (Russo et al., 1996). These vIRFs have 
some homology to cellular IRFs, but they are predicted not to bind to DNA directly 
as they encode only 2 of the 5 tryptophan repeats found within the DNA-binding 
domain (DBD) of cellular IRFs (Cunningham et al., 2003).  
 
1.5.1. vIRF1 
The lytic vIRF1 protein can downregulate both the IFN production pathway and 
the JAK-STAT signalling pathway and is thus an important immunomodulatory 
protein. vIRF1 inhibits the activation of IFNα by binding to CBP/p300  (Burysek et 
al., 1999a).  vIRF1 competes with IRF3 for binding to CBP, leading to a reduction 
of IRF3-CBP complexes (Lin et al., 2001). This complex is important in the 
formation of the IFNβ enhanceosome (see section 1.4.6). vIRF1 also inhibits the 
activation of ISRE-containing reporters (Gao et al., 1997, Li et al., 1998). This viral 
protein may also contribute to tumour formation as it inhibits the activation and 
stabilisation of  the tumour suppressor, p53 (Baresova et al., 2013) . p53 responds 
to signals, such as DNA damage, or viral infections and can halt the cell cycle and 
lead to apoptosis. Attenuation of p53 function is a frequent event leading to 
development of human cancers (Vogelstein et al., 2000). 
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1.5.2. vIRF2 
The lytic vIRF2 is the focus of much of this thesis. Studies performed by Burysek 
et al, (1999b) examined only the first exon encoded by ORF K11.1 which they 
believed to be the full length vIRF2. However, it was later shown that full length 
vIRF2 is encoded by ORFs K11.1 and K11. Nonetheless, Burysek et al, (1999b) 
identified that the ORF K11.1 encoded protein could downregulate activation of 
the IFNα promoter (Burysek et al., 1999b). Later, experiments examining the 
effects of full length vIRF2 upon the IFN production pathways found that it also 
inhibited the activation of the IFNβ promoter. vIRF2 forms a multi-protein complex 
with IRF3 and caspase-3 that leads to the turnover of IRF3, meaning that the IFNβ 
promoter cannot be effectively transactivated (Areste et al., 2009, Fuld et al., 
2006). Additionally, vIRF2 also downregulates JAK-STAT signalling and one 
proposed mechanism for this inhibition is through decreasing levels of the ISGF3 
components, STAT1 and IRF9 (Mutocheluh et al., 2011, Fuld et al., 2006). The 
mechanisms of such degradation are unknown.  
 
As discussed in section 1.4.10.1, another activity of the 1st exon of vIRF2 is to bind 
to the IFN induced PKR kinase, and inhibit the subsequent phosphorylation of eIF-




The spliced vIRF3 gene product is expressed in latently infected PEL and MCD 
cells, but not in KS lesions. vIRF3 interacts with IRF7 to prevent the cellular 
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protein from binding DNA, thereby inhibiting IFNα promoter activation (Joo et al., 
2007). vIRF3 also associates with IRF5. IRF5 can be activated by DNA damage, 
as well as by TLR7 and TLR9 signalling resulting in the activation of pro-
inflammatory cytokines (Takaoka et al., 2005). IRF5 can also activate type I IFN 
promoters (Barnes et al., 2001). vIRF3 represses the activation of ISRE and IFNβ 
promoter elements by inhibiting binding of IRF5 to them (Wies et al., 2009). 
Moreover, the IκB kinase (see section 1.4.3.1) is targeted by vIRF3 decreasing 
NFκB activation (Seo et al., 2004). Additionally, vIRF3 targets the activity of the 
ISG product, PKR. vIRF3 expression decreases the PKR-mediated inhibition of 
protein synthesis and was shown to decrease the phosphorylation of eIF-2alpha 
(Esteban et al., 2003). 
 
vIRF3 is classed as an oncogene as it inhibits the activity of p53. This viral protein 
directly interacts with p53 resulting in inhibition of p53 transcriptional activation. 
(Rivas et al., 2001). vIRF3 also activates the transcription of the cellular oncogene, 
c-Myc. c-Myc activates the expression of many genes involved in cell growth, 
proliferation and survival. vIRF3 interacts with an inhibitor of c-myc activity called 
Myc modulator 1 (MM-1). This interaction prevents MM-1 from suppressing c-myc 
activity, and thus increases activity of the oncogene  (Lubyova et al., 2007).  
 
1.5.4. vIRF4 
Limited studies to date suggest that the lytic vIRF4 protein has no effect on the 
IFN production pathway, as no reduction in IFNβ promoter activity was observed 
following activation with Sendai Virus in the presence of vIRF4 (Kanno et al., 
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2006). The effect of vIRF4 on the JAK-STAT signalling pathway remains to be 
identified, and much of this thesis focuses on this area.  
 
Like vIRF1 and vIRF3, vIRF4 can also affect the tumour suppressor p53. Lee et al, 
(2009) showed that vIRF4 can interact with murine double minute 2 (MDM2), 
leading to decreased levels of p53. MDM2 can ubiquitinate p53, which targets it 
for proteasome-mediated degradation. The stability of MDM2 is self regulated, 
through autoubiquitination. vIRF4 stabilizes MDM2 by inhibiting MDM2 
autoubiquitination, hence increasing MDM2 levels and therefore decreasing p53 
levels (Lee et al., 2009). This is therefore one mechanism by which KSHV can 
evade the antiviral effects p53.  
 
vIRF4 also interacts with Ubiquitin-specific-processing protease 7 (USP7) also 
known as herpesvirus-associated ubiquitin-specific protease (HAUSP). USP7 is a 
deubiquitylating enzyme, which can deubiquitinate p53, for example, protecting it 
from MDM2-mediated degradation (Lee et al., 2011). 
 
1.5.5. Other KSHV-encoded inhibitors of type I IFN signalling 
As well as the vIRFs, KSHV encodes other proteins which downregulate type I IFN 
signalling. As described in section 1.4.7, LANA competes with IRF3 for binding to 
the IFNβ promoter and therefore prevents the expression of this cytokine (Cloutier 
and Flamand, 2010). The immediate early protein K-bZIP, encoded by ORFK8 
inhibits IRF3 from binding to the to IFNβ promoter. K-bZIP binds directly to the 
PRD I and III regions of the IFNβ promoter which causes low levels of IFNβ 
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transcription. However, this binding also prevents IRF3 from binding to the IFNβ 
promoter and inhibits the formation of the enhanceosome (Lefort et al., 2007). 
ORF45 is a key tegument protein, and an immediate-early gene. It can inhibit 
virus-mediated activation of type I IFN genes by suppressing IRF7 
phosphorylation, which in turn prevents IRF7 nuclear accumulation and the 
subsequent transcription of IFNα and IFNβ (Zhu et al., 2002).  
 
RTA, the lytic switch protein can also inhibit the type I IFN response. It does so by 
increasing the association between RTA-Associated Ubiquitin Ligase (RAUL) and 
USP7. RAUL can cause the proteasome-mediated degradation of IRF3 and IRF7, 
and USP7 stabilises RAUL. RTA enhances this interaction, and thus increases 
IRF3 and IRF7 degradation, leading to an inhibition in the activation of type I IFN 
promoters (Yu and Hayward, 2010). The KSHV regulator of IFN function (RIF) 
protein can also inhibit ISRE-containing reporter plasmids. It decreases 
phosphorylation of STAT1, STAT2 and inhibits their nuclear translocation. RIF 
associates with STAT2, JAK1 and both subunits of the IFN receptor, but the 
mechanism of it action is presently unclear (Bisson et al., 2009). 
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1.6. Aims and objectives of this thesis 
The aims and objective of this thesis are divided into aims relating to the function 
fo vIRF2 and to those relating to the function of vIRF4. 
 
1.6.1. Aims and objectives concering vIRF2 
The aim of this thesis is to investigate if and how the KSHV-encoded vIRF2 and 
vIRF4 proteins can downregulate type I IFN signalling. The vIRF2 protein has 
been shown to downregulate both the IFN production pathway and JAK-STAT 
signalling. The mechanisms of such inhibitions are not fully understood and 
therefore more detailed understanding of the biology of vIRF2 in IFN signalling will 
be sought.  
 
The objectives of this thesis are to: 
1) Confirm the effect of vIRF2 on the IFN production pathway  
2) Confirm the effect of vIRF2 on the JAK-STAT signalling pathway  
3) Determine if vIRF2 can inhibit binding of the ISGF3 complex to ISRE 
sequences 
4) Identify whether vIRF2 reduces levels of the components of the JAK-STAT 
signalling pathway 
5) Identify the cellular protein binding partners of vIRF2 and investigate their 
relevance in IFN signalling 
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1.6.2. Aims and objectives concering vIRF4 
Through limited studies to date, vIRF4 is not thought to modulate the IFN 
production pathway. However, its effects on JAK-STAT signalling are unknown. 
Therefore vIRF4 will be investigated in the context of JAK-STAT signalling and 
where any inhibitory effect is identified, the molecular mechanism will be sought.  
 
The objectives are to: 
1) Assess the effect of vIRF4 on the IFN production pathway  
2) Assess the effect of vIRF4 on the JAK-STAT signalling pathway  
3) Elucidate the mechanism of vIRF4-mediated inhibition on either of these 
pathways by identifying the cellular partner proteins of vIRF4 and 
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2.1. Tissue culture methods  
The following will outline the materials and methods used for tissue culture 
techniques. All such techniques were carried out in laminar flow hoods under 
sterile conditions. Table 2.1 provides a list of media and supplements used for 
tissue culture techniques. 
 
Table 2.1 Tissue culture media and supplements 
Item Source 
Dulbecco’s Modified Eagle’s 
Medium (DMEM) 
Sigma (D6429) 
MemAQ Sigma (M0446) 
RPMI Sigma (R8758) 
Foetal Calf Serum (FCS) PAA (A15-101) 
Foetal Calf Serum (FCS) –No 
Tetracycline 
Clone tech (631107) 
Penicillin/Streptomycin Invitrogen (15070063) 
Glutamine Invitrogen (25030123) 
Trypsin Invitrogen (12605010) 
Non essential amino acids (NEAA) Sigma (M7145) 
DMEM complete 
DMEM supplemented with 10% FCS, 
1%Glutamine, 1%Penicillin/ Streptomycin 
and 1% NEAA. 
SILAC-DMEM  
DMEM supplemented with 10% FCS-No 
Tetracycline, 1%Glutamine, 1%Penicillin/ 
Streptomycin and 1% NEAA. 
Zeocin Invitrogen (R250-01) 
Blasticidin Merck Millipore (203351) 
Tetracycline Sigma (T7660) 
Freezing media 90% FCS, 10% Dimethyl sulfoxide (DMSO) 
Fibronectin Sigma (F0895)  
Trypan blue Sigma (T10282) 
Recombinant IFN α2b Stratech (11115-1) 
Phorbol myristate acetate (PMA) Sigma (P8139) 
 
2.1.1. Cell lines 
Table 2.2 summarises the cell lines used throughout this study, detailing the 
media required for their maintenance. All cells lines were grown and maintained at 
CHAPTER 2  Materials and methods 
~ 50 ~ 
 
37°C in a humidified environment supplied with 5% CO2. Cells were grown on 
various treated plastic vessels. For passage of adherent cells, the existing medium 
was removed, cells were then washed with phosphate buffered saline (PBS) and 
trypsin was added (37°C, until cells detached). Culture medium was then added to 
quench the trypsin and the cells were pelleted by centrifugation (5 minutes, 300g). 
Pellets were resuspended in fresh media, plated at the required number and 
stored in the incubator. For suspension cells, cells were pelleted by centrifugation 
(5 minutes, 300g), washed in PBS and resuspended at the required concentration 
using fresh media. 
 













DMEM complete with 
5μg/mL 
Blasticidin 
BCBL1 Suspension PEL Human RPMI 














2.1.1.1. T-Rex-293 cell line 
The Tetracycline-Regulated Expression (T-REX) cell lines stably express the 
tetracycline (Tet) repressor, from the pcDNA™6/TR plasmid which carries the 
Blasticidin resistance gene. These cells were used to create stable, tetracycline 
inducible, cell lines expressing the vIRF2-NTAP, vIRF4-NTAP or NTAP proteins. 
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The plasmids of choice (pvIRF2-NTAP, pvIRF4-NTAP or pCDNA4TO-NTAP) were 
linearised and transfected into these cells. Selection of stable transfectants was 
performed using Zeocin™ and Blasticidin. 
 
2.1.2. Cell counting 
Cell suspensions were diluted in Trypan blue solution at a 1:1 ratio and 10μl of this 
mixture was transferred to each chamber of a heamocytometer. The cells were 
counted under a light microscope. Since dead cells take up trypan blue dye it is 
possible to distinguish between dead and live cells.  
 
2.1.3. Cryopreservation of cell lines 
To keep a permanent stock, cells were stored as frozen stocks in liquid nitrogen. 
Cells were pelleted through centrifugation (5 minutes, 300g), the supernatant was 
removed and the cell pellet was resuspended in 1ml of freezing medium 
(90%FBS, 10% DMSO), in general, 1 x106 cells/ml of freezing medium, and added 
to a sterile 1.5ml cryovial. These vials were placed in a cryopreservation box (Mr 
Frosty, Nalgene), containing isopropanol, which was placed in a -80oC freezer, 
allowing the cells to cool by 1oC per minute. This method prevents lysis of cells 
through the freezing of water molecules.  Vials were transferred into liquid nitrogen 
for long term storage.  
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2.1.4. Recovery of cryopreserved cells 
Stock culture cell lines stored in liquid nitrogen were thawed in a 37C water bath 
and washed in 10ml of appropriate complete media. The cells were then 
centrifuged (5 minutes, 300g) and the resultant pellet was resuspended in 
appropriate complete media before seeding in the normal manner.  
 
2.1.5. Generating stable HEK-293 cell lines  using the T-Rex system from 
Invitrogen 
T-Rex-293 cells which stably express the tetracycline repressor, were plated out in 
a 6 well plate (4 X 105 per well) and left to adhere over night in antibiotic free 
media. The cells were transfected, using Lipofectamine 2000 with either the EV-
NTAP, vIRF2-NTAP or vIRF4-NTAP vector which had been linearised with PvuI. 
24 hours post transfection, the medium was changed to DMEM complete with 
5µg/ml Blasticidin. After 24 hours, the cells were trypsinised and plated out in a T-
25, in selective medium (DMEM complete with 5µg/ml Blasticidin and 200µg/ml 
Zeocin). This selective medium was changed every 3-4 days until Zeocin resistant 
colonies were detected. These colonies were cultured until the T-25 was 
confluent.  
 
2.1.5.1. USP7 inhibitor 
The P22077 USP7 inhibitor was purchased from R&D (4485). It was made up to a 
10mM solution with DMSO, aliquotted and stored at -20º. Prior to use, an aliquot 
was thawed and diluted in DMEM to the desired concentration and added to cells.   
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2.1.6. Transfection of cells 
Cells were transfected using Lipofectamine 2000 (Invitrogen), according to the 
manufacturer’s instructions. Lipofectamine 2000 is a lipid-based system of 
delivering DNA plasmids into cultured eukaryotic cells. The amount of 
Lipofectamine 2000 and DMEM used were dependent on the size of the cell 
culture plate containing cells to be transfected.  The required amount of DNA was 
added to one volume of DMEM, while at the same time adding Lipofectamine to 
another one volume of DMEM. These solutions were incubated at room 
temperature for five minutes, combined and left to incubate for a further 20 
minutes, before being added drop wise onto cells.  
 
2.2. Dual luciferase reporter assay  
The dual luciferase reporter assay (DLA) system (Promega) measures the 
activities of two distinct luciferase enzymes, firefly (Photinus pyralis) and Renilla 
(Renilla reinformis), expressed from the same sample. The firefly luciferase signal 
is expressed by the promoter of interest and relates to the activity of that promoter. 
The constitutively active Renilla luciferase signal serves as internal control, to 
which the experimental reporter gene (firefly signal) is normalised. Cells were 
transfected (using Lipofectamine 2000 as described in section 2.1.6) with reporter 
plasmids containing either the firefly luciferase gene (driven by the promoter of 
interest), or the constitutively active Renilla luciferase plasmid (pRLSV40). After a 
specific time (dependent on the experiment), the cell medium was removed and 
the cells were washed gently with PBS.  Cells were lysed using Passive Lysis 
Buffer (Promega) for a minimum of 10 minutes. To obtain results, 20μl of each 
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sample was added to the wells of a 96-well microtitre plate (Nunc) in duplicate. 
Samples were assayed using a luminometer (Gene Flow) which was purged by 
repeat priming with 2 ml of sterile distilled water per auto-injector, followed by 
priming with 600 µl of Luciferase Assay Reagent II (LARII) and 600 µl of the Stop 
& Glo Reagent through separate injectors. The programme for assaying samples 
is shown in Table 2.3. Relative activity is calculated by normalising the firefly 
values to their Renilla counterparts. Reporter plasmids use in this thesis are 
shown in Table 2.4. 
 
Table 2.3: The programme for reading DLAs 
Reporter plasmid Information Purpose 
LARII 50μl Activate firefly luciferase 
Measurement 10 seconds Measure firefly luciferse 
Stop & Glo 50μl Quenches firefly luciferase and 
Measures Renilla luciferase 
Measurement 10 seconds Measure Renilla luciferse 
 
 
Table 2.4: Reporter plasmids 
Reporter plasmid Information 
p125-luc Full length IFN-beta promoter driving expression of a firefly 
luciferase reporter gene 
pISRE-luc Luciferase reporter vector containing tandem repeats of 
the ISRE element driving expression of the firefly 
luciferase reproter gene 
 
2.3. Immunoblotting 
Solutions and buffers used for immune blotting are shown in Table 9.1. 
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2.3.1. Protein extraction- sonication 
Cells were washed twice with ice-cold PBS, on ice. 50μl (per well of a 6 well plate) 
of ice-cold sonication buffer was then added to the cells and they were collected 
using a cell scraper and transferred to a microfuge tube and placed on ice. Cells 
were sonicated for 15 seconds and centrifuged (10 minutes, 16,000g 4˚C) to 
remove cell debris. The supernatant was then transferred to a new tube and 
stored at -80˚C until further use.  
 
2.3.2. Protein extraction- non-ionic detergent lysis buffer 
Cells were washed twice with ice-cold PBS, on ice. 50ul (per well of a 6 well plate) 
of ice-cold non-ionic lysis buffer (see  Table 9.1) was then added to the cells, 
which were then collected using a cell scraper, transferred to a fresh tube and 
placed on ice. The samples were rotated in a cold room (30 minutes, 4°C) before 
being centrifuged (10 minutes, 16,000g 4˚C) to remove cell debris. The 
supernatant was then transferred to a new tube and stored at -80˚C until further 
use. 
 
2.3.3. Determination of protein concentration 
Protein concentrations were determined by Bradford assay (Bio-Rad). Briefly, 5μl 
of each sample was mixed with 45μl of dH2O, and 10μl aliquots of this mixture 
were pipetted into the wells of a 96 well plate in triplicate. Bovine serum albumin 
(BSA) standards, of known concentrations were made up in dH2O and 10μl 
aliquots were also pipetted into the wells of the plate in triplicate. Bradford reagent 
was diluted 1:4 with dH2O and 200μl of this mixture was added to each well. 
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Absorbance readings, at 595nm, were determined using a microplate reader and 
sample concentrations were calculated using a standard curve generated from the 
absorbance of the standards. 
 
2.3.4. Sodium Dodecyl Sulphate-polyacrylamide gel electrophoresis, (SDS-
PAGE) 
SDS-polyacrylamide gels were cast using the Mini-Protean 3 electrophoresis kit 
(BioRad, UK). The resolving part of the gel was prepared first based on the SDS 
percentage required (Table 9.2). Following addition of the ammonium persulphate 
(APS) & TEMED, the solution was poured into glass plate sandwiches and 
allowed to polymerise. The stacking gel was then prepared (Table 9.2), poured on 
top of the resolving gel, and combs were inserted. Once this gel had polymerised, 
the combs were removed and the wells were washed with sterile distilled water 
(SDW). Protein samples in 2X loading buffer mixtures were loaded into wells of 
the gels alongside a protein molecular weight marker. Gels were run at 100 V in 1 
x running buffer for 1-2 hours.  
 
2.3.5. Western blotting 
Following electrophoresis the resolved protein samples, contained within the SDS-
polyacrylamide gel, were transferred to a nitrocellulose membrane using the Mini-
Protean 3 transblot apparatus (Biorad). The gel was first removed from the glass 
plates and sandwiched with an activated nitrocellulose between two layers of 3MM 
filter paper (Whatman). This sandwich was placed in the transblot apparatus and 
run at 90V for 1.5 hours with an ice block in the tank. Post transfer the non-specific 
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antibody binding sites on the blotted membrane were blocked with milk or BSA 
(depending on primary antibody) for a minimum of 1 hour. The membrane was 
probed overnight with the desired primary antibody (see Table 9.3) diluted in 
blocking buffer. Following primary antibody incubation, the membrane was 
washed (3 x 15 minutes) with TBS-T or PBS-T (depending on the primary antibody 
used). The membrane was then incubated for at least 1 hour with the desired 
secondary antibody (see Table 9.4) diluted in blocking buffer. The membrane was 
then washed (3 x 15 minutes) with TBS-T or PBS-T (depending on the antibody 
used). Immunoreactive bands were detected using Enhanced chemiluminescence 
(ECL) and visualised using autoradiography on hyperfilm and developed on a 
automatic X-ray film processor.  
 
2.4. Co-Immunoprecipitation 
Cells lysates from cells transfected with pvIRF2-HisMax or pvIRF4-HisMax vectors 
were prepared as in section 2.3.2.  A sample of each lysate was removed to be 
kept as an ‘input’ lysate. 250µg of each sample was pre-cleared by incubation with 
protein G-Sepharose 4B fast flow (Sigma-Aldrich) on a rotating wheel (at least 1 
hour, 4°C). Supernatants were collected by centrifugation (1 minute, 16,000g, 
4°C) and were incubated with anti-Xpress or the mouse isotype control (see Table 
2.5) on a rotating wheel (5 hours, 4°C). Protein G-Sepharose 4B fast flow was 
then added to these samples to allow immunoprecipitation and they were left to 
incubate further on the rotating wheel (overnight, 4°C). The beads were washed 
three times by centrifugation (1 min, 16,000g, 4°C) and careful removal of the 
supernatant followed by addition of ice cold PBS. Proteins were recovered by 
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boiling the samples in 50µl of 2 x loading sample buffer for 5 minutes. Samples 
were then centrifuged (1 minute, 16,000g, 4°C) and the supernatants were 
collected in a fresh tube. Immunoprecipitates were analysed by western blot.  
 
Table 2.5: Antibodies used for immunoprecipitation 
Antibody Dilution Supplier 
Xpress 1µl per sample Invitrogen (R910-25) 
Mouse IgG1 
 Isotype control 
Matched to that of 
primary antibody 
R&D Systems (MAB002) 
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2.5. Identifying Protein Interaction Partners Using SILAC-based Proteomics 
To identify protein binding partners of vIRF2 and vIRF4, stable isotope labelling of 
amino acids in cell culture (SILAC) was used in conjunction with mass 
spectrometry.  
 
2.5.1. Labelling of Amino acids  
The EV-NTAP, vIRF2-NTAP and vIRF4-NTAP stable cell lines were cultured in 
SILAC-DMEM (Invitrogen 41965-039) lacking arginine (R) and lysine (K), 
Differentially labelled versions of these amino acids, containing different levels of 
12C/13C and 14N/15N or deuterium 2H (see Table 2.6 and Table 2.7), were used to 
supplement the SILAC-DMEM in order to produce ‘light’ media, ‘medium’ media 
and ‘heavy’ media. Normal L-arginine and L-lysine were added to the ‘light’ media, 
L-arginine 13C and L-lysine 4,4,5,5-D4  to the ‘medium’ media, and L-arginine 
13C/15N and L-lysine 13C/15N to the ‘heavy’ media (see Table 2.7). Arginine and 
lysine were added to final concentrations of 84µg/ml and 146µg/ml respectively. 
Cells were maintained in the labelled SILAC-DMEM medias, supplemented with 
10% dialysed FBS with a 10kDa cutoff (Dundee cell products), to ensure that no 
amino acids were added from the FBS, and 5% penicillin/streptomycin for at least 
5 cell divisions to obtain complete labelling of cells. Trypsinisation was avoided to 
prevent addition of un-labelled amino acids and cell dissociation buffer (Invitrogen) 
was used instead. This method is based on that of Trinkle-Mulcahy et al, (2008). 
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Table 2.6: The amino acids used to label cells 
R= Arginine, K = Lysine 
Amino acids Source 
R0 Sigma (A8094) 
K0 Sigma (L8862) 
R6 Cambridge isotype labs (CLM-2265) 
R10 Cambridge isotype labs (CNLM – 539) 
K4 Cambridge isotype labs (DLM-2640) 
K8 Cambridge isotype labs (CNLM-291) 
 
 
Table 2.7: Radiolabelled amino acids 
Composition Arginine composition Lysine Composition 
R0K0 (Light) (12C6, 14N4) (12C6, 14N2) 
R6K4 (Medium) (13C6, 14N4) D4 (Deuterium)  
R10K8 (Heavy) (13C6, 15N4) (13C6, 15N2) 
 
2.5.2. Preparation of SILAC labeled samples for immunoprecipitation 
For each sample to be immunoprecipitated, one T-75 flask of labelled cells was 
used. The SILAC-labelled cells were prepared for immunoprecipitation by scraping 
the cells from the flask and pooling in a tube. Cells were pelleted (10 minutes, 
16,000g 4˚C). The pellets were washed three times by addition of ice cold PBS 
and centrifuged (5 minutes, 16,000g 4˚C). To lyse the cells, 1ml of IP lysis buffer 
(see Table 9.1) was added to each sample which was then pipetted up and down 
10 x and left on ice for 5 minutes. Samples were then syringed up and down 10 x 
with a blunt needle before incubation on ice for a further 5 minutes. After 
centrifuging (1 minute, 16,000g 4˚C), the supernatant was collected, and the 
protein concentration determined by Bradford assay (see section 2.3.3). The 
samples were then normalised with IP lysis buffer to the concentration of the 
lowest sample. 50µl of these samples were kept aside for subsequent analysis 
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(lysate sample), the remainder was submitted for purification by 
immunoprecipitation. 
 
2.5.3. Immunoprecipitation of SILAC samples 
To pull out the NTAP-tagged proteins, streptavin beads were used. First, the 
beads were washed in 300µl of ice cold PBS by centrifugation (5 minutes, 16,000g 
4˚C) after which the supernatant was discarded. 5ml of IP lysis buffer was then 
added to the beads and this mix was centrifuged (5 minutes, 16,000g 4˚C) and 
again the supernatant was discarded. This process was repeated 3 times, and 
following the final wash, the beads were resuspended in 1ml of IP lysis buffer. 
100µl of this mix was added to each normalised SILAC lysate sample and left 
overnight on a rotating wheel in a cold room. The following day, the samples were 
centrifuged (5 minutes, 16,000g, 4˚C) and before discarding the supernatant, 50µl 
was kept aside for subsequent analysis (‘flow through sample’). The beads were 
washed three times with IP lysis buffer. On the final removal of supernatant, care 
was taken to ensure all the supernatant was removed. The beads and associated 
proteins were boiled in 50µl of 2x loading buffer at 95˚C for 5 minutes, followed by 
centrifugation (5 minutes, 16,000g 4˚C). The supernatant (‘final eluate’), which 
contained the NTAP-tagged proteins and binding partners was collected. Equal 
volumes of the samples labelled with light, medium and heavy amino acids were 
pooled and sent for processing at the proteomics facility at the University of 
Bristol.  
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2.5.4. Preparation of samples for LC-MS/MS by the University of Bristol 
Proteomics Facility 
The following information was provided directly from the by the Proteomics Facility 
at the University of Bristol (Dr Kate Heesom, k.heesom@bristol.ac.uk): 
Each sample was run briefly on a one-dimensional SDS-PAGE (4-12% Bis-Tris 
Novex mini-gel, Invitrogen) and the whole sample was excised as a single band 
and subjected to tryptic digestion using a ProGest automated digestion unit 
(Digilab UK). The resulting peptides were fractionated using a Dionex Ultimate 
3000 nanoHPLC system in line with an LTQ-Orbitrap Velos mass spectrometer 
(Thermo Scientific). Briefly, peptides in 1% (v/v) formic acid were injected onto an 
Acclaim PepMap C18 nano-trap column (Dionex). After washing with 0.5% (v/v) 
acetonitrile, 0.1% (v/v) formic acid peptides were resolved on a 250 mm × 75 μm 
Acclaim PepMap C18 reverse phase analytical column (Dionex) over a 150 min 
organic gradient, using 7  gradient segments (1-6% solvent B over 1min., 6-15% 
solvent B over 58min., 15-32% solvent B over 58min., 32-40% solvent B over 
3min., 40-90% solvent B over 1min., held at 90% solvent B for 6min and then 
reduced to 1% solvent B over 1min.) The flow rate was 300 nl min−1. Solvent A 
was 0.1% formic acid and Solvent B was aqueous 80% acetonitrile in 0.1% formic 
acid. Peptides were ionized by nano-electrospray ionization at 2.1 kV using a 
stainless steel emitter with an internal diameter of 30 μm (Thermo Scientific) and a 
capillary temperature of 250°C. Tandem mass spectra were acquired using an 
LTQ-Orbitrap Velos mass spectrometer controlled by Xcalibur 2.1 software 
(Thermo Scientific) and operated in data-dependent acquisition mode. The 
Orbitrap was set to analyse the survey scans at 60,000 resolution (at m/z 400) in 
the mass range m/z 300 to 2000 and the top six multiply charged ions in each duty 
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cycle selected for MS/MS in the LTQ linear ion trap. Charge state filtering, where 
unassigned precursor ions were not selected for fragmentation, and dynamic 
exclusion (repeat count, 1; repeat duration, 30s; exclusion list size, 500) were 
used.  Fragmentation conditions in the LTQ were as follows: normalised collision 
energy, 40%; activation q, 0.25; activation time 10ms; and minimum ion selection 
intensity, 500 counts. 
 
The raw data files were processed and quantified using Proteome Discoverer 
software v1.2 (Thermo Scientific) and searched against the UniProt/SwissProt 
Human database release version 57.3 (20326 entries) plus vIRF sequences using 
the SEQUEST (Ver. 28 Rev. 13) algorithm. Peptide precursor mass tolerance was 
set at 10ppm, and MS/MS tolerance was set at 0.8Da. Search criteria included 
carbamidomethylation of cysteine (+57.0214) as a fixed modification and oxidation 





15N4-Arg for triplex) as variable modifications. 
Searches were performed with full tryptic digestion and a maximum of 1 missed 
cleavage was allowed. The reverse database search option was enabled and all 
peptide data was filtered to satisfy false discovery rate (FDR) of 5%. The 
Proteome Discoverer software generates a reverse “decoy” database from the 
same protein database and any peptides passing the initial filtering parameters 
that were derived from this decoy database are defined as false positive 
identifications.  The minimum cross-correlation factor (Xcorr) filter was readjusted 
for each individual charge state separately to optimally meet the predetermined 
target FDR of 5% based on the number of random false positive matches from the 
reverse decoy database. Thus each data set has its own passing parameters.  
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Quantitation was done using a mass precision of 2ppm.  After extracting each ion 
chromatogram the Proteome Discoverer software runs several filters to check for, 
among other things, interfering peaks and the presence of the expected isotope 
pattern. Peptides which did not pass these filters are not used in calculating the 
final ratio for each protein.  
 
2.5.5. Silver staining 
Silver staining was used to ensure the presence of protein bands before sending 
samples for mass spectrometric analysis. 10µl of the final eluted samples were 
run on a 10% Bis-Tris NuPage gel (Invitrogen) using MES buffer (Invitrogen) 
according to the manufacturer’s instructions. Gels were then silver-stained using 
the Silverquest silver-staining kit (Invitrogen) and the manufacturers ‘rapid’ 
protocol. 
 
2.6. Immunofluorescence assay 
2.6.1. Plating, fixing and permeabilizing – Adherent cells 
For adherent cells, cells were grown on glass 12-well multispot microscope glass 
slides (Hendley-Essex). PBS was used to wash the cells prior to fixing in 4% (w/v) 
paraformaldehyde (10 minutes). Ice cold methanol was then to permeabilize the 
cells (10 minutes) and then cells were blocked in blocking solution (1 hour, room 
temperature), which comprised of 20% heat inactivated normal goat serum 
(HINGS), diluted to 20% (v/v) in PBS. 
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2.6.2. Plating, fixing and permeabilizing – suspension cells 
Suspension cells (that were BCBL1 cells only in this thesis) were grown in normal 
tissue culture dishes, and then spotted onto the microscope slides. The cells were 
left to dry for 2 minutes before being fixed in ice cold Methanol:Acetone 1:1 (5 
minutes) then permeabilized in 0.5% Triton-X-100 (Triton-X-100 detergent, diluted 
to 0.5% (v/v) in PBS, 10 minutes). Cells were then blocked in blocking solution (1 
hour, room temperature).  
 
2.7. Immunofluorescence staining 
Primary antibodies (see Table 2.8) were diluted in blocking solution and incubated 
on cells (overnight, 4˚C). The next day, the slides were washed three times in PBS 
before addition of the secondary antibody (see Table 9.4 ), also diluted in blocking 
solution, and incubated in the dark (1 hour, room temperature). Slides were again 
washed three times and incubated in Bisbenzamide (25µg/ml in PBS) (1minute, 
room temperature). After a final wash, the slides were mounted with prolong gold 
(Invitrogen) and protected with 20-70 mm glass coverslips (Menzel-Gläser).  
 
2.7.1. Cell imaging 
Cells were viewed using a LSM 510 META confocal laser scanning microscope 
(Carl Zeiss). Either a 40x or 63x oiled objective was used and each laser was set 
to an equal optical slice and a pinhole diameter of approximately 1 Airy unit.  
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Table 2.8: Primary antibodies used in immunofluorescence assay 
Antibody Dilution Supplier 
RTA (ORF50) 1:100 From our laboratory 
Rabbit Isotype control Matched to primary Abcam ab37415 
Anti-Xpress 1:200 Invitrogen (R910-25) 
 
Table 2.9: Primary antibodies used in immunofluorescence assay 
Antibody Dilution Supplier 
Anti rabbit FITC Conjugate 1:50 Sigma: F1262 
Anti-mouse 594 1:500  
 
2.8. DNA-binding ELISAs 
TransAM Kits (Active motif) are DNA-binding ELISAs which allow transcription 
factor activation to be assayed from cell extracts. In this thesis, the TransAM IRF3 
kit was used to measure the activation of IRF3 in the presence and absence of 
vIRF2. Whole cell lysate (containing the activated IRF3) was added to the wells of 
the kit, which contained oligonucleotides with the IRF3 binding sequence. The 
binding of these oligonucleotides to activated IRF3 could then be quantified using 
the anti-activated IRF3 antibody (included in the kit), which is specific for the 
bound, active form of the transcription factor. A HRP-conjugated secondary 
antibody was then used to binding to the primary antibody, and provide a means 
of quantification (using a spectrophotometer at 450nm). This experiment was 
performed according to the IRF3 TransAM protocol, and all solutions and buffer 
were provided in the kit.  
 
2.9. Electrophoretic mobility shift assay (EMSA) 
EMSA is a method used to examine DNA and protein interactions. A labelled 
probe, which contains the DNA sequence of interest, is mixed with a protein 
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sample, and loaded onto a non-denaturing polyacrylamide gel. Because 
complexes of DNA and protein move through the gel slower than unbound DNA a 
band shift is observed. The intensity of this DNA:protein band is a measure of the 
amount of protein bound. This intensity is measured by densitometry. Traditionally, 
the DNA probes have been labelled with radioactive isotopes. However, the 
methods throughout this thesis utilised the IRDye-700 flurophore.    
 
2.9.1. Solutions, buffers and probes 
The solutions used for EMSA are outlined in Table 2.10. The sequences of the 
probes used are shown in Table 2.11. 
 
Table 2.10: Solutions used in EMSA 
Solution Composition 
1% TBE Buffer 10.8g Tris, 4.5g orthoboric acid and 0.74g EDTA in 1 litre 
SDW, 10mls in 990mls of SDW. 
0.5% TBE Buffer Diluted from 1% TBE in SDW 0.5% and autoclaved 
Odyssey EMSA Buffer 
Kit 
LI-COR (829-07910) 
STAT2 (C-20) Santa Cruz (sc-476) 
 
Table 2.11: Probes used in EMSA 
Probe Sequence 
ISRE FWD-IRDye-700 end labelled 5′-GATCAGGAAATAGAAACTG-3′ 
ISRE REV- unlabelled 5′-CAGTTTCTATTTCCTGATC-3′ 
ISRE FWD- unlabelled 5′-GATCAGGAAATAGAAACTG-3′ 
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2.9.2. Nuclear and cytosolic protein extractions 
Cells of interest were seeded in tissue culture dishes and allowed to adhere. 24 
hours later, the medium was removed, and replaced with serum-free medium so 
that only basal level transcription factor binding would be observed in untreated 
samples. 24 hours later, the cells were treated/stimulated, as appropriate for the 
specific assay. Cells were washed in ice-cold PBS and cell lysis and nuclear and 
cytosolic protein extraction was performed using the NE-PER nuclear and 
cytosolic extraction reagents according to the manufacturers instructions (Pierce 
Biotechnology, 78833). Briefly, CERI reagent (100μl), containing protease 
inhibitors, was added to the cells and the lysates were scraped, collected and 
transferred to 1.5ml tubes. Samples were vortexed (15 seconds) and incubated on 
ice (10 minutes). CERII (5.5μl) was then added to each sample, vortexed and 
incubated on ice (1 minute). Lysates were then centrifuged (5 minutes, 13000g, 
4°C) and the supernatant, containing the cytoplasmic fraction, was removed and 
transferred to a clean 1.5ml tube. The nuclear pellet was resuspended in NERI 
(50μl), containing protease inhibitors, on ice and vortexed (15 seconds) every 10 
minutes for 40 minutes. Samples were then centrifuged (10 minutes, 13000g, 4°C) 
and the supernatant containing the nuclear fraction was removed and transferred 
to 1.5ml tubes. Protein concentration was measured as described previously 
(section 2.3.3) and samples stored at –80°C until required.  
 
2.9.3. Preparation and annealing of probes 
The ISRE probe sequences were based on the ISRE consensus sequence 
(GAAANNGAAACT). The actual sequence used was that of the ISG54 response 
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element (Darnell et al., 1994). The single stranded EMSA probes were produced 
by MWG, and the sequences are shown in Table 2.11. Probes were created by 
annealing one end-labelled probe with a complementary non-labelled probe 
specific. Briefly, the oligonucleotides were diluted with DEPC treated water to 
100pmole and 5μl of each of the complementary probes were mixed with 90μl of 
Restriction buffer B (Roche). This mixture was incubated (95°C for 10 minutes) in 
a heat block, which was then switched off to allow the samples to cool overnight in 
the dark and anneal. The annealed probes were then aliquoted (20μl), covered in 
foil (to protect from light) and stored at –20°C until further use. Labelled probed 
was produced by annealing the ISRE FWD-IRDye-700 end labelled probe with the 
ISRE REV- unlabelled. The ‘cold competitor’ probe was produced by annealing 
the ISRE FWD- unlabelled probes with the ISRE FWD- unlabelled.  
 
2.9.4. DNA: Protein binding reactions 
Nuclear lysates (5μg) were mixed with 1µl of 5′-IRDye-700-labelled EMSA probe, 
2µl of 10x binding buffer (Odyssey EMSA Buffer Kit), 2µl 25mM DTT/2.5% Tween-
20, 1µl poly(I:C), and made up to 20ul with DEPC treated water. Reagents were 
incubated (30 minutes, room temperature, in the dark). 2µl of gel loading buffer 
(Odyssey EMSA Buffer Kit) was then added to each sample and samples were 
resolved on 6 % polyacrylamide-TBE gels (Invitrogen). The bands were visualized 
and quantified using an Odyssey infrared imaging system (LI-COR 
Biotechnology). For supershift experiments, the STAT2 antibody was used.  
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2.10. Cloning 
The vIRF4 and vIRF2 genes were cloned into various vectors throughout this 
study. Expression plasmids into which vIRF2 or vIRF4 genes were cloned are 
described below and detailed in Table 2.12. Primers used for cloning procedures 
thought this thesis are shown in Table 2.14. For specific cloning procedures, see 
the results sections. Restriction enzymes were purchased from New England 
Biolabs, Promega or Roche and used according to the manufacturers instructions. 
DNA inserts, generated by PCR or through restriction digestion from an existing 
vector were separated by agarose gel electrophoresis and purified using a Qiagen 
gel extraction kit. Vector DNA was restriction digested and gel purified. 
Alternatively, pCR-Blunt was used to clone blunt-ended PCR fragments. A typical 
ligation reaction consisted of DNA insert (6µl), recipient vector (2µl), T4 DNA 
ligase buffer (1µl) and T4 DNA ligase (1µl). Ligation reactions were incubated 
overnight at 16˚C before being used to transform competent E. coli cells. 
 
2.10.1.1. pCDNA4TO-NTAP 
This vector (provided by Prof. Ian Goodfellow, University of Cambridge) consists 
of the N-terminal tandem affinity purification (NTAP)-tag cloned into the pCDNATO 
Invitrogen vector. The NTAP-tag encodes two copies of the IgG binding units of 
protein G from Streptococcus spp and a streptavidin binding peptide separated by 
a Tobacco Etch Virus (TEV) protease cleavage sequence. This vector was the 
backbone for some cloning procedures in this thesis, however, the pCDNA4TO-
NTAP vector produces a protein in its own right which is referred to as the ‘NTAP’ 
protein throughout this thesis. Either the vIRF2 or the vIRF4 genes were cloned 
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into this vector to produce the pvIRF2-NTAP and pvIRF2-NTAP vectors 
respectively.  The proteins produced from these vectors are referred to as vIRF2-
NTAP and vIRF4-NTAP respectively.  
 
2.10.1.2. pcDNA4/HisMax 
The pcDNA4/HisMax vector (Invitrogen) was used as the backbone for the 
pvIRF2-His/Max and pvIRF4-His/Max vectors. These vectors encode an Xpress 
and a polyhistidine tag, contiguous to the vIRF2 and vIRF4 proteins enables their 
detection. 
 
Table 2.12: The expression plasmids used throughout this thesis 
 
2.10.2. Transformation reactions 
Frozen One Shot Chemically Competent E. coli (Invitrogen), or in the case of 
pCR-Blunt cloning, One Shot® TOP10 (Invitrogen) were thawed on ice. The 
plasmid or the product of a ligation reaction was added to the competent cells, 
mixed, and kept on ice for 30 minutes. The cells were subject to a heat shock  
(42°C, 45 seconds) and then transferred to 900μl of room temperature SOC media 
Plasmid name Source 
pCDNA4TO-NTAP 
Prof. Ian Good fellow (University of 
Cambridge) 
pvIRF2-NTAP vIRF2 cloned into pCDNA4TO-NTAP 
pvIRF4-NTAP vIRF4 cloned into pCDNA4TO-NTAP 
pcDNA4/HisMax Invitrogen    
pvIRF2-His/Max vIRF2 cloned into pcDNA4/HisMax 
pvIRF4-His/Max vIRF2 cloned into pcDNA4/HisMax 
CBP-GFP 
Provided by A.Turnell (University of 
Birmingham) 
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(Invitrogen). This mixture was then incubated (1 hour, 37˚C). Bacteria were then 
plated on agar contained 100μg/ml ampicillin or 50μg/ml Kanomycin (dependent 
on the plasmids) to select transformed cells. The chemically competent cells and 
vectors used are shown in Table 2.13. 
 
2.10.3. Small-scale preparation of plasmid DNA: Mini prep 
A single bacterial colony from an agar plate was selected with a sterile loop and 
used to inoculate 3ml of LB medium containing 100μg/ml of ampicillin or 50μg/ml 
Kanomycin. The cells were cultured at 37˚C overnight in a shaking incubator 
(150rpm). The following day the cells were pelleted by centrifugation (5 minutes 
16,000g) and DNA was extracted from the resultant pellet using a QIAprep spin 
miniprep kit (Qiagen) according to the manufacturer’s instructions.  
 
2.10.4. Large-scale preparation of plasmid DNA: Maxi Prep 
For bulk preparation of DNA, a 3ml starter culture of LB media with antibiotics was 
inoculated with a single colony and grown overnight at 37˚C in a shaking incubator 
(150rpm). 250ml of L-broth (containing 100μg/ml of ampicillin) was inoculated with 
1ml of the starter culture and grown overnight at 37°C in a shaking incubator 
(150rpm). The cells were centrifuged (15 minutes 5000g) and the resultant pellets 





CHAPTER 2  Materials and methods 
~ 73 ~ 
 
Table 2.13: Chemically Competent cells and cloning vectors used in this 
study 
Product name Source 
One Shot® MAX Efficiency® DH5α Invitrogen (12297-016) 
One Shot® TOP10 Chemically Competent 
E. coli  
Invitrogen (C4040-10) 
pCR®-Blunt vector Invitrogen  
pCDNA4TO-NTAP 
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Table 2.14: Primers used for cloning. 
Primers were ordered from Invitrogen 
Primer Name Primer Sequence 5’-3’ 
vIRF4 Forward BCBL1 
vIRF4 Reverse BCBL1 
ATCGGTTTCTGTGTCGGACCATG 
GGACTACAAGATTACATCCGGTTTT 
vIRF4 Forward Acc65I NTAP-PCR blunt 
vIRF4 Reverse XbaI NTAP-PCR blunt 
GGTTTCGGGTACCACCATGCCTC 
CGGTTTTCTAGATCACATATATG 
vIRF2 forward with BsIWI 
vIRF2 reverse with XbaI 
ATCTTACGTACGATGCCTCGCTACA 
CCACTGTGCTGTCTAGATGCAGGCG 
vIRF4 Forward HisMaxA-BamHI 
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2.11. PCR and qRT-PCR 
For both PCR and qRT-PCR assays, RNA, extracted from cells was used as a 
template for cDNA synthesis. This cDNA was then used in subsequent PCR or 
qRT-PCR reactions. Table 2.15 provides details of the reagents used for PCR and 
qRT-PCR techniques throughout this thesis.  
 
Table 2.15: Reagents used for PCR and qRT-PCR techniques 
Product name Source 
RNeasy mini kit  Qiagen 
GoTaq DNA Polymerase Promega (M3171) 
Velocity DNA Polymerase Bioline (BIO-21098) 
RNase-Free DNase Promega (M6101) 
Random primers Promega (C1181) 
dNTP mix Invitrogen (10297018) 
Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV-RT) 
Invitrogen (28025013) 
RNAseOUT Invitrogen (10777019) 
DEPC treated water Ambion (AM9906) 
VIC labelled huGAPDH primer/probe set  Applied Biosystems (4310884E) 
MicroAmp Optical 96 well PCR plates  Applied Biosystems (403012) 
 
2.11.1. RNA extraction  
RNA was extracted from cell pellets using the RNeasy mini kit (Qiagen), according 
to the kit instructions. The resultant RNA was quantified and DNase treated using 
RNase-Free DNase (promega), according to the manufacturer’s instructions. The 
samples were then subject to cDNA synthesis, or stored at -80oC for future 
experiments.   
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2.11.2. Complementary DNA (cDNA) synthesis 
For each sample, cDNA synthesis was performed by mixing 500ng of the 
extracted RNA, with 50ng of random primers and 1ul of 10mM dNTP mix in a 
volume made up to 11µl with sterile distilled water. This was heated (5 minutes, 
65°C) followed by a quick chill on ice. To each sample, 4ul of 5X First-Strand 
Buffer and 2µl of 0.1 M DTT (part of the M-MLV-RT kit, Invitrogen) was added 
along with 1 unit of RNAseOUT, to minimise degradation of the RNA. The 
contents were mixed and incubated (2 minutes, 37°C) followed by the addition of 
200U of M-MLV RT. Samples were incubated (10 minutes, 25°C), and then further 
incubated (50 minutes, 37°C). Inactivation of the reaction was achieved through 
heating at 70°C for 15 minutes. 80µl of DEPC treated water was added to the 
resultant cDNA and it was stored at -80oC until used as a template for 
amplification in PCR or qPCR experiments. 
 
2.11.3. Polymerase chain reaction (PCR) 
PCR reactions were carried out using GoTaq DNA Polymerase (promega), except 
when cloning, where velocity DNA polymerase (Bioline) was used. In sterile PCR 
tubes, the desired amount of template cDNA was mixed with 10µl of 5x GoTaq 
Reaction Buffer 1, 1µl of dNTPs (10mM), 1µl of forward primer (200ng/ul), 1µl of 
reverse primer (200ng/ul) and 0.5µl of GoTaq DNA Polymerase and made up to 
50ul with DEPC treated water. The tubes were spun (5 seconds) in a 
microcentrifuge and PCRs were performed as indicated in  
Table 2.16. 
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Table 2.16: PCR protocol 
Step Temperature Time Number of cycles 
Initial 
Denaturation 
95°C 2 minutes 1 cycle 








25–35 cycles (from Denaturation 
to extension) 
Final Extension 72°C 5 minutes 1 cycle 
Soak 4°C Indefinite 1 cycle 
 




Forward:5’- GCATCGCGAAGAAGAATAGG -3‘ 
Reverse: 5’- TGGTAAAATGGGGCAAGGTA-3’ 
vIRF4 
Forward:5’- GGGATGGTGGCCTCAGGGCG  -3‘ 
Reverse: 5’- CTAGCACATTGGCCGCTTTG-3’ 
 
2.11.4. Agarose gel electrophoresis 
Agarose (Sigma) was dissolved in a solution of 1 x Tris/Boric EDTA (TBE) using a 
microwave, resulting in a final concentration of 0.8-2.0% (w/v) depending on the 
size of fragments to be separated. Ethidium bromide was added to a final 
concentration of 0.5μg/ml prior to pouring into a Mini Sub Gel GT Electrophoresis 
Tank (BioRad). DNA samples were mixed with loading buffer (at a ratio of 5:1) and 
loaded on the gel. The gel was run at 50-80V (dependent on gel percentage), for a 
time sufficient to separate desired bands, in 1 x TBE. DNA bands were visualised 
with a UV light box.  
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Table 2.18: Solutions for Agarose gel 
Solution Composition/Source 
Agarose Sigma 
1 x Tris/Boric EDTA (TBE) 
45mM Tris HCl, 45mM orthoboric acid and 1mM 
EDTA, pH 8.0 
Loading buffer 
25mg Bromophenol Blue, 1.5g Ficoll 400, 10ml 
sterile distilled water 
 
 
2.11.5. Real time quantitative PCR (qPCR) 
qPCR was performed on cDNA generated as described in section 2.11.2. 
Primer/probe sets for vIRF2 and vIRF4 genes were designed to span intron-exon 
boundaries to ensure mRNA specific amplification (Table 2.19). Primers were 
ordered from Invitrogen, while FAM labelled probes were ordered from Alta 
Bioscience. As an internal control for each reaction, a VIC labelled human GAPDH 
primer/probe set was used, to which data was normalised. Reactions were set up 
using the values shown in Table 2.20. A master mix was generated based on the 
number of samples to be analysed and 20µl of this was pipetted into the wells of a 
96 well PCR plate. 5µl of cDNA template was then added separately, for each 
sample in the 96well plate. Negative controls (no template and samples 
synthesised in the absence of reverse transcriptase) were also included for each 
experiment. Samples were analysed on an Applied Biosystems 7500 Sequence 
Detection System using the following conditions 95°C for 10 minutes, followed by 
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Table 2.19: The sequences of primer and probes used to quantify levels of 
mRNA by qPCR 
Gene Sequence/Source 
vIRF2  
Forward:5’- TCAGCTGCGGAGGATGTTG -3‘ 
Reverse: 5’- CCATGATGACAAACACAGAGAAAAG -3’ 
FAM-labelled  Probe:5’- CGGCCTCCCTCTGGGCTTTTTTTC -3’  
vIRF4 
Forward:5’- GCCCCTGCCTCCTCGTA  -3‘ 
Reverse: 5’- TGTCCCCCCCAATGCA -3’ 
FAM-labelled Probe:5’- CTTTGTTCTCTAGTGTCACTGCGTCGCG -3’ 
GAPDH Applied Biosystems (4310884E ), VIC-labelled   
 
Table 2.20: qPCR reaction mix. The volumes used for 1 sample are given.  
Component Volume 
TaqMan Universal Mastermix x2 
Applied Biosystems (4324018) 
12.5ul 
Forward primer 2.5ul 
Reverse primer 2.5ul 
FAM-labelled probe 1ul 
VIC-labelled GAPDH primers/probe 
Applied Biosystems (4310884E) 
0.5ul 
DEPEC treated water 1ul 
cDNA template ( added to plate) 5ul 
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2.12. Polysome profiling experiments 
The following methods were performed by Dr Nicolas Locker (University of 
Surrey). The following details how he performed the experiments.  
 
2.12.1. Sucrose Density Gradient Centrifugation  
Sucrose density gradient centrifugation enables the separation of small ribosomes 
through centrifuging cell lysates in a sucrose gradient at high centrifugal force. 
Components come to rest when their density is equivalent to that of the 
surrounding sucrose, allowing cellular components to be analysed according to 
density. 10X TMN buffer was diluted 1 in 10 to produce 1X TMN buffer. 1X TMN 
buffer was then used to produce sucrose solutions at 10%, 18%, 26%, 34%, 42%, 
50% and 60% sucrose in 20ml 1X TMN. To each of these, 1mg/ml cyclohexamide 
was added. Sucrose solutions were layered in ultracentrifuge tubes (Beckman 
Coulter Inc., Brea, CA, USA) at a volume of 1.6ml for each concentration by 
deposition and subsequent freezing of each layer at -80ºC, with the most dense 
layer (60% sucrose) at the bottom and the least dense (10%) at the top. Gradients 
were frozen at -20ºC overnight and thawed the morning before ultracentrifugation 
to allow layers to equilibrate. Upon thawing, 500µl of cytoplasmic cell lysates were 
added to the top of the thawed gradients and ultracentrifuged (150,000g, 2 hours, 
4ºC). 
 
2.12.2. Polysome Profiling 
Polysome profiling is the spectrophotometric analysis of lysates ultracentrifuged 
through a sucrose gradient at 254nm, an absorbance wavelength of RNA. Peaks 
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at higher densities are indicative of polysomes, which are strands of mRNA being 
translated by multiple ribosomes. Peaks at lower densities are indicative of rRNA 
in singular 40S and 60S subunits, as well as free RNAs. Previously 
ultracentrifuged lysates were run through a density gradient fractionator (Teledyne 
ISCO, Lincoln, NE, USA), using 70% sucrose with 0.1% bromophenol blue as a 
dense chase solution (dispensed using a syringe pump (kd Scientific 
Inc.,Holliston, MA, USA)) to displace the gradient upwards. Absorbance was 
measured using PeakTrak software (Teledyne ISCO). 
 




10X TMN buffer 
3M NaCl, 150mM MgCl2, 150mM Tris-HCl at pH 7.5, 
10mg.ml-1 heparin 
Cyclohexamide Sigma-Aldrich 
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2.13. EMCV plaque assay 
Plaque assays were used to quantify titres of Encephalomyocarditis virus (EMCV), 
which had been grown in rIFNα pre-treated EV-NTAP, vIRF2-NTAP or vIRF4-
NTAP cell lines.   
 




DMEM containing 1% penicillin-streptomycin 
Overlay 
medium 
Overlay medium (10% v/v Minimum Essential Medium (MEM) 
with  10X Earl’s salt, 1% v/v L-glutamine, 2% v/v foetal calf 
serum heat inactivated, 1% v/v penicillin/streptomycin) 
Crystal violet 0.5g crystal violet, 20ml ethanol, 0.9gNaCl, 100ml 40% 
formaldehyde, 880ml dH20 
 
2.13.1. Infection of cells with EMCV 
The EV-NTAP, vIRF2-NTAP or vIRF4-NTAP cell lines were plated into 6-well 
plates at a density of 5 x 105 cells per well and left overnight to adhere in a culture 
medium of DMEM complete with 5μg/mL Blasticidin and 200µg/ml zeocin. After 24 
hours, the medium was replaced with DMEM complete, supplemented again with 
with 5μg/ml Blasticidin and 200µg/ml Zeocin but also with 0.125μg/ml 
Tetracycline, to induce the expression of the desired proteins. 24 hours later, 
rIFNα (final concentration of 300U /ml), or medium without rIFNα was added to the 
cells. After a further 24 hours, culture medium was carefully removed and the cells 
were infected with the EMCV virus at a multiplicity of infection (MOI) of 0.1 in 500µl 
of culture medium (1 hour at 37oC). The medium was removed from the cells, 
which were then washed twice with sterile PBS, and left in fresh culture medium 
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with or without rIFNα (300U/ml). 24 hours later the supernatant was harvested in 
order to quantify EMCV by plaque assay.   
 
2.13.2. Plaque assay 
To determine the titre of the EMCV virus in the supernatants from EMCV infected 
EV-NTAP, vIRF2-NTAP or vIRF4-NTAP cell lines, plaque assays were performed 
using L929 cells. L929 cells were plated in 12-well plates in DMEM complete 
medium and grown until a monolayer of cells formed. The supernatants from 
EMCV infected EV-NTAP, vIRF2-NTAP or vIRF4-NTAP cells were diluted from 10-
1 to 10-7 in plaque assay medium (Table 2.22). 250 µl of each of each of these 
dilutions was then used to infect the L929 cells by carefully pipetting the volume 
onto the cells and incubating (30 minutes, 37oC). Overlay medium (Table 2.22) 
was mixed with molten 2% agar, to give a final agar concentration of 0.6%. 1ml of 
this mixture was then added to each well of infected L929 cells. The plates were 
left at room temperature for about 30 minutes until the overlay medium had set 
and then the L929 cells were incubated at 37oC for between 72-96 hours, so that 
plaques could form.  
 
2.13.3. Counting plaques 
To visualise the plaques, 1ml of crystal violet was added to each well and the 
plates were incubated (10 minutes, room temperature) with gentle agitation. To 
remove the overlay gel the plates were carefully washed in tap water. The Plaques 
were easily observed at the bottom of each well. To calculate the titre of virus in 
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plaque forming units per ml (PFU/ml), the number of plaques per well was 
multiplied by 4 (to account for the 250ul of virus dilution used to infect each well, 
giving the titre per ml). This value was then multiplied by the dilution factor of the 
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3.1. Introduction to chapter 3 
The aim of this thesis is to understand how a cancer-causing virus regulates the 
type I interferon system.  My studies centre on the function of the KSHV-encoded 
vIRF2 and vIRF4 proteins. In this chapter, the effects of vIRF2 and vIRF4 on the 
type I IFN signalling are examined.  
 
Type I IFN signalling is a key mechanism through which host cells activate an 
initial antiviral response to invading viruses. The outcome is reduced virus 
replication and dissemination throughout the host, limiting possible disease 
development. An initial signalling pathway, the IFN production pathway, is invoked 
when virus-associated features are detected by the cell, leading to production of 
type I IFNs. This pathway leads to the nuclear translocation of NFκB and IRF3 
from the cytoplasm and the formation of the IFNβ enhanceosome, consisting of 
NFκB, IRF3 and ATF-2/c-Jun. The IFNβ enhanceosome, together with the 
recruited CBP/p300 co-activator proteins, activates the transcription of the IFNβ 
gene, which leads to the production of this cytokine (see sections 1.4.2 and 1.4.6). 
Type I IFNs are released from the cell and then activate JAK-STAT.  
 
Type I IFNs bind to their cognate receptors and induce another signalling 
pathway, the JAK-STAT pathway, in both an autocrine and paracrine fashion. This 
response is orchestrated by a heterotrimeric complex the ISGF3, formed from 
IRF9 and activated STAT1 and STAT2.  ISGF3 transactivates ISGs, by binding to 
CHAPTER 3                           The KSHV proteins, vIRF2 and vIRF4, downregulate IFN signalling  
 
 
~ 87 ~ 
 
the ISREs in the promoters of these genes (see section 1.4.8). The activation of 
these genes collectively brings about an antiviral response (see section 1.4.10). 
 
Both the IFN production pathway and the JAK-STAT signalling pathway are 
heavily targeted by proteins encoded by a wide array of viruses (see sections 
1.4.7 and 1.4.9). KSHV is unique among human viruses in that it encodes a family 
of four vIRFs which share some homology to cellular IRFs (Cunningham et al., 
2003). As discussed in chapter 1, vIRF1, vIRF2 and vIRF3 have been shown to 
modulate type I IFN signalling.   
 
vIRF1 downregulates the activation of the IFNβ promoter (Burysek et al., 1999a). 
It is thought to act though its association with CBP/p300, by inhibiting the 
transactivation of CBP and the histone acetyltransferase activity of p300 (Lin et al., 
2001). CBP and p300 are components of the CBP/p300-IRF3 complex, which is 
vital for the activation of the IFNβ promoter. vIRF1 is also able to downregulate 
IFNβ induced JAK-STAT signalling (Gao et al., 1997). 
 
vIRF2 has been shown, by our group, to downregulate the activation of the IFNβ 
promoter by accelerating the turnover of IRF3 (a key player in IFNβ promoter 
activation)  in a mechanism involving caspase-3  (Areste et al., 2009, Fuld et al., 
2006). vIRF2 is also able inhibit ISRE-containing promoter activation, following 
IFN activation. It does this by targeting pSTAT1, a component of the ISGF3 
complex, but the precise mechanism for this is unknown (Fuld et al., 2006, 
Mutocheluh et al., 2011).  
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vIRF3 is able to interact with either the DNA binding domain or the central 
association domain of IRF7, leading to a suppression in IFNα production (Joo et 
al., 2007). It can also target IRF5 leading to an inhibition of type I IFN, and ISRE 
promoter activation (Takaoka et al., 2005, Wies et al., 2009). 
 
There is only one published study that has investigated vIRF4 function with 
respect to IFN signalling in which the authors concluded that this KSHV protein 
does not inhibit the activation of the IFNβ promoter in response to Sendai Virus 
infection (Kanno et al., 2006). The effect of vIRF4 on IFN stimulated ISRE-
containing promoter activation has not been published. Since vIRF4 shares 
homology with cellular IRFs, and since the other three vIRFs can downregulate 
type I IFN signalling, the hypothesis that vIRF4 can modulate type I IFN signalling 
was investigated further.  
 
The aims of this chapter are to: 
1) Confirm that vIRF2 can inhibit both activation of the IFNβ promoter and 
activation of ISRE-containing promoters 
2) Reasses the effect of vIRF4 on IFN gene activation by examining activation 
of the IFNβ promoter 
3) Investigate the effect of vIRF4 on JAK-STAT signalling and therefore ISRE-
containing promoter activation 
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This chapter details how the vIRF4 gene was obtained from BCBL1, a cell line 
naturally infected with KSHV, and subsequently cloned into the pCDNA4TO-NTAP 
vector, resulting in the pvIRF4-NTAP expression vector. 
 
This expression vector was used in reporter studies to investigate the effect of 
vIRF4 on the IFN production pathway (through examining activation of the IFNβ 
promoter) and the JAK-STAT signalling pathway (through examining activation of 
an ISRE-containing promoter). Since previous work in our laboratory has shown 
that vIRF2 downregulates the IFN production pathway (Fuld et al., 2006, Areste et 
al., 2009)  -and the IFN signalling pathway (Fuld et al., 2006, Mutocheluh et al., 
2011), vIRF2 was used as a positive control throughout experiments. 
 
To study in detail the effects of vIRF2 on IFN signalling, the effect of vIRF2 on the 
IFN production pathway was further investigated through DNA-binding ELISAs, 
which measured the activation of IRF3. The aim was to identify if vIRF2 could 
decrease IRF3 activity. Finally, the effects of truncated vIRF2 proteins on the IFN 
production and the IFN signalling pathways were also examined through reporter 
assays. These experiments revealed which regions of the vIRF2 protein could 
downregulate IFN signalling.  
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3.2. Cloning of vIRF4 cDNA, obtained from BCBL1 cells, and cloning itinto 
the pCR-Blunt vector 
In order to perform in vitro functional studies with vIRF4, the vIRF4 gene was 
obtained from BCBL1 cells and cloned into the pCR-Blunt cloning vector. This 
vector was subsequently used to clone vIRF4 into other expression vectors 
(described in later chapters). 
 
Firstly, vIRF4 mDNA was obtained from lytically infected BCBL1 cells, in order to 
amplify the spliced vIRF4 gene (Figure 3.1). BCBL1 is a PEL cell line that is 
latently infected with KSHV but is EBV negative (Renne et al., 1996). To induce 
expression of the lytic vIRF4 gene, KSHV was re-activated into lytic cycle by PMA 
treatment for 48 hours before harvesting the cells. In order to verify that lytic 
replication had been induced, a portion of the harvested cells were set aside to 
measure expression of the KSHV lytic switch protein, RTA, through western blot 
analysis (Figure 3.2 A).  RNA was extracted from the remaining cell pellet and 
subject to RT-PCR using primers specific for vIRF4 (Table 2.14, ‘vIRF4 Forward 
BCBL1’ and ‘vIRF4 Reverse BCBL1’). Following gel electrophoresis, a PCR 
product corresponding to the expected size of the spliced vIRF4 gene (2736bp) 
was observed (Figure 3.2B). The vIRF4 band was excised, purified and ligated 
with pCR-Blunt. This ligation reaction was then transformed into One Shot TOP10 
Chemically Competent E. coli (Invitrogen). The identity of the pCR-Blunt-vIRF4 
construct was confirmed by restriction digestion with EcoRI (Figure 3.2C) and 
sequencing. 
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Figure 3.1: Illustration of genomic vIRF4 and vIRF4 mRNA 
(A) An illustration of the genomic vIRF4 from accession number NC_009333. The 
numbers refer to the position within the KSHV genome. (B) The spliced vIRF4 
mRNA obtained from BCBL1 cells and cloned into the pCR-Blunt vector. The 
numbers refer to base pairs along the vIRF4 spliced gene. 
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Figure 3.2: Cloning the vIRF4 gene into the pCR-Blunt cloning vector.  
(A) Detection of the KSHV lytic switch protein, RTA. Lysate (20μg), from BCBL1 
cells which were incubated with (+) or without (-) PMA (20ng/ml for 48 hours), was 
analysed by western blot to detect RTA. Primary antibodies: anti-ORF50 
(detecting RTA) and anti-β-actin. Secondary antibodies: anti-rabbit IRDye800LT-
conjugated secondary antibody and anti-mouse IRDye680LT-conjugated 
secondary antibody. The bands were visualised using the ‘Odyssey’ imaging 
system (LI-COR). (B) Amplification of the vIRF4 spliced gene from PMA-treated 
BCBL1 cells. RNA, extracted from PMA-treated BCBL1 cells was subject to 
reverse transcription. The resultant cDNA was amplified with vIRF4 primers (Table 
2.14, vIRF4 Forward BCBL1’ and ‘vIRF4 Reverse BCBL1’). The PCR product was 
separated by agarose gel electrophoresis. The lanes shown were from the same 
gel, but were not contiguous, hence the gap. (C) Confirmation that pCR-Blunt-
vIRF4 contains a fragment of the same size as that expected for vIRF4 (2736bp). 
pCR-Blunt, transformed with the PCR product from Figure 3.2B was digested with 
EcoRI and visualised following agarose gel electrophoresis. The labelled bands 
correspond in size to pCR-Blunt and the vIRF4 gene. The lanes shown were from 
the same gel, but were not contiguous, hence the gap M, marker. 
  
CHAPTER 3                           The KSHV proteins, vIRF2 and vIRF4, downregulate IFN signalling  
 
 
~ 93 ~ 
 
3.3. Cloning the vIRF4 gene into the pCDNA4TO-NTAP vector 
In order to express the vIRF4 protein in eukaryotic cells, the vIRF4 gene was 
cloned into the pCDNA4TO-NTAP expression vector. This vector contains a 
tandem affinity purification (TAP) tag which facilitates the tandem purification of 
proteins containing this tag, along with their binding partners. NTAP-vIRF4 could 
therefore aid investigations into vIRF4 binding partners as well as enabling vIRF4 
functional studies to be performed. An overview of the cloning scheme is 
illustrated in Figure 3.3. To enable the cloning of vIRF4 into the pCDNA4TO-NTAP 
vector, specific PCR primers (Table 2.14 ‘vIRF4 Forward Acc65I NTAP-PCR blunt’ 
and ‘vIRF4 Reverse XbaI NTAP-PCR blunt’) containing appropriate restriction 
sites (XbaI and Acc65I) were used to amplify the vIRF4 gene from the pCR-Blunt-
vIRF4 template (Figure 3.3B). The fragment produced was ligated into pCR-Blunt 
(Figure 3.3C). The resultant pCR-Blunt-vIRF4 (XbaI and Acc65I) (Figure 3.3D) 
was confirmed by restriction digestion (Figure 3.4). The vIRF4 gene was excised, 
via enzymatic digestion from pCR-Blunt-vIRF4 (XbaI and Acc65I) with XbaI and 
Acc65I (Figure 3.3E). This fragment was ligated into the pCDNA4TO-NTAP vector 
which had been digested with XbaI and BsiWI (Figure 3.3F). Acc65I cleaves to 
leave ends compatible with BsiWI. The resultant vIRF4-NTAP construct (Figure 
3.3G) was confirmed by sequencing.  
 
3.4. Transient expression of vIRF4 in 293 cells 
To ensure the vIRF4-NTAP expression vector expressed the vIRF4-NTAP protein 
in 293 cells a transfection titration was performed. 293 cells were transfected with 
increasing amounts of NTAP-vIRF4 plasmid from 0-1000ng. Following 16 hours 
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incubation the cells were harvested. The NTAP-tag contains protein G that will 
bind any immunoglobulin. In this experiment, the primary β-actin and secondary 
antibody bound to both β-actin, and the NTAP-tag. However, because the bands 
were separated by SDS gel electrophoresis, they were distinguished based on 
their size. Western blot analysis showed, as expected, that as the amount of 
vIRF4-NTAP plasmid transfected increases, the expression level of vIRF4-NTAP 
also increases (Figure 3.5). This experiment confirmed that the vector could be 
used to sucessfully express vIRF4 in 293 cells.  
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Figure 3.3: Cloning the vIRF4 gene into the pCDNATO-NTAP vector.  
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Figure 3.4: Electrophoretic analysis confirming that pCR-Blunt-vIRF4(XbaI 
and Acc65I) contains a fragment equal in size to that of vIRF4 with XbaI and 
Acc65I restriction sites.  
The pCR-Blunt-vIRF4 vector was digested with EcoRI and analysed by gel 
electrophoresis. Bands were observed at around 2700-2800kb and around 
3500kb corresponding to vIRF4 with XbaI and Acc65I and pCR-Blunt. M, marker.  
 
 
Figure 3.5: vIRF4 expressed in 293 cells transfected with the vIRF4-NTAP 
vector.   
293 cells were transfected with the vIRF4-NTAP vector (0-1000ng, as indicated in 
figure), and harvested 16 hours later. The lysate (20μg) was analysed by western 
blot to detect the NTAP-tag. Primary antibody: anti-β-actin. Secondary antibody: 
anti-mouse IRDye 680LT-conjugated secondary antibody. The NTAP tagged 
vIRF4 (vIRF4-NTAP) and the TAP tag produced from EV-NTAP transfected cells 
are indicated (NTAP). β-actin is also indicated. The anti-mouse IRDye 680LT-
conjugated secondary antibody was sufficient to detect the NTAP-tag as it 
contains protein G. As a control for the specificity of these NTAP-containing 
bands, un-transfected cell lysate was also analysed (Lane 1). The bands were 
visualised using the ‘Odyssey’ imaging system (LI-COR).  
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3.5. Optimisation of dual luciferase reporter assays to measure IFNβ and 
ISRE promoter activities 
The dual luciferase assay (DLA) reporter system (see section 2.2) enabled 
examination into the effect of vIRF2 and vIRF4 on the IFN production and JAK-
STAT signalling pathways. The activity of the IFN production pathway was 
measured using a p125-luc reporter plasmid (see Table 2.4), containing the IFNβ 
promoter. The JAK-STAT pathway was measured with the pISRE-luc reporter 
plasmid (see Table 2.4), containing an ISRE promoter. DLAs make dual 
measurements of both firefly (Photinus pyralis) and Renilla (Renilla reniformis) 
luciferase activities from the same sample. The firefly luciferase measurement, 
expressed from the promoter to be studied (IFNβ or ISRE element), relates to the 
activity of the promoter of interest. The constitutively expressed Renilla luciferase 
signal normalises changes in luminescence due to factors other than the 
transcriptional control being studied, for example transfection efficiency between 
samples. In order to assay the role of vIRF2 and vIRF4 in modulating IFNβ and 
ISRE promoters, DLA conditions were optimised. 
 
DLAs were performed using poly(I:C) to activate the IFNβ promoter in order to 
assess its activity. poly(I:C) is a synthetic dsRNA which interacts with TLR3 and 
triggers activation of the IFN signalling pathway. The active form of IRF3 
translocates into the nucleus and activates the IFNβ promoter. Hence, transfection 
of poly(I:C) leads to the activation the IFNβ promoter. Previous work in our group 
has determined the optimal concentrations and duration of poly(I:C) treatment on 
cells (Areste et al., 2009, Fuld et al., 2006).  
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rIFNα was used to activate the ISRE-containing promoter in order to assess its 
activity. IFN binds to receptors (IFNAR1 and IFNAR2) on the cell surface, which 
results in activation of the JAK-STAT signalling pathway. This pathway drives the 
activation of the ISRE promoter. To determine the conditions for optimum 
activation of the ISRE reporter plasmid, an interferon titration and a time course 
were performed separately on 293 cells. Normalised luciferase activity, and hence 
ISRE-containing promoter activity, peaked after 16 hours of rIFNα treatment 
(Figure 3.6A, row 5) and with 300IU/ml (Figure 3.6B, row 6).  
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Figure 3.6: ISRE-luc expression peaked 16 hours post rIFNα treatment and 
following treatment with 300 IU/ml rIFNα.  
(A) 293 cells were co-transfected with pISRE-luc (250ng) and the constitutively 
expressing Renilla luciferase plasmid (pRLSV40-luc, 1ng). Following 5 hours 
incubation, the cells were treated with rIFNα (300IU/ml) for different durations of 
time (shown in figure), before being harvested and subject to DLA. pRLSV40-luc 
was added as an internal control to which firefly luciferase levels were normalised. 
The data has been normalised to give fold increase compared to the un-stimulated 
samples (no rIFN). Each time point represents the mean  SEM of three 
independent experiments, which were each assayed in duplicate. For results from 
individual experiments see Figure 9.1. (B) The experiment was performed as 
described in A, except that the cells were treated with different amount of rIFNα 
(shown in figure) for 16 hours and then harvested for DLA. Again, luciferase levels 
were normalised to Renilla levels, and the data have been normalised to give fold 
increase compares to the un-stimulated (no rIFN) samples. Each point 
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represents the mean  SEM of three independent experiments which were 
assayed in duplicate. For results from individual experiments see Figure 9.2. 
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3.6. Investigating the effect of vIRF2 upon early and late IFN signalling 
As discussed in chapter 1, the KSHV vIRF2 protein has been shown to inhibit both 
the IFN production pathway and the JAK-STAT signalling pathway. This thesis 
aims to further examine the molecular mechanism by which vIRF2 causes these 
effects. Since vIRF2 has been previously shown to inhibit both the IFN production 
and JAK-STAT signalling pathways, it was also used as a positive control for 
experiments with vIRF4. Section 3.5 described the optimum conditions for 
assaying IFNβ and ISRE activity in DLAs. To confirm the inhibitory effect of vIRF2 
on both the IFNβ promoter and an ISRE-containing promoter IFNβ and ISRE 
activities were measured in the context of vIRF2 expression.  
 
3.6.1. Inhibition of poly(I:C)-driven activation of the IFNβ promoter by vIRF2 
protein expression 
To confirm the effect of vIRF2 on the transactivation of the IFNβ promoter, a 
reporter plasmid containing this promoter (p125-luc) was co-transfected into 293 
cells with either the constitutively expressing vIRF2 plasmid (vIRF2-His/Max), or 
the corresponding empty vector (pcDNA4His/Max). 24 hours later poly(I:C) was 
transfected into the cells to activate IRF3. As expected firefly luciferase expression 
and therefore the IFNβ promoter transactivation was significantly inhibited (up to 
75%) in the vIRF2 transfected cells compared to cells transfected with the empty 
vector control (Figure 3.7, compare rows 3 and 4). 
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3.6.2. Inhibition of rIFNα-driven expression of pISRE-luc by vIRF2 protein 
expression 
To confirm the effect of vIRF2 on IFN signalling, reporter gene studies were 
conducted with the pISRE-luc vector. 293 cells were co-transfected with pISRE-luc 
and either the vIRF2 expression vector (vIRF2-His/Max) or corresponding empty 
vector (pcDNA4His/Max), in the presence or absence of rIFNα (300IU/ml). Under 
these conditions, ISRE-containing promoter transactivation was significantly 
inhibited by up to 88% in the vIRF2 transfected cells compared to the empty vector 
control as measured by firefly luciferase expression (Figure 3.8, compare rows 3 
and 4).  
 
3.6.3. vIRF2 inhibits IRF3 activity  
Section 3.6.1 showed that vIRF2 inhibited poly(I:C) driven activation of the IFNβ 
promoter. Recent data from our group has shown that vIRF2 mediates IRF3 
degradation by a mechanism involving caspase-3 (Areste et al., 2009). To confirm 
the effect of vIRF2 on the early IFN pathway and to investigate if vIRF2 can 
reduce IRF3 activity, IRF3 activity was quantified in the presence and absence of 
vIRF2 by IRF3 binding assays. An IRF3 TransAM kit (Active Motif) was used to 
quantify levels of active IRF3 in cells transfected with the vIRF2-expression 
plasmid, compared to those transfected with the corresponding EV (see section 
2.8 for method). The results show that vIRF2 decreased IRF3 activation 
significantly (up to 65%) when compared to the EV transfected cells (Figure 3.9, 
compare rows 2 and 3). 
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Figure 3.7: vIRF2 inhibits the poly(I:C) activated IFNβ promoter.  
293 cells were transfected with p125-luc (containing the full length IFNβ promoter; 
250ng) and 500ng of either the vIRF2-His/Max expression plasmid or the empty 
vector pcDNA4His/Max plasmid. 24 hours post-transfection, the cells were 
transfected with poly(I:C) (10µg/ml). After 20 hours the cells were harvested and 
subject to DLA. For all results, the pRLSV40 plasmid (1ng) constitutively 
expressing Renilla luciferase was added as an internal control to which firefly 
luciferase levels were normalised. The data were normalised to give fold increase 
compared to cells transfected with empty vector minus poly(I:C) stimulation (row 
1). The data represent the mean and the SEM of three independent experiments 
that were each assayed in duplicate.  *** = p<0.001 ANOVA followed by a Dunnett 
post hoc test compared to empty vector plus poly(I:C) (row 2). For results from 
individual experiments see Figure 9.3 (Appendix I)  
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Figure 3.8: vIRF2 inhibits the rIFNα activated ISRE-containing promoter.  
293 cells were transfected with pISRE-luc (250ng) and 500ng of either the vIRF2-
His/Max expression plasmid or the empty vector pcDNA4His/Max plasmid. 5 h 
post-transfection, the cells were treated with rIFNα (300 IU/ml) and harvested 16 h 
later. For all results, the pRLSV40 plasmid (1ng) constitutively expressing Renilla 
luciferase was transfected as an internal control to which firefly luciferase levels 
were normalised. The data were normalised to give fold increase compared to 
transfections with empty vector minus rIFNα stimulation (row 1). The data 
represent the mean and the SEM of three independent experiments which were 
each assayed in duplicate.  *** = p<0.001 ANOVA followed by a Dunnett post hoc 
test compared to empty vector plus rIFNα (row 2). For results from individual 
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Figure 3.9: vIRF2 decreases the activity of IRF3.  
IRF3 transcription factor activation was measured by TransAM assay. 293 cells 
were transfected with 500ng of either the vIRF2-His/Max expression plasmid or 
the empty vector pcDNA4His/Max plasmid. 24 hours post-transfection, the cells 
were transfected with poly(I:C) (10µg/ml). 20 hours later, the cells were lysed. 5µg 
of each sample was used in duplicate in the TransAM assay. The data were 
normalised to give fold increase compared to transfections with empty vector 
minus poly(I:C) stimulation (row 1). The data represent the mean and the SEM of 
three independent experiments which were each assayed in duplicate.  * = p<0.05 
ANOVA followed by a Dunnett post hoc test compared to empty vector plus 
poly(I:C) (row 2). For results from individual experiments see Figure 9.5.  
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3.7. Investigating the effect of vIRF4 upon early and late IFN signalling 
To investigate any possible inhibitory effects vIRF4 might have on IFNβ promoter 
activation and ISRE-containing promoter activation, the activities of these 
promoters were measured in the context of vIRF4 expression.  
 
3.7.1. vIRF4 does not inhibit poly(I:C)-driven activation of the IFNβ 
promoter in 293 cells. 
To examine the effect of vIRF4 on the transactivation of the full-length IFNβ 
promoter, and hence early IFN signalling, the IFNβ promoter reporter plasmid 
(p125-luc) was co-transfected with increasing amounts of the constitutively 
expressing vIRF4 plasmid (vIRF4-NTAP). The empty parental plasmid backbone, 
pCDNA4TO-NTAP, was added as a “stuffer” plasmid to equalize the amount of 
DNA in each transfection to 1000ng. After 24 hours, poly(I:C) was transfected to 
activate IRF3 and therefore the p125-luc reporter promoter. The results show that 
even with up to 1000ng of vIRF4-NTAP transfected into the cells, p125-luc activity, 
and therefore IFNβ promoter activity did not decrease (Figure 3.10, rows 7-14). 
Since vIRF2 inhibits poly(I:C)-driven activation of the IFNβ promoter (section 
3.6.1), it provided a positive control (Figure 3.10, compared rows 3 with 4). 
 
3.7.2. vIRF4 inhibits rIFNα-driven expression of pISRE-luc in 293 cells.   
To examine the effect of vIRF4 on JAK-STAT signalling, reporter gene studies 
were performed with the pISRE-luc vector. 293 cells were co-transfected with 
pISRE-luc and increasing amounts of the constitutively expressing vIRF4 plasmid 
(vIRF4-NTAP). The empty parental plasmid backbone, pCDNA4TO-NTAP, was 
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added as a “stuffer” plasmid to equalize the amount of DNA in each transfection to 
1000ng. 5 hours post transfection the cells were treated with rIFNα (300IU/ml), to 
activate the IFN-sensitive reporter promoter. Under these conditions, luciferase 
expression and therefore ISRE transactivation was inhibited in a manner that 
depended upon the amount of vIRF4-NTAP expression vector (Figure 3.11, rows 
7-14). ISRE transactivation was reduced by 51% in the presence of 1000ng of 
vIRF4-NTAP (Figure 3.11, row 14). Since vIRF2 can inhibit rIFN driven activation 
of the ISRE-containing promoter, the pvIRF2-His/Max or corresponding empty 
vector pcDNA4His/Max plasmid were transfected into 293 cells in parallel 
experiments and compared to show ISRE inhibition (Figure 3.11, compare rows 3 
and 4).  
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Figure 3.10: vIRF4 does not inhibit poly(I:C)-driven activation of the IFNβ 
promoter.   
Rows 5-14: 293 cells were transfected with p125-luc (250ng) and increasing 
amounts of the vIRF4-NTAP expression vector (rows 6 and 8-14). 24 hours post-
transfection, the cells were transfected with poly(I:C) (10µg/ml) and harvested 20 
hours later. The empty parental plasmid backbone, pCDNA4TO-NTAP was added 
as required to equilibrate all transfectants to 1000ng of DNA. The pRLSV40 
plasmid (1ng), was added as an internal control to which firefly luciferase levels 
were normalised. The results are shown as fold increase compared to the empty 
vector (pCDNA4TO-NTAP) transfections which were un-stimulated (row 5). The 
data represent the mean ± the SEM of the three independent experiments which 
were each assayed in duplicate. *** = p<0.001 ANOVA followed by a Dunnett post 
hoc test compared to empty vector (pCDNA4TO-NTAP) plus poly(I:C) (row 7). As 
a positive control for the assay, vIRF2 was used to show inhibition of 125-luc 
activity (rows 1-4, dark grey). To achieve this, the vIRF2-His/Max plasmid 
(1000ng) or pcDNA4His/Max plasmid (1000ng), were transfected into 293 cells 
with the p125-luc (250ng) pRLSV40 (1ng) plasmids. These results were 
normalised again using the pRLSV40 plasmid. These dark grey results are shown 
as fold increase compared to the empty vector (pcDNA4His/Max) transfections 
which were un-stimulated with poly(I:C) (row 1). The data represent the mean ± 
the SEM of the three independent experiments which were each assayed in 
duplicate. *** = p<0.001 ANOVA followed by a Dunnett post hoc test compared to 
empty vector (pcDNA4His/Max) plus poly(I:C) (row 3). For results from individual 
experiments see Figure 9.6 (Appendix I).  
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Figure 3.11: vIRF4 inhibits rIFNα-driven expression of pISRE-luc.   
293 cells were transfected with pISRE-luc (250ng) and increasing amounts of the 
vIRF4-NTAP expression vector (rows 6 and 8-14). 5 hours post transfection, the 
cells were treated with rIFNα (300IU/ml) and harvested 16 hours later. The empty 
parental plasmid backbone, pCDNA4TO-NTAP was added as required to 
equilibrate all transfectants to 1000ng of DNA. The pRLSV40 plasmid (1ng), was 
added as an internal control to which firefly luciferase levels were normalised. The 
results are shown as fold increase compared to the empty vector (pCDNA4TO-
NTAP) transfections which were un-stimulated with rIFNα (row 5).The data 
represent the mean ± the SEM of the three independent experiments which were 
each assayed in duplicate. *** = p<0.001 ANOVA followed by a Dunnett post hoc 
test compared to empty vector (pCDNA4TO-NTAP) plus rIFNα (row 7). As a 
positive control for the assay, vIRF2 was used to show inhibition of ISRE-luc 
activity (rows 1-4, dark grey). To achieve this, the vIRF2-His/Max plasmid 
(1000ng) or pcDNA4His/Max plasmid (1000ng), were transfected into 293 cells 
with the pISRE-luc (250ng) pRLSV40 (1ng) plasmids. These results were 
normalised again using the pRLSV40 plasmid. The dark grey results are shown as 
fold increase compared to the empty vector (pcDNA4His/Max) transfections which 
were un-stimulated (row 1). The data represent the mean ± the SEM of the three 
independent experiments which were each assayed in duplicate. *** = p<0.001 
ANOVA followed by a Dunnett post hoc test compared to empty vector 
(pcDNA4His/Max) plus rIFNα (row 3). For results from individual experiments see 
Figure 9.7.  
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3.8. Examining the effect of vIRF2 truncated mutants on IFNβ-promoter and 
ISRE-containing promoter activity 
To identify the region of vIRF2 responsible for the inhibition of the on IFNβ-
promoter and ISRE-containing promoter, vIRF2 truncated mutants were used in 
DLAs. To produce these mutants, different regions of the vIRF2 gene were cloned 
into the pcDNA4His/Max expression vector (cloning performed by Christina 
Areste) (Figure 3.12A). The expression of each mutant in 293 cells was confirmed 
by western blot analysis (Figure 3.12B). 
 
3.8.1. The effect of vIRF2 truncated mutants on the IFNβ-promoter 
To examine the effect of vIRF2 mutants on the transactivation of the full-length 
IFNβ promoter, DLAs were performed, similar to section 3.6.1, with the full length 
IFNβ promoter reporter plasmid and with the different truncated forms of vIRF2, 
F1-F8, (Figure 3.13, rows 5-12). 24 hours later poly(I:C) was transfected into the 
cells to activate IRF3. The activities in these samples were compared to 
transfections containing the empty vector control and to those containing the full 
length vIRF2 expression plasmid (Figure 3.13, rows 3 and 4). The mutants that 
were able to significantly (p<0.001) inhibit the activity of the IFNβ promoter, 
compared to the empty vector, were F2 (by 42%) F3 (by 58%) F4 (by 40%) and F8 
(p<0.01) (by 34%) compared to the empty vector (Figure 3.13, rows 6, 7, 8 and 
12). Mutant F2 spans from amino acid residues 1-320, while F3 spans from amino 
acid residues 1-518 and mutant F4 spans from amino acid residues 118-680. The 
region in common between these three mutants is from amino acid residues 118-
320. This is the region which the F8 mutant spans.  
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3.8.2. The effect of vIRF2 truncated mutants on the ISRE-containing 
promoter 
To examine the effect of the vIRF2 mutants on the transactivation of the ISRE-
containing promoter, DLAs were performed, similar to section 3.6.2 with the ISRE-
containing promoter reporter plasmid. This plasmid was co-transfected with the 
different vIRF2 mutants, F1-F8, (Figure 3.14, rows 5-12). After 5 hours incubation, 
rIFNα was added to the cells to activate JAK-STAT signalling. The luciferase 
activities of these samples were compared to transfections containing the empty 
vector control and to those containing the full length vIRF2 expression plasmid 
(Figure 3.14, rows 3 and 4). The full length vIRF2 protein inhibited ISRE activity by 
70% (Figure 3.14, row 4), but of the mutants, only F3 and F4 were able to 
significantly (p<0.001) inhibit the activity of the ISRE-containing promoter when 
compared to the empty vector (Figure 3.14, rows 7 and 8). Mutant F3 inhibited 
ISRE activity by 52%, whereas mutant F4 inhibited by 64%. The region in common 
between these two mutants is from amino acid residues 118-518.  
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Figure 3.12: vIRF2 truncated mutants and their expression in 293 cells.  
(A) Diagram of the vIRF2 truncated mutants F1-F8. FL=Full length protein. (B) 
Western blot showing the expression of the vIRF2 truncated mutants in 293 cells. 
293 cells were transfected with 1000ng of the full length vIRF2-His/Max, or one of 
the truncated mutants pcDNA4/F1 - pcDNA4/F8 and harvested 16 hours later. The 
lysates (20μg) were analysed by western blot to detect the His-tag. Primary 
antibody: anti-His. Secondary antibody: anti-mouse HRP-conjugated secondary 
antibody. The position of each His-tagged protein is indicated tagged by *. β-actin, 
the loading control, is also indicated.  
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Figure 3.13: The effect of the vIRF2 truncated mutants on poly(I:C)-driven 
activation of the IFNβ promoter. 
To examine the effect of the vIRF2 truncated mutants on the transactivation of the 
full-length IFNβ promoter, the full length IFNβ promoter firefly reporter plasmid 
was co-transfected with either the constitutively expressing vIRF2 plasmid 
(pcDNA4/vIRF2), or one of the truncated mutants pcDNA4/F1 - pcDNA4/F8 or the 
corresponding empty vector (pcDNA4His/Max). 24 hours later poly(I:C) was 
transfected to activate IRF3. For all results, the pRLSV40 plasmid (1ng) 
constitutively expressing Renilla luciferase was transfected as an internal control 
to which firefly luciferase levels were normalised. The results are shown as fold 
increase compared to the empty vector (pcDNA4His/Max) transfections which 
were un-stimulated (row 1). The data represent the mean ± the SEM of the three 
independent experiments which were each assayed in duplicate. ** = p<0.01, *** = 
p<0.001 ANOVA followed by a Dunnett post hoc test compared to empty vector 
(pcDNA4His/Max) plus poly(I:C (row 3)). For results from individual experiments 
see Figure 9.8. 
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Figure 3.14 The effect of the vIRF2 truncated mutants on IFNα activation of 
an ISRE-containing promoter.  
To examine the effect of the vIRF2 truncated mutants on the transactivation of an 
ISRE containing promoter, 293 cells were co-transfected with pISRE-luc (250ng) 
and 1000ng of either the constitutively expressing vIRF2 plasmid (vIRF2-His/Max), 
or one of the truncated mutants pcDNA4/F1 - pcDNA4/F8 or the corresponding 
empty vector (pcDNA4His/Max). 5 h post-transfection, the cells were treated with 
rIFNα (300IU/ml) and harvested 16 h later. For all results, the pRLSV40 plasmid 
(1ng) constitutively expressing Renilla luciferase was transfected as an internal 
control to which firefly luciferase levels were normalised. The results are shown as 
fold increase compared to the empty vector (pcDNA4His/Max) transfections minus 
rIFNα (row 1). The data represent the mean ± the SEM of the three independent 
experiments which were each assayed in duplicate. *** = p<0.001 ANOVA 
followed by a Dunnett post hoc test compared to empty vector (pcDNA4His/Max) 
plus poly(I:C) (row 3). For results from individual experiments see (Figure 9.9). 
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3.9. Discussion of Chapter 3 
The experiments in this chapter confirmed the ability of vIRF2 to inhibit activation 
of both the IFNβ promoter (Figure 3.7) and the ISRE-containing promoter (Figure 
3.8). Because of the inhibitory effect of vIRF2 on both the IFN production pathway, 
and the JAK-STAT pathway, it was used as a positive control throughout the 
experiments concerning vIRF4. Previous experiments performed in our laboratory 
revealed that vIRF2 is able to accelerate the caspase-3-dependent process of 
IRF3 turnover (Areste et al., 2009), suggesting a mechanism for inhibition of IFNβ 
promoter inactivation. However, vIRF2 is also able to repress IFNβ activity in the 
absence of caspase-3 (Areste et al., 2009). These observations reveal that vIRF2 
can inhibit IFNβ promoter activity by more than one mechanism. To deduce 
whether or not vIRF2 could inhibit IRF3 activity, as well as the degradation of IRF3 
as shown in Areste el at, (2009), IRF3 DNA binding assays were performed 
(Figure 3.9). These results showed that vIRF2 suppressed IRF3 activity, providing 
a further mechanism by which vIRF2 inhibits IFNβ promoter activity.  
 
The mechanism behind the vIRF2 mediated inhibition of the JAK-STAT signalling 
pathway has not been fully identified. Mutochelu et al, (2011) showed that vIRF2 
decreases levels of pSTAT1 in 293 cells. However, the mechanism underlying this 
activity is unknown. This area will be explored in further detail in the following 
chapters. 
 
There is very little in the literature concerning the effects of vIRF4 on IFN 
signalling. Kanno et al, (2006) reported that vIRF4 is unable to repress the IFNβ 
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promoter when activated by Sendai virus, suggesting that vIRF4 cannot suppress 
the IFN production pathway. The results in this chapter support this conclusion; 
Figure 3.10 shows that vIRF4 is unable to inhibit the poly(I:C) driven activation of 
the IFNβ promoter. However, this chapter also investigated the effect of vIRF4 on 
the later part of type I IFN signalling, the JAK-STAT signalling pathway. Figure 
3.11 demonstrates that vIRF4 can inhibit the rIFNα activated ISRE promoter by up 
to 51%. The involvement of vIRF4 in this later stage of the type I IFN response 
has not been reported in the literature previously, and hence this is a novel result.   
 
The inhibition of ISRE activity by vIRF4 was 51% compared to the 76% inhibition 
by vIRF2 (Figure 3.11). However, comparing the inhibition by these proteins in 
these experiments is not meaningful, as differences in the extent of inhibition 
could simply be due to differences in their relative expression levels.   
 
When examining the effect of the vIRF2 truncated mutants on the IFNβ promoter 
activity, mutants F2, F3, F4 and F8 significantly inhibited ISRE activity compared 
to the EV control (Figure 3.13). However, even though equal amounts of each 
plasmid was transfected into 293 cells, the protein expression of these mutants 
was not equal (Figure 3.12B), mutants F3 and F5 don’t express as well as the rest 
of the mutants. Therefore, the inhibition by the F3 mutant on the IFNβ promoter 
may be greater than observed in Figure 3.13. In a similar manner, the lack of IFNβ 
promoter inhibition by F5 could be due to the low protein expression of this 
mutant. Nonetheless, the region in common between the mutants F2, F3 and F4 is 
the amino acid residues 118-320; the region which the F8 mutant spans. These 
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results indicate that the region of vIRF2 responsible for the inhibition of IFNβ 
promoter activity is encompassed by the F8 mutant. Further experiments could 
narrow down the region responsible through construction of more mutants 
containing regions within the amino acids 118-320.   
 
When examining the effect of the vIRF2 truncated mutants on ISRE activity, it was 
found that only mutants F3 and F4 significantly inhibited ISRE activity compared to 
the EV control (Figure 3.14), and the extent of their inhibition (52% and 64% 
respectively) was comparable to that of the full-length vIRF2 (70%). Again, due to 
unequal protein expression of the mutants (Figure 3.12B) the inhibition of ISRE 
activity by the F3 may be greater than observed of in Figure 3.14 and the lack of 
ISRE promoter inhibition by F5 could be due to the low protein expression of this 
mutant. The region in common between the F3 and F4 mutants is amino acids 
118-518. This result therefore suggests that amino acid residues 118-518 are 
necessary for ISRE inhibition by vIRF2. To test this theory, an additional vIRF2 
mutant could be produced, comprising of amino acids 118-518.  
 
Interestingly, the vIRF2 truncated mutant F1 is unable to inhibit either IFNβ 
promoter activity or ISRE-containing promoter activity. This mutant comprises the 
N-terminal region of vIRF2, which shares some homology to the DBD of the IRF 
family of transcription factors (Cunningham et al., 2003). This observation 
suggests that the mechanism of action of vIRF2 is not dependent on direct binding 
to DNA.  
 
CHAPTER 3                              The KSHV proteins, vIRF2 and vIRF4, downregulate IFN signalling  
 
 
~ 118 ~ 
 
In summary, this chapter confirms the inhibition of both IFNβ promoter activity and 
ISRE-containing promoter activity by vIRF2 and demonstrates that vIRF2 can 
reduce IRF3 activity. The region of vIRF2 responsible for the inhibition of IFNβ 
promoter activity appears to be between amino acids 118-320, whereas the region 
responsible for inhibition of the ISRE-containing promoter seems to be a larger 
area between amino acids 118-518. Importantly, this chapter shows that like 
vIRFs 1-3, vIRF4 also negatively regulates the type I IFN response, but doesn’t 
target the early IFN production pathway, rather it targets JAK-STAT signalling. In 
the next chapters, the mechanisms behind the inhibition of the ISRE-containing 
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4.1. Introduction to chapter 4 
Chapter 3 described how the vIRF4 gene was cloned into the pCDNATO-NTAP 
vector in order to perform in vitro functional studies. These functional studies 
revealed that, like vIRF2, vIRF4 is also able to inhibit rIFNα stimulated 
transactivation of an ISRE-containing promoter. These experiments were 
performed via transient transfection using the pvIRF4-NTAP vector with the 
pCDNA4TO-NTAP parental vector as a control. Throughout these studies, the 
effect of vIRF2, expressed from pvIRF2-His/Max, provided a positive control. In 
order to examine the mechanism by which vIRF2 and vIRF4 exert their inhibitory 
effect on the ISRE-containing promoter, it is necessary to have stable cell lines 
which express the vIRF2 or vIRF4 proteins. The advantage of stable cell lines 
compared with transiently transfected cells is that all the cells in a population will 
express the vIRF2 or vIRF4 protein, instead of only those which are transfected. 
This means that any effects of the vIRF2 or vIRF4 proteins are not masked by 
cells which don’t express these proteins.  
 
This chapter describes the production and characterisation of cell lines, which 
were engineered to contain antibiotic selectable plasmids that could be induced to 
express either the vIRF2-NTAP or vIRF4-NTAP proteins, or the NTAP protein. The 
NTAP protein is a tag expressed from the pCDNA4TO-NTAP vector, which is 
expressed contiguous to the vIRF2 or vIRF4 proteins in their respective cell lines. 
Throughout this thesis, these cell lines will be collectively referred to as ‘stable cell 
lines’.  
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The aims of this chapter are to: 
1) Clone the vIRF2 gene into the pCDNA4TO-NTAP expression vector and 
ensure that this vector expresses vIRF2-NTAP in 293 cells. 
2) Create three stable cell lines expressing the NTAP-protein, the vIRF2-
NTAP protein or the vIRF4-NTAP protein. 
3) Confirm that these cell lines express the vIRF2 and vIRF4 proteins, and 
show that they behave as previously observed in chapter 3. 
4) Determine whether the levels of the vIRF2 and vIRF4 mRNA in the stable 
cell lines are comparable to those in a naturally infected KSHV cell line. 
 
It was decided that vIRF2 should be cloned into pCDNA4TO-NTAP, to form the 
resultant pvIRF2-NTAP vector, for a number of reasons. Firstly, the vIRF4 gene 
had been previously cloned into this vector and was shown to express well 
(chapter 3). The empty vector control, pCDNA4TO-NTAP, would be the same 
control for both pvIRF2-NTAP and pvIRF4-NTAP meaning vIRF2 and vIRF4 could 
be compared better. Secondly, previous studies on vIRF2 have found that its 
constitutive expression is detrimental to cells (Fuld & Blackbourn, un-published 
data). Because of this negative effect, any cell line engineered to express vIRF2 
would ideally be inducible for the expression of this viral protein, so that its 
expression can be controlled. The pCDNA4TO-NTAP vector can be used to create 
stable cell lines which are tetracycline inducible, by transfecting the vector into a 
cell line which expresses the tetracycline repressor (Yao et al., 1998). Finally, the 
pCDNA4TO-NTAP vector encodes an N-terminal-TAP-tag which would be 
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expressed contiguously with the vIRF2 or vIRF4 proteins. This tag will enable the 
purification of the vIRF2 or vIRF4 proteins along with any protein binding partners. 
The identity of such partners may lead to understanding of how vIRF2 or vIRF4 
exert their inhibition on the JAK-STAT signalling pathway.  
 
The expression of vIRF2-NTAP from the pvIRF2-NTAP vector was demonstrated 
in 293 cells by western blotting, and the inhibitory effect of vIRF2 on both the IFN 
production and JAK-STAT signalling pathways was shown to be consistent with 
initial studies using the vIRF2-His/Max vector (section 3.6). 
 
Stable cell lines containing the pCDNA4TO-NTAP, pvIRF2-NTAP, or pvIRF4-
NTAP were produced. These cell lines were analysed to ensure that they 
expressed the NTAP, vIRF2-NTAP or vIRF4-NTAP proteins following tetracycline 
stimulation. The vIRF2-NTAP and vIRF4-NTAP cell lines were evaluated for their 
ability to inhibit IFN signalling, compared to the EV-NTAP control. These cell lines 
were further analysed to identify the sub cellular location of vIRF2-NTAP and 
vIRF4-NTAP, and to compare the levels of vIRF2 and vIRF4 mRNA with that of 
those in BCBL1 cells. 
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4.2.  Cloning the vIRF2 gene into the pCDNATO-NTAP vector  
Chapter 3 described how the vIRF4 gene was cloned into the pCDNATO-NTAP 
vector in order to perform in vitro functional studies. As explained in the 
introduction to this chapter, it was also necessary to clone the vIRF2 gene into the 
pCDNATO-NTAP vector. An overview of the cloning scheme is illustrated in Figure 
4.1. The vIRF2 gene had been cloned into the pCR-Blunt sub-cloning vector in the 
past (performed by members of the Blackbourn lab). Therefore, the vIRF2 gene 
was amplified from pCR-Blunt-vIRF2, using specific primers containing BsiWI and 
XbaI restriction sites (see Table 2.14 ‘vIRF2 forward with BsiWI’ and ‘vIRF2 
reverse with XbaI’). The PCR product was separated through gel electrophoresis, 
excised, purified, and ligated into pCR-Blunt. The resultant pCR-Blunt-vIRF2 
(BsiWI and XbaI) was then digested with XbaI and BsiWI, separated through gel 
electrophoresis, excised, purified, and ligated and ligated into the purified NTAP 
vector which had been digested with XbaI and BsiWI. The resultant pvIRF2-NTAP 
construct was confirmed by sequencing (data not shown).  
 
4.3. Transient expression of vIRF2 in 293 cells 
To ensure the pvIRF2-NTAP expression vector expressed the vIRF2-NTAP 
protein in 293 cells a transfection titration was performed. 293 cells were 
transfected with varying amounts of vIRF2 from 0-1000ng and 16 hours later the 
cells were harvested. Western blot analysis showed, as expected, that as the 
amount of pvIRF2-NTAP transfected increased, the expression levels of vIRF2-
NTAP also increased up to 500ng. The amount of vIRF2-NTAP is the same in the 
1000ng sample compared to the 500ng indicating that the optimum expression of 
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Figure 4.1: Cloning the vIRF2 gene into the pCDNATO-NTAP vector.  
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Figure 4.2: vIRF2 expression in 293 cells transiently transfected with the 
pvIRF2-NTAP vector.  
293 cells were transfected with the pvIRF2-NTAP vector (0-1000ng), and 
harvested 16 hours later. The lysate (20μg) was analysed by western blot to 
detect the NTAP-tag. Primary antibody: anti-β-actin. Secondary antibody: anti-
mouse HRP-conjugated secondary antibody. The NTAP tagged vIRF2 (vIRF2-
NTAP) and the TAP tag produced from EV-NTAP transfected cells are indicated 
(NTAP). β-actin is also indicated. The use of the anti-mouse HRP-conjugated 
secondary antibody was sufficient to detect the NTAP-tag as this tag contains 
protein G binding domains. As a control for the specificity of these bands, un-
transfected cell Lysate was also loaded. This experiment was repeated completely 
and the resultant blot is shown in Figure 9.10 
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4.4. Confirmation that vIRF2, expressed from the pvIRF2-NTAP vector,  
inhibits poly(I:C)-driven activation of the IFNβ promoter in 293 cells 
To confirm that the vIRF2 protein, expressed from the pvIRF2-NTAP vector, can 
inhibit transactivation of the full-length IFNβ promoter, a reporter plasmid 
containing the full length IFNβ promoter was co-transfected with increasing 
amounts of the pvIRF2-NTAP vector. 24 hours later poly(I:C) was transfected to 
activate IRF3. As expected firefly luciferase expression and therefore the IFNβ 
promoter transactivation was significantly inhibited in the vIRF2 transfected cells 
compared to the empty vector control (Figure 4.3, compare columns 3 with 4, 5 
and 6). IFNβ transactivation was inhibited by up to 70% in the presence of 1000ng 
of pvIRF2-NTAP (Figure 4.3, compare columns 3 and 6). 
 
4.5. Confirmation that vIRF2, expressed from the pvIRF2-NTAP vector,  
inhibits rIFNα-driven expression of pISRE-luc in 293 cells 
To confirm that the vIRF2 protein, expressed from the pvIRF2-NTAP vector, can 
inhibit the transactivation of the ISRE promoter, reporter gene studies were 
performed with the pISRE-luc vector. 293 cells were transiently co-transfected with 
pISRE-luc and increasing amounts of the constitutively expressing vIRF2 plasmid 
(pvIRF2-NTAP). 5 hours post transfection the cells were treated with rIFNα, to 
activate the JAK-STAT signalling pathway. Under these conditions, firefly 
luciferase expression and therefore the ISRE-containing promoter transactivation 
was significantly inhibited in the vIRF2 transfected cells compared to the empty 
vector control (Figure 4.4 compare column 3 with 4, 5 and 6). ISRE transactivation 
was inhibited by up to 70% in the presence of 1000ng of pvIRF2-NTAP (Figure 
4.4, compare columns 3 and 6).  
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Figure 4.3: vIRF2, expressed from the pvIRF2-NTAP vector, inhibits 
poly(I:C)-driven activation of the IFNβ promoter.   
293 cells were transfected with p125-luc (250ng) and increasing amounts of the 
pvIRF2-NTAP expression vector (indicated in figure, 0-1000ng). 24 hours post-
transfection, the cells were transfected with poly(I:C) (10µg/ml) and harvested 20 
hours later. The empty parental plasmid backbone, pCDNA4TO-NTAP was added 
as required to equilibrate all transfectants to 1000ng of DNA. The pRLSV40 
plasmid (1ng), was added as an internal control to which firefly luciferase levels 
were normalised. The results are shown as fold increase compared to the empty 
vector (pCDNA4TO-NTAP) transfections which were un-stimulated (lane 2). The 
data represent the mean ± the SEM of three independent experiments which were 
each assayed in duplicate. * = p<0.5, * = p<0.01, *** = p<0.001 ANOVA followed 
by a Dunnett post hoc test compared to empty vector (pCDNA4TO-NTAP) plus 
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Figure 4.4: vIRF2, expressed from the pvIRF2-NTAP vector, inhibits rIFNα-
driven expression of pISRE-luc.   
293 cells were transfected with pISRE-luc (250ng) and increasing amounts of the 
pvIRF2-NTAP expression vector (indicated in figure, 0-1000ng). 5 hours post 
transfection, the cells were treated with rIFNα (300 U/ml), or left untreated and 
harvested 16 hours later. The empty parental plasmid backbone, pCDNA4TO-
NTAP was added as required to equilibrate all transfectants to 1000ng of DNA. 
The pRLSV40 plasmid (1ng), was added as an internal control to which firefly 
luciferase levels were normalised. The results are shown as fold increase 
compared to the empty vector (pCDNA4TO-NTAP) transfections which were un-
stimulated (lane2). The data represent the mean ± the SEM of three independent 
experiments which were each assayed in duplicate. *** = p<0.001 ANOVA 
followed by a Dunnett post hoc test compared to empty vector (pCDNA4TO-
NTAP) plus rIFNα (lane 3). For results from individual experiments see Figure 
9.12 (Appendix I). 
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4.6. Production of stable cell lines that express either vIRF2-NTAP, vIRF4-
NTAP or the NTAP-tag 
To facilitate experiments which aim to study the mechanism of the vIRF2 and 
vIRF4 proteins, stable cell lines, which express the NTAP-tag only, the vIRF2-
NTAP or the vIRF4-NTAP proteins were produced. T-REX cell lines (see section 
2.1.5), which express the tetracycline repressor under the selection of Blasticidin, 
were transfected with either the pCDNA4TO-NTAP, pvIRF2-NTAP or pvIRF4-
NTAP vectors which had been linearised with PvuI. This enzyme cuts each 
plasmid once outside the inserted gene (vIRF2 of vIRF4).  Cells were treated with 
Blasticidin and Zeocin to select for transfected cells, and colonies were 
established. For details see section 2.1.5. The resultant cell lines (called EV-
NTAP, vIRF2-NTAP and vIRF4-NTAP) were cultured in 5μg/mL Blasticidin and 
200µg/ml Zeocin. 
 
4.7. Optimising vIRF2 &-4 expression with tetracycline 
The EV-NTAP, vIRF2-NTAP and vIRF4-NTAP cell lines can be induced by 
tetracycline to express the NTAP, vIRF2-NTAP and vIRF4-NTAP proteins 
respectively. To confirm that these cell lines express the specific proteins, and to 
characterise the amount of tetracycline and time course of induction required to 
induce expression of the TAP-tagged proteins, optimisation experiments were 
performed.  
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4.7.1. Optimising the amount of tetracycline necessary to induce vIRF2 & 4 
protein expression  
To identify a suitable amount of tetracycline to induce the EV-NTAP, vIRF2-NTAP 
and vIRF4-NTAP cell lines to express their respective proteins, a tetracycline 
titration was performed. The cell lines were stimulated with tetracycline (ranging 
between 0–2μg/ml) and samples were obtained for western blot analysis 24 hours 
later. Figure 4.5 shows the results. The indicated bands correspond in size to that 
of each of the specific proteins (vIRF2 140kDa, vIRF4 130kDa) with the NTAP tag 
attached. In the three cell lines, 0.125μg/ml of tetracycline was sufficient to induce 
the expression of the respective proteins to their peak amount for this experiment 
(Figure 4.5 A, B and C, lanes 2); as a result 0.125μg/ml of tetracycline was used in 
all further experiments.   
 
4.7.2. Optimising the tetracycline treatment time to induce vIRF2 & 4 
protein expression  
The time course of tetracycline stimulation of the vIRF2-NTAP, vIRF4-NTAP and 
NTAP proteins from their corresponding cell lines was investigated in order to aid 
in the design of further experiments. Cell lines were stimulated with tetracycline 
(0.125μg/ml) and samples were obtained for western blot analysis at specific time 
points post tetracycline stimulation (0, 8, 24, 48 and 72 hours). For the EV-NTAP 
and vIRF2-NTAP cell lines, 8 hours of tetracycline induction was sufficient to 
induce the expression of the NTAP and vIRF2-NTAP proteins respectively (Figure 
4.6 A and B, lane 2). Expression of these proteins was maintained until at least 72 
hours after treatment. This protein is present in similar quantities up to 72 hours 
post tetracycline stimulation. In the case of the vIRF4-NTAP cell line, weak 
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expression of the vIRF4-NTAP protein is observed after 8 hours of tetracycline 
induction (Figure 4.6C, lane 2), but after 24 hours of tetracycline, the level of 
protein increases (Figure 4.6 lane 3). Overall vIRF4-NTAP is expressed weaker 
than the vIRF2-NTAP and NTAP proteins. Based on these results, it was 
concluded that, in order to get optimum protein expression, further experiments 
using these cell lines should ideally be performed between 24-72 hours post 
tetracycline stimulation. 
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Figure 4.5: 0.125μg/ml of tetracycline is sufficient to induce expression of 
the NTAP-tagged proteins.  
EV-NTAP, vIRF2-NTAP and vIRF4-NTAP cell lines were treated with tetracycline 
at different concentrations from 0-2μg/ml (lane 1=0μg/ml, 2=0.125μg/ml, 
3=0.25μg/ml, 4=0.5μg/ml, 5=1μg/ml and lane 6=2μg/ml). Cells were harvested 24 
hours later. The lysates (20μg per sample) were analysed by western blot to 
detect the NTAP-tag and β-actin. Primary antibody: anti-β-actin. Secondary 
antibody: anti-mouse HRP-conjugated secondary antibody (for β-actin detection). 
The use of the anti-mouse HRP-conjugated secondary antibody was sufficient to 
detect the NTAP-tag in all the cell lines as this tag contains protein G. The NTAP, 
and vIRF4-NTAP proteins produced from the EV-NTAP, vIRF2-NTAP and vIRF4-
NTAP cell lines respectively are indicated. Probing for β-actin confirmed equal 
loading.  
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Figure 4.6: 24 hours of tetracycline treatment is necessary for expression of 
the NTAP-tagged proteins.  
EV-NTAP, vIRF2-NTAP and vIRF4-NTAP cell lines were treated with tetracycline 
(0.125μg/ml), and harvested between 0-72 hours later. The lysates (20μg per 
sample) were analysed by western blot to detect the NTAP-tag and β-actin. 
Primary antibody: anti-β-actin. Secondary antibody: anti-mouse HRP-conjugated 
secondary antibody (for β-actin detection). The use of the anti-mouse HRP-
conjugated secondary antibody was sufficient to detect the NTAP-tag in all the cell 
lines as this tag contains protein G. The NTAP, vIRF2-NTAP and vIRF4-NTAP 
proteins produced from the EV-NTAP, vIRF2-NTAP and vIRF4-NTAP cell lines 
respectively are indicated. Probing for β-actin confirmed equal loading. This 
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4.8. Confirming the presence of vIRF2 and vIRF4 gene expression in the cell 
lines 
Section 4.7 described the concentration and duration tetracycline treatment to 
induce expression of the vIRF2-NTAP, vIRF4-NTAP and NTAP proteins. Western 
blot analyses demonstrated the presence of bands corresponding to the predicted 
sizes of the NTAP, vIRF2-NTAP and the vIRF4-NTAP proteins (30, 140 and 
130kDa respectively). However to fully and more conclusively demonstrate that 
the cell lines do express the specific proteins, PCR analysis was used to 
demonstrate the presence of vIRF2 and vIRF4 mRNA. 
 
4.8.1. Confirming the presence of vIRF2 and vIRF4 mRNA in the vIRF2-
NTAP and vIRF4-NTAP expressing stable cell lines respectively 
The EV-NTAP, vIRF2-NTAP and vIRF4-NTAP cell lines were stimulated with 
tetracycline for 24 hours and harvested. RNA was extracted from each sample, 
which was then DNAse treated and cDNA was created from these templates. PCR 
was performed on the cDNA samples using primers specific for either vIRF2 or 
vIRF4 (Table 2.17). These specific primers were designed to span the exon 
boundaries of the vIRF2 or vIRF4 genes. Primers which span the exon boundary 
do not provide any advantage when dealing with the stable cell lines (as they are 
stably transfected with expression plasmids that do not contain the intron of the 
vIRF2 of vIRF4 genes), however it may provide an advantage in further 
experiments examining the vIRF2 and vIRF4 mRNA in the context of KSHV 
infection.  
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As expected, the vIRF2-NTAP cell line contained mRNA which was amplified with 
the vIRF2 specific primers (Figure 4.7A, lane 3). No positive signals were 
observed for either the EV-NTAP of vIRF4-NTAP cell lines (lanes 1 and 5) 
indicating that these cell lines do not express the vIRF2 protein and there were no 
positive signals in the –RT samples and the no template control (lanes 2, 4, 6 and 
7) demonstrating no contamination.  
 
Similarly, the vIRF4-NTAP cell line contained mRNA which was amplified with the 
vIRF4 specific primers (Figure 4.7A, lane 5). Again, no positive signals were 
observed for either the EV-NTAP of vIRF2-NTAP cell lines (lanes 1 and 3) and 
there were no signals for the –RT or no template control samples (lanes 2, 4, 6 
and 7). These results provide further confirmation that the vIRF2-NTAP and the 
vIRF4-NTAP cell lines express the vIRF2 and vIRF4 proteins respectively.  
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Figure 4.7: The vIRF2-NTAP and vIRF4-NTAP cell lines contain vIRF2 or 
vIRF4 mRNA respectively. 
EV-NTAP, vIRF2-NTAP and vIRF4-NTAP cell lines were treated with tetracycline 
(0.125μg/ml) for 24 hours and harvested. RNA was extracted and the samples 
were DNAse treated. Reverse transcription was performed followed by PCR using 
(A) vIRF2 primers and (B) vIRF4 primers (Table 2.17). –RT=samples not treated 
with reverse transcriptase, H2O=no template control. The gap between lanes 6 
and 7 in B, is because the samples were not loaded contiguously. However, lane 
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4.9. Investigating the function of vIRF2 and vIRF4 expressed in the vIRF2-
NTAP and vIRF4-NTAP cell lines. 
In order to confirm that the vIRF2-NTAP and vIRF4-NTAP proteins, expressed in 
the stable cell lines, were functioning in the same way, with respect to IFN 
signalling, as previously described in transient transfection experiments, DLAs 
were performed.   
 
4.9.1. vIRF2 inhibits IFNβ promoter activation, while vIRF4 has no effect on 
IFNβ promoter activation 
Section (3.7.1) showed that transient transfection of the vIRF2-His/Max plasmid 
into 293 cells resulted in inhibition of the polyI:C driven transactivation of the IFNβ 
promoter. However, transient transfection of the vIRF4-NTAP plasmid into 293 
cells did not affect the IFNβ promoter (Figure 3.10).  
 
To confirm that these effects are recapitulated in the stable cell lines, a DLA was 
performed using the IFNβ promoter reporter plasmid. The EV-NTAP, vIRF2-NTAP 
and vIRF4-NTAP cell lines were treated with tetracycline to induce protein 
expression, then transfected with the full length IFNβ promoter. 24 hours later 
poly(I:C) was transfected to activate IRF3. Cells were harvested and assayed by 
DLA 20 hours later. As expected, firefly luciferase expression and therefore the 
IFNβ promoter transactivation was significantly (p=0.01) inhibited (by 72%) in the 
vIRF2 expressing cell lines compared to EV-NTAP cell lines (Figure 4.8, compare 
columns 4 and 5). The vIRF4 expressing cell line showed no inhibition of IFNβ 
promoter transactivation when compared to the EV-NTAP cell line (Figure 4.8, 
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compare columns 4 and 6). These results confirm and support the results obtained 
through transient transfection experiments in chapter 3. 
 
4.9.2. The vIRF2 and vIRF4 expressing cell lines inhibit ISRE-containing 
promoter activation 
To confirm that vIRF2 and vIRF4 proteins, expressed from the stable cell lines, 
inhibit the rIFNα induced transactivation of an ISRE-containing promoter, as 
observed in section 3.7.2, ISRE-reporter assays were performed. The vIRF2-
NTAP, vIRF4-NTAP and the EV-NTAP control cell lines were stimulated with 
tetracycline to induce the expression of the specific proteins and the ISRE-
containing promoter was co-transfected with the constitutively expressing Renilla 
pRLSV40 plasmid. 5 hours later the cells were treated with rIFNα to activate the 
JAK-STAT signalling cascade. As expected firefly luciferase expression and 
therefore the ISRE-containing promoter transactivation was significantly inhibited 
(p=0.001) in both the vIRF2 and the vIRF4 expressing cell lines compared to the 
EV-NTAP cell lines. In the case of vIRF2, the level of inhibition was 80% (Figure 
4.9, compare columns 4 and 5) and for vIRF4 it was 64% (Figure 4.9, compare 
columns 4 and 6). These results confirm and support the results obtained through 
transient transfection experiments in chapter 3. 
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Figure 4.8: vIRF2 inhibits IFNβ promoter activation, while vIRF4 has no effect 
on IFNβ promoter activation.  
The EV-NTAP, vIRF2-NTAP and vIRF4-NTAP cell lines were treated with 
tetracycline (0.125μg/ml)). 24 hours later, the cells were   transfected with p125-
luc (250ng) and the pRLSV40 plasmid (1ng). 24 hours post-transfection, the cells 
were transfected with poly(I:C) (10µg/ml) and harvested 20 hours later. The 
pRLSV40 plasmid (1ng), was added as an internal control to which firefly 
luciferase levels were normalised. The results are shown as fold increase 
compared to the EV-NTAP cell which was un-stimulated (column 1). The data 
represent the mean ± the SEM of the three independent experiments which were 
each assayed in duplicate. ** = p<0.01 ANOVA followed by a Dunnett post hoc 
test compared to EV-NTAP plus poly(I:C) (column 4). For results from individual 
experiments see Figure 9.14 (Appendix I).  
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Figure 4.9: vIRF2 and vIRF4 inhibit ISRE-containing promoter activation. The 
EV-NTAP, vIRF2-NTAP and vIRF4-NTAP cell lines were treated with tetracycline 
(0.125μg/ml) for 24 hours and then transfected with pISRE-luc (250ng) and the 
pRLSV40 plasmid (1ng). 5 hours post transfection, the cells were treated with 
rIFNα (300 U/ml) and harvested 16 hours later. The pRLSV40 plasmid was added 
as an internal control to which firefly luciferase levels were normalised. The results 
are shown as fold increase compared to the EV-NTAP cell which was un-
stimulated (column 1). The data represent the mean ± the SEM of the three 
independent experiments which were each assayed in duplicate. *** = p<0.001 
ANOVA followed by a Dunnett post hoc test compared to EV-NTAP plus rIFNα 
(column 4). For results from individual experiments see Figure 9.15(Appendix I).  
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4.10. Comparing the levels of vIRF2 or vIRF4 in stable cell lines and a PEL 
cell line 
The experiments performed in following sections utilize the EV-NTAP, vIRF2-
NTAP and vIRF4-NTAP stable cell lines. Ectopically expressing these proteins in 
this way can aid understanding of the mechanisms of action of vIRF2 and vIRF4. 
However, since the cell lines ectopically express the viral proteins, it is important 
to compare the levels of vIRF2 and vIRF4 in the stable cells with those of naturally 
infected cells, such as PEL cells, providing biological relevance to natural KSHV 
infection. 
 
Whilst methods such as western blotting and flow cytometry would be preferable 
to quantify vIRF2 or vIRF4 protein levels, there are no functional antibodies which 
can detect native vIRF2 and vIRF4. These antibodies would be necessary for the 
detection of wild type vIRF2 and vIRF4 in PEL cells, since these proteins do not 
have a tag. Instead, qPCR was employed to compare vIRF2 and vIRF4 mRNA 
levels in engineered and naturally infected cells. 
 
4.10.1. Optimisation of qPCR assay to detect vIRF2 and vIRF4 mRNA 
Primers and probes were designed against both vIRF2 and vIRF4 (See Table 
2.19), the probes for each gene spanned an exon boundary in order to distinguish 
between message and genomic DNA. To validate the qPCR assay for the vIRF2 
gene, experiments were performed which confirmed the specificity and optimised 
the primer and probe concentrations. For the vIRF2 qPCR assay, the pvIRF2-
NTAP plasmid was used as a template for the assay, and added at varying 
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amounts from 102 - 106 copies. It was found that the assays for vIRF2 worked best 
with primer concentrations of 3µM, and probe concentrations of 5µM (Figure 
9.16A). The same approach was taken for vIRF4, using the pvIRF4-NTAP as a 
template. For this assay the optimum primer concentrations were again 3µM but 
the probe concentration was increased to 10µM (Figure 9.16B). As expected, no 
amplification was observed when water was substituted for DNA, furthermore, 
vIRF2 primer/probe sets, did not amplify vIRF4 plasmid samples and vice versa, 
indicating specificity of the assays (data not shown). 
 
4.10.2. Optimum time of vIRF2 and vIRF4 gene expression following BCBL1 
reactivation 
To find the peak vIRF2 and vIRF4 gene expression in BCBL1 cells, a KSHV 
reactivation time course experiment was performed. BCBL1 cells were treated 
with PMA, and collected at intervals from 0 hours – 144 hours later. At each time 
point samples were collected for analysis by immunofluorescence and qPCR. 
Immunofluorescence assays, staining for RTA (the lytic switch protein), were 
performed in order to investigate the percentage of cells which were reactivated. 
RTA expression peaked between 72 hours and 96 hours post PMA treatment. At 
72 hours 56% of stained for RTA while at 96 hours this value was 60% of cells 
(Figure 4.10). From the qPCR data, it was found that vIRF2 expression peaked in 
BCBL1 cells following 72 hours of PMA treatment (Figure 4.11A, column 5), while 
expression of vIRF4 peaked a further 24 hours later at 96 hours post PMA 
treatment (Figure 4.11B, column 6). 
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Figure 4.10: Time course of 
RTA expression in BCBL1 
cells following reactivation. 
PMA-treated (20ng/ml, for times 
shown in figure) BCBL1 cells 
were spotted onto slides, and 
fixed and permeabilized with 
methanol. The cells were 
stained for RTA (primary 
antibody: RTA (ORF50) see 
Table 2.8, secondary antibody: 
Anti-rabbit FITC Conjugate  
Table 2.9) and the nucleus 
(Bisbenzamide) and mounted 
using prolong gold. Results 
were visualised using confocal 
microscopy. The isotype control 
was stained with Rabbit IgG 
(see Table 2.8). To calculate 
the percentage of RTA positive 
cells, cells were counted 
manually. This experiment was 
repeated completely and the 
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Figure 4.11: Optimum expression of vIRF2 and vIRF4 mRNA in BCBL1 cells, 
following lytic reactivation of KSHV.  
(A) RNA extracted from PMA-treated (20ng/ml, for times shown in figure) BCBL1 
cells was subject to reverse transcription. The resultant cDNA was used in qPCR 
assays with vIRF2 primers (3µM) and probe (5µM) (see Table 2.19). Data were 
normalized to cellular GAPDH levels, which were determined in the same qPCR 
reaction using the VIC-labelled reference GAPDH assay primer and probe set 
(see Table 2.19). Results were expressed relative to 0 hours (column 1). The data 
represent the mean from one representative experiment which was assayed in 
duplicate; the range between duplicate values is indicated. A negative control 
lacking reverse transcriptase was included for each sample as well as a no 
template control, and these were both negligible (data not shown). (B) Performed 
as in A, but with vIRF4 primers (see Table 2.20) 10µM and the FAM-labelled 
probe (see Table 2.19, vIRF4) used at 5µM. These experiments were repeated 
completely and the resultant graphs are shown in Figure 9.18 (Appendix).  
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4.10.3. Levels of vIRF2 and vIRF4 mRNA in the stable cells lines, compared 
to the levels in BCBL1 cells 
The results obtained in 4.10.2, showed that vIRF2 mRNA levels peaked in BCBL1 
cells which had been treated with PMA for 72 hours, whereas the vIRF4 mRNA 
levels peaked after 96 hours of reactivation. To compare the levels of vIRF2 or 
vIRF4 mRNA in the stable cell lines with those in the BCBL1 cells, RNA was 
obtained from BCBL1 cells which were treated with PMA for 0, 72 and 96 hours. 
RNA was also obtained from the EV-NTAP, vIRF2-NTAP and vIRF4-NTAP stable 
cell lines which had been treated with tetracycline for 24 hours. 24 hours of 
tetracycline treatment was chosen because this resulted in peak expression of the 
vIRF2 and vIRF4 proteins (see section 4.7.2). Following reverse transcription, the 
samples were analysed by qPCR using the vIRF2 or the vIRF4 primers at their 
optimised concentrations (see section 4.10.1).  
 
The level of vIRF2 mRNA in the vIRF2-NTAP cell line was 3.8 fold (experiment 1), 
3.5 fold (experiment 2) and 2.4 fold (experiment 3) greater than that in BCBL1 
cells (Figure 4.12 compare columns 2 and 5 in all three experiments).  
 
Likewise vIRF4 mRNA in the vIRF4-NTAP cell line was 2.9 fold (experiment 1), 
6.4 fold (experiment 2) and 2.9 fold (experiment 3) greater than that in BCBL1 
cells (Figure 4.13, compare columns 3 and 6 in all three experiments).  
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Figure 4.12: Comparing vIRF2 mRNA levels in stable cells and BCBL1 cells.  
RNA was extracted from the EV-NTAP, vIRF2-NTAP and vIRF4-NTAP stable cell 
lines, which had been treated with tetracycline (0.125μg/ml). RNA was also 
extracted from PMA-treated (20ng/ml, for times shown in figure) BCBL1 cells. 
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Following reverse transcription, samples were analysed by qPCR using vIRF2 
specific primers (3µM) and probe (5µM) (see Table 2.19). Data were normalized to 
cellular GAPDH levels, which were determined in the same qPCR reaction using 
the VIC-labelled reference GAPDH assay primer and probe set (see Table 2.19) 
and expressed relative to BCBL1 0 hours (column 4). The data shows the results 
of three independent experiments which were each assayed in duplicate; the 
range between duplicate values is indicated. 
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Figure 4.13: Comparing vIRF4 mRNA levels in stable cells and BCBL1 cells.  
Performed as in Figure 4.12, expect vIRF4 specific primers were used at 3µM and 
the probe was used at 10µM (see Table 2.19).   
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4.11. The location of the vIRF2 and vIRF4 proteins  
Previous studies have examined the cellular location of the vIRF2 and vIRF4 
proteins in various cell types. In our own laboratory, vIRF2 has been shown to 
reside predominantly in the cytoplasm (Areste et al., 2009). vIRF4 has been found 
predominantly in the nucleus, but sometimes in the cytoplasm (Kanno et al., 2006, 
Xi et al., 2012). 
 
To examine the subcellular location of the vIRF2 and vIRF4 proteins in the vIRF2-
NTAP and vIRF4-NTAP cell lines, immunofluorescence assays were performed. 
The stable cell lines were seeded onto coverslips and induced to express the 
specific proteins. Cells were then fixed, permeabilized, stained and mounted. The 
staining patterns were visualised by confocal microscopy. Consistent with our 
previous work, vIRF2 was localised in the cytoplasm, while vIRF4 was found in 
both the nucleus and cytoplasm (Figure 4.14). Because the cell lines express the 
vIRF2 or vIRF4 proteins attached to the NTAP-tag, which is formed in part by two 
modules of protein G, any antibody will bind to the NTAP-tag. It was therefore 
important to ensure appropriate controls confirmed that staining was specific to the 
vIRF2 or vIRF4 proteins. The T-Rex parental cell line from which the vIRF2-NTAP 
and vIRF4-NTAP cell lines were created were used as a negative control (Figure 
4.14, labelled parental cell line). The EV-NTAP cell line was used to show the 
location of the NTAP-tag only, which was found throughout the cell (Figure 4.14). 
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staining of the vIRF2 
and vIRF4 proteins.  
The EV-NTAP, vIRF2-NTAP 
of vIRF4-NTAP cell lines 
were plated on coverslips at 
the bottom of a 24 well 
plate. Following tetracycline 
treatment (0.125μg/ml, 24 
hours), cells were fixed in 
4% paraformaldehyde and 
permeabilized with ice cold 
methanol (10 minutes). 
Staining was achieved using 
secondary antibody only 
(Anti-rabbit FITC, see  
Table 2.9) which detected 
the NTAP-tagged protein. 
Nuclear staining was 
achieved with 
Bisbenzamide. Results were 
visualised by confocal microscopy. T-Rex cells were treated in the same manner, to provide a negative control for the staining (labelled parental cell 
line). A. Experiment 1. B. Experiment 2.   
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4.12. Discussion 
This chapter discusses the generation and characterisation of stable cell lines 
expressing the NTAP, vIRF2-NTAP and vIRF4-NTAP proteins. An aim of this work 
was to establish stable cell lines, which would aid future experiments designed to 
identify the mechanism of how vIRF2 and vIRF4 inhibit JAK-STAT signalling.   
 
Following the cloning of the vIRF2 gene into the pCDNATO-NTAP vector, three 
stable cell lines were created using the pCDNATO-NTAP, pvIRF2-NTAP and 
pvIRF4-NTAP vectors. These stable cell lines can be induced, through tetracycline 
treatment, to express the NTAP, vIRF2-NTAP and vIRF4-NTAP proteins 
respectively. Experiments were therefore performed to identify the optimum 
amount, and time frame of tetracycline treatment. Figure 4.5 and Figure 4.6 show 
that optimum expression of the NTAP, vIRF2-NTAP and vIRF4-NTAP proteins 
was achieved following 0.125μg/ml of tetracycline for 24-72 hours. This 
information was necessary for future experiments (in later chapters), and as a 
result, future assays were performed within the 24-72 hours post 0.125μg/ml of 
tetracycline treatment, ensuring optimum protein expression.  
 
Additionally PCR and qPCR analysis of cDNA from the EV-NTAP, vIRF2-NTAP 
and vIRF4-NTAP cell lines showed the presence of vIRF2 mRNA in the vIRF2-
NTAP cell line, and vIRF4 mRNA in the vIRF4-NATP cell line (Figure 4.7, Figure 
4.12 and Figure 4.13). The western blots, showing presence of the vIRF2 or vIRF4 
proteins, and the PCR experiments showing presence of vIRF2 and vIRF4 mRNA 
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in the specific stable cell lines show the these stable cell lines are expressing the 
required proteins in an inducible manner. 
 
Since the cell lines were shown to express the desired KSHV proteins, they were 
then characterised by examining the effect of the vIRF2 and vIRF4 proteins on IFN 
signalling. The vIRF2 and vIRF4 proteins were confirmed to function as described 
for transiently transfected cells in chapter 3. vIRF2 inhibited both the IFNβ 
promoter and ISRE-containing promoter activity (Figure 4.8 and Figure 4.9). vIRF4 
was unable to inhibit IFNβ promoter activity (Figure 4.8) but significantly inhibited 
ISRE-containing promoter activation (Figure 4.9). These results provide further 
evidence for the inhibitory activity of the vIRF2 protein on IFN signalling, and 
confirm that the vIRF4 protein inhibits the JAK-STAT signalling pathway. Because 
these cell lines are functioning as previously observed, they will be used in further 
experiments which aim to understand the molecular mechanisms behind the 
action of vIRF2 and vIRF4.  
 
The stable cell lines, created in this chapter, overexpress the vIRF2 or vIRF4 
proteins. It is useful to know the protein levels of vIRF2 or vIRF4 relative to those 
of KSHV infected cell lines. The BCBL1 cell line is infected with KSHV, but not 
with EBV. KSHV within these cells is predominantly latent, but can be induced to 
the lytic state through treatment with the phorbol ester PMA (Renne et al., 1996). 
Comparison of the vIRF2 and vIRF4 protein levels in the stable cell lines and the 
BCBL1 cell lines was not possible because there are no available antibodies 
which recognise the wild type vIRF2 or vIRF4 proteins. The levels of vIRF2 and 
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vIRF4 mRNA were therefore examined. Optimum expression of vIRF2 and vIRF4 
mRNA was determined in BCBL1 cells treated with PMA, to reactivated KSHV lytic 
replication, for varying times. It was necessary to reactivate the KSHV, because 
both vIRF2 and vIRF4 are lytic genes (Cunningham et al., 2003), therefore 
optimum levels of their mRNA would be detected in lytic replicating KSHV. It was 
found that vIRF2 mRNA expression peaked 72 hours post PMA treatment, 
whereas vIRF4 mRNA expression peaks after 96 hours (Figure 4.11). These 
results confirm, as reported in the literature, that vIRF2 and vIRF4 mRNAs display 
lytic kinetics (Cunningham et al., 2003). Using this information, the levels of vIRF2 
or vIRF4 mRNA were compared between BCBL1 cells, at 72 and 96 hours post 
PMA treatment, and the stable cell lines. Levels of vIRF2 mRNA range from 2.4 
fold – 3.8 fold greater in the stable cell lines compared to BCBL1 cells (Figure 
4.12). vIRF4 mRNA levels ranged from  2.9 fold – 6.4 fold greater in the stable cell 
lines compared to BCBL1 cells (Figure 4.13). Whilst this result shows that vIRF2 
and vIRF4 are overexpressed in the stable cell lines, it doesn’t account for the fact 
that not all the BCBL1 cells contained lytic KSHV. Figure 4.10 shows BCBL1 cells 
which are stained for RTA, the KSHV lytic switch protein, at different time points 
post PMA treatment. Even at 72 hours and 96 hours post PMA treatment (time 
points containing the greatest percentage of cells with RTA) only 56% and 60% of 
cells respectively showed positive RTA staining, indicating not every cell contained 
reactivated KSHV. Because just over half of the cells contained reactivated KSHV, 
half the cells would therefore not be expressing vIRF2 or vIRF4 at their optimum 
amounts. An argument could be made that the levels of vIRF2 and vIRF4 mRNA, 
detected in the PMA treated BCBL1 cells, would be higher if 100% of the cells 
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contained reactivated KSHV. The values for the vIRF2 and vIRF4 mRNA levels in 
PMA treated BCBL1 cells could therefore be increased based on the percentage 
of cells which were actually reactivated. This would decrease the difference in 
vIRF2 or vIRF4 levels between the BCBL1 cells and the stable cell lines. However, 
due to time constraints, RTA staining was not performed in parallel to the qPCR 
experiments shown in Figure 4.12 and Figure 4.13, meaning an exact RTA 
positive cell percentage could not be determined on a per-experiment basis. 
Nonetheless, based on the RTA staining observations in Figure 4.10 and the 
replicate experiment Figure 9.17, it is clear that reactivation of every cell is not 
likely. Therefore it can be assumed that the calculated fold difference in viral 
mRNA levels, between BCBL1 cells and the stable cell lines, is larger than in 
reality. It should also be noted that the expression patterns observed in BCBL1 
cells will not be the same as the patterns in other KSHV infected tissues, as these 
could be either higher or lower.  
 
Finally, the location of the vIRF2 and vIRF4 proteins within the engineered cells 
was examined by immunofluorescence microscopy. vIRF2 was located in the 
cytoplasm, consistent with previous observations in our laboratory (Areste et al., 
2009) and vIRF4 is found both in the cytoplasm and the nucleus, as reported by 
Kanno et al, (2006). 
 
In summary, the work described in this chapter has detailed how stable cell lines 
which express either the EV-NTAP, vIRF2-NTAP or vIRF4-NTAP proteins were 
created. The vIRF2 or vIRF4 proteins expressed from these cell lines functioned 
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as previously described (Chapter 3) with respect to IFN signalling. These cell lines 
can therefore be used in subsequent experiments aiming to understand the 
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5.1. Introduction 
Chapter 3 and 4 have shown through luciferase reporter assays that both vIRF2 
and vIRF4 inhibit rIFNα stimulated ISRE promoter activation, and thus inhibit the 
JAK-STAT signalling pathway. Chapter 4 described the production and 
characterisation of stable cell lines which can be induced to express the EV-
NTAP, vIRF2-NTAP or the vIRF4-NTAP proteins. The present chapter describes 
the use of these cell lines to examine the mechanisms of the vIRF2 and vIRF4 
proteins in the context of IFN signalling.  
 
The aims of this chapter are to: 
1) Examine the anti-IFN effect of vIRF2 and vIRF4 in a biological context by 
assessing their ability to rescue the titre of the IFN-sensitive virus EMCV 
2) Identify if vIRF2 and vIRF4 can reduce binding of the ISGF3 complex to the 
ISRE sequence via EMSA studies 
3) Determine whether vIRF2 or vIRF4 affect levels of individual ISGF3 
components through western blot analysis.  
 
To examine the biological significance of the vIRF2 or vIRF4 mediated inhibition of 
JAK-STAT signalling the hypothesis that vIRF2 and vIRF4 could rescue EMCV 
titre due to their anti-IFN effects was tested. The stable cell lines were infected 
with EMCV in the presence or absence of rIFNα, and EMCV titres were 
determined. This experiment provided in vitro results on the potential physiological 
significance of vIRF2 and vIRF4 in KSHV biology.  
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Having established that vIRF2 and vIRF4 inhibit ISRE promoter activation, the 
mechanism by which these proteins interfere with JAK-STAT signalling was 
sought. To identify where these proteins are interfering, the pathway must be 
examined in more detail.  
 
Since ISRE activation is inhibited by vIRF2 and vIRF4, it follows that these 
proteins may inhibit the binding of the ISGF3 complex to ISRE promoter 
sequences. Therefore, EMSA studies were performed to determine the 
abundance of functional amounts of ISGF3 within the stable cell lines. EMSA 
studies are used to measure protein–DNA interactions. They can be used to verify 
that a protein mixture can bind to a specific DNA sequence, and determine the 
amount of binding taking place. A probe, consisting of the ISRE consensus 
sequence, was assayed with the nuclear lysates of rIFNα-stimulated EV-NTAP, 
vIRF2-NTAP and vIRF4-NTAP stable cell lines. The resultant bands, 
corresponding to the ISGF3-ISRE protein-DNA complexes, were measured and 
compared amongst all samples.  
 
The three components of the ISGF3 complex, pSTAT1, pSTAT2 and IRF9, are 
essential in the JAK-STAT signalling pathway. Reduction in the levels of one of 
these components would decrease ISRE promoter activity. Many viruses encode 
proteins which target the levels of ISGF3 components (discussed in section 1.4.9). 
Therefore the levels of these proteins were compared among the stable cell lines, 
to identify if any were reduced in vIRF2 or vIRF4 expressing cell lines compared 
with the EV control cell line.  
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5.2. Examining the effect of vIRF2 and vIRF4 on EMCV titres following rIFNα 
treatment 
Since vIRF2 and vIRF4 inhibit ISRE promoter activation (chapters 3 and 4), the 
hypothesis that these viral proteins can rescue the IFN sensitive EMCV from the 
antiviral pathway was tested. These experiments therefore examined the 




EMCV belongs to the Picornaviridae family, a diverse group of viruses that cause 
disease in both humans and animals. EMCV is a positive-strand RNA virus which 
is associated with sporadic cases and outbreaks of myocarditis and encephalitis in 
a wide range of vertebrates, but particularly in domestic pigs (Billinis et al., 1999). 
 
5.2.2. Using EMCV to examine the biological effect of proteins which inhibit 
JAK-STAT signalling 
The treatment of cells with rIFNα prior to EMCV infection results in reduced viral 
yield (Morrison and Racaniello, 2009, Whitaker-Dowling and Youngner, 1986, 
Munoz and Carrasco, 1981) and EMCV can therefore be classed as an IFN 
sensitive virus. Since EMCV is IFN sensitive, EMCV titre can provide a biological 
read out of the effectiveness of a protein that is believed to inhibit JAK-STAT 
signalling. If a protein inhibits JAK-STAT signalling, it will downregulate the 
antiviral IFN response to a certain degree, and therefore increase the EMCV titre. 
This premise has been used in other studies, for example, Morrison and 
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Racaniello, (2009) showed that the enteroviral 2A proteinase rescues the 
replication of EMCV in rIFNα pre-treated cells, using plaque assays to determine 
the virus titre.  
 
5.2.3. vIRF2, but not vIRF4 is able to rescue EMCV titre from the effects of 
IFN 
To test the hypothesis that, due to their inhibitory effect on JAK-STAT signalling, 
vIRF2 and vIRF4 can rescue  EMCV titre following rIFNα treatment, plaque assays 
were performed. Monolayers of EV-NTAP, vIRF2-NTAP or vIRF4-NTAP cells were 
pre-treated with rIFN and infected with EMCV at a MOI of 0.1 (see section 2.13.1 
for details). The cell supernatant was harvested 24 hours later for quantification of 
the viral titre by plaque assay (see section 2.13.2 for plaque assay details and 
section 2.13.3 for how the plaques were counted).  
 
Samples which were not treated with rIFNα resulted in similar EMCV titres. EV-
NTAP cells gave an average EMCV titre of 5.9x107 PFU/ml, the vIRF2-NTAP cells 
produced 3.2x107 PFU/ml and the vIRF4-NTAP cells produced 2.5x107 PFU/ml 
(Figure 5.1A, columns 1, 3 and 5 respectively). As expected, pre-treatment with 
rIFN decreased the yield of EMCV in the EV-NTAP cells by two orders of 
magnitude, to 3.1x105 PFU/ml (Figure 5.1A, compare columns 1 and 2). In 
contrast, the EMCV titre from the rIFN treated vIRF2-NTAP cells (2.9x107 
PFU/ml) was not decreased compared to the cells untreated with rIFN (Figure 
5.1A, compare columns 3 with 4). However in the case of vIRF4-NTAP cells 
treated with rIFN the EMCV titre fell to 3.8x105 PFU/ml, which is a drop of about 
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two orders of magnitude compared to the untreated vIRF4-NTAP cells (Figure 
5.1A, compare columns 5 and 6). This value is comparable with that of rIFNα 
treated EV-NTAP cells. Pictures of a plaque assay from one representative 
experiment are shown in Figure 5.1B. The number of plaques in the EV-NTAP and 
vIRF4-NTAP samples can be seen to reduce in the presence of rIFNα, whereas 
for the vIRF2-NTAP samples, the number of plaques are similar in the –rIFNα and 
+rIFNα samples.   
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Figure 5.1 vIRF2, but not vIRF4 is able to rescue EMCV titre from the effects 
of rIFN.  
Monolayers of the EV-NTAP, vIRF2-NTAP or vIRF4-NTAP cell lines were pre-
treated with tetracycline (0.125g/ml) for 24 hours and then either rIFN (300 
IU/ml) or no rIFN for 24 hours. The cells were then infected with EMCV (MOI = 
0.1) and 24 hours later the culture medium was collected. EMCV titres were 
determined by plaque assays on L929 cells. (A) The mean EMCV titres +/- SEM 
from three independent experiments are shown. For results from individual 
experiments see Figure 9.20. (B) The results of one representative plaque assay.  
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5.3. The vIRF2 and vIRF4 expressing cell lines reduce the binding of ISGF3 
components to an ISRE promoter sequence 
Since both vIRF2 and vIRF4 have been shown to inhibit JAK-STAT signalling in 
chapters 3 and 4, their effect on this pathway was investigated further. JAK-STAT 
signalling results in the formation of the ISGF3 complex, which translocates into 
the nucleus and binds to ISRE sequences, causing activation of ISGs. Since 
vIRF2 and vIRF4 inhibit this pathway, it was hypothesised that they may reduce 
levels of functional ISGF3 available to bind ISRE sequences. To test this 
hypothesis, the binding of ISGF3 to an ISRE sequence was measured by EMSA. 
Nuclear extracts (see section 2.9.2) from EV-NTAP, vIRF2-NTAP and vIRF4-
NTAP cell lines were subject to EMSA experiments. EMSA was performed as 
detailed in section 2.9.4 using an IRDye-700-labelled ISRE probe (see section 
2.9.3 for details on how the probe was made). The results show that as expected 
the band corresponding to the ISGF3-ISRE complex increased through stimulation 
with rIFNα (Figure 5.2A, lane 1 compared with lane 2). In the vIRF2 and vIRF4 
expressing cell lines, bands corresponding to the ISGF3-ISRE complex were 
reduced when compared to the EV-NTAP cell lines in the presence of rIFNα 
(Figure 5.2A, compare lane 2 with lanes 4 and 6), indicating that vIRF2 and vIRF4 
reduced ISGF3-ISRE complex formation. 
 
To ensure that the bands identified were actually the ISFG3 complex, two controls 
were run alongside the EMSA assay. Firstly, a ‘cold’ competitor probe (see Table 
2.11) was incubated (in excess) with nuclear lysate, from the EV-NTAP cells 
stimulated with rIFNα, along with the other components of the EMSA binding 
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reaction (see section 2.9.4). This probe is an unlabelled identical probe to the 
IRDye-700-labelled ISRE probe. The results for this control show that the ISGF3 
EMSA band density was reduced, indicating that the cold probe was competing for 
the binding to the ISGF3 complex with the IRdye-700-labelled probe. This result 
demonstrates that the EMSA shift (indicated ISGF3 on Figure 5.2A) was a result 
of a protein complex binding to the ISRE sequence. The second control was a 
‘supershift’ experiment. The STAT2 antibody was incubated with the nuclear 
lysate, from the EV-NTAP cells stimulated with rIFNα, along with the other 
components of the EMSA binding reaction (see section 2.9.4) and run alongside 
the EMSA gel. The results show that the ISGF3 band has ‘shifted’ higher than the 
other bands in the experiment, due to the increase in molecular weight from the 
STAT2 antibody (Figure 5.2A, compare lane 2 with lane 8). This result shows that 
the STAT2 protein is part of the protein:DNA complex, and this control confirms 
the presence of ISGF3 as part of this band. 
 
The densitometry of the ISGF3-ISRE bands from Figure 5.2A were quantified 
using the Odyssey infrared imaging system and the results are shown in Figure 
5.2B. From this graph, is clear that in the presence of vIRF2 or vIRF4, the intensity 
of the ISGF3-ISRE bands are reduced compared to the EV control in rIFNα 
stimulated conditions (Figure 5.2B, compare column 2 with columns 4 and 6). 
Figure 5.2C shows the zoomed bands from Figure 5.2A, lanes 1-6.  
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A portion of the extracted nuclear lysate was used in a western blot to detect 
TATA-binding protein (TBP), a nuclear protein (Figure 5.2D) which confirmed 
equal loading of nuclear lysates in the EMSA assay.  
 
Taken together the results of Figure 5.2 demonstrate reduced binding of ISGF3 to 
the ISRE probe in both the vIRF2-NTAP and the vIRF4-NTAP cell lines when 
compared to the EV-NTAP cell lines. This experiment was repeated three times, 
and the densitometry results were collected together. The inhibition in ISGF3-
ISRE complex binding was found to be a significantly decrease in rIFNα treated 
vIRF2-NTAP cells and vIRF4-NTAP cells compared to EV-NTAPS cells (p<0.01) 
(Figure 5.3 compare column 2 with columns 4 and 6).  
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Figure 5.2: vIRF2  and vIRF4 inhibit binding of ISGF3 to an ISRE probe.  
The EV-NTAP, vIRF2-NTAP and vIRF4-NTAP cell lines were treated with 
tetracycline (0.125μg/ml) for 24 h and treated or not with 300IU/ml rIFNα, as 
indicated, for 6 h. Nuclear extracts were then prepared by using a NE-PER 
nuclear extraction kit (Pierce Biotechnology). EMSAs were performed by 
incubating 5μg of each nuclear lysate sample with an ISRE probe for 30 minutes 
in a binding reaction (see Table 2.11) containing a 5′-IRDye-700-label. After 
binding, the reaction mixtures were resolved on 6 % polyacrylamide-TBE gels 
(Invitrogen) and the bands were visualized by using an Odyssey infrared imaging 
system (LI-COR Biotechnology) (see section 2.9.4 for further details of method). 
(A) One representative EMSA experiment, demonstrating reduced nuclear binding 
in the rIFNα treated vIRF2-NTAP and vIRF4-NTAP samples (lanes 4 and 6 
respectively). To ensure the bands were specific for ISGF3, a ‘cold competitor’ 
probe was added (3µl) to the rIFNα treated EV-NTAP sample and analysed in 
parallel (lane 7), which showed a reduction in band intensity compared to the 
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rIFNα treated EV-NTAP sample containing labelled probe only (compare lane 7 
and lane 2). As an additional control, the STAT2 antibody (see 2.9.1 was added to 
the rIFNα treated EV-NTAP sample and analysed in parallel (lane 8) as a 
‘supershift’ control. This resulted in the ISGF3 band migrating slower due to 
antibody increasing the size of the complex. (B) Western blot analysis of TBP with 
was performed in parallel on the nuclear extracts shown used in A, to confirm 
equal sample loading for the EMSA. This experiment was repeated twice more, 
and the EMSA results obtained, along with the band intensities and the TBP blots 
are shown in Figure 9.19. 
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Figure 5.3: The vIRF2-NTAP and vIRF4-NTAP proteins reduce binding of 
ISGF3 to the ISRE sequence.  
The band intensities from 3 independent EMSA assays performed as in Figure 5.2 
are shown as fold increase compared to the EV-NTAP cell which was un-
stimulated (column 1). The data represent the mean ± the SEM. *** = p<0.01 
ANOVA followed by a Dunnett post hoc test compared to EV-NTAP plus rIFNα 
(lane 2). For results from individual experiments see Figure 9.19 . 
  
CHAPTER 5               The biological significance and investigation of the mechanism…  
  
~ 169 ~ 
 
5.4. Examining components of the JAK-STAT signalling pathway by western 
blotting 
To investigate if the mechanism of the ISRE-containing promoter inhibition by 
vIRF2 and vIRF4 is due to modulation of ISGF3 components, the relative levels of 
these components were measured via western blotting.  
 
The induced stable cell lines were treated with rIFNα to activate the JAK-STAT 
signalling pathway. Lysates were analysed for the presence of the NTAP, vIRF2-
NTAP and vIRF4-NTAP proteins (Figure 5.4 rows 4 and 5) and the relative levels 
of IRF9, STAT1 and pSTAT1 were visualised. The levels of IRF9 and STAT1 were 
constant among all samples in both the presence and absence of rIFNα treatment 
(Figure 5.4 rows 1 and 2, look at all lanes). This lack of change indicates that 
neither vIRF2 nor vIRF4 decrease the levels of IRF9 or STAT1. As expected, 
pSTAT1 was only detected in rIFNα treated samples, as phosphorylation arises 
following rIFNα stimulation. In the rIFNα treated vIRF2-NTAP sample, the level of 
pSTAT1 was reduced compared to the rIFNα treated EV-NTAP sample (Figure 
5.4, row 3, compare lanes 2 and 4). This reduction can be seen in all three 
experiments (Figure 9.21), and confirms that the presence of vIRF2 results in a 
decrease of pSTAT1 levels. The levels of pSTAT1 are unchanged in rIFNα 
stimulated vIRF4-NTAP samples compared to EV-NTAP samples, indicating that 
vIRF4 does not affect levels of pSTAT1 to any detectable extent (Figure 5.4, row 
3, compare lanes 2 and 6). 
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Figure 5.4: pSTAT1 is reduced in the vIRF2-NTAP cell line compared to the 
EV-NTAP cell line.  
EV-NTAP, vIRF2-NTAP or vIRF4-NTAP cell lines were pre-treated with 
tetracycline (0.125g/ml) for 24 hours and then stimulated with rIFN (300IU/ml), 
or left un-stimulated, before being harvested 16 hours later. Lysates (40μg) were 
analysed by western blot to detect components of the JAK-STAT signalling 
pathway (IRF9, STAT1 and pSTAT1). For primary antibody concentrations and 
conditions see Table 9.3 . Probing for β-actin indicated equal loading and the 
NTAP, vIRF2-NTAP and vIRF4-NTAP proteins were detected using anti-mouse 
HRP-conjugated secondary antibody. The presence of bands in vIRF4-NTAP 
samples corresponding in size to that of the NTAP protein is most likely due to 
degradation of the vIRF4-NTAP protein (row 6 lanes 5 and 6). This experiment 
was repeated twice and the resultant blots are shown in Figure 9.21 
  
CHAPTER 5               The biological significance and investigation of the mechanism…  
  
~ 171 ~ 
 
5.5. Examining STAT2 and pSTAT2 levels in the vIRF2 and vIRF4 expressing 
cell lines 
The previous section detailed how the levels of ISGF3 components were 
compared among the stable cell lines. However, the levels of STAT2 and pSTAT2 
were not analysed in this way. The vIRF2-NTAP and the vIRF4-NTAP proteins 
exhibit degradation, resulting in bands which appear on the western blot. One of 
the vIRF4-NTAP degradation products results in a band which runs at the same 
size as STAT2 and pSTAT2, meaning that the level of pSTAT2 cannot be 
distinguished from the degradation products. To illustrate this problem, the lysates 
from the stable cell lines were separated on an SDS-PAGE gel, transferred and 
probed with anti-rabbit secondary-HRP antibody only. This analysis resulted in 
bands which correspond to the vIRF2-NTAP or vIRF4-NTAP proteins, along with 
their degradation products (Figure 5.5A), as they contain the NTAP tag which is 
comprised of protein G domains. Bands were observed in the vIRF4-NTAP lysates 
at a similar size to that of pSTAT2 (Figure 5.5A, lanes 7 and 8, marked with *). To 
confirm that these bands would obscure the visualisation of pSTAT2 bands, the 
same membrane was then probed for pSTAT2. The resultant blot shows clear 
pSTAT2 bands in the 293 cells, EV-NTAP and vIRF2-NTAP lysates from cells 
stimulated with rIFNα (Figure 5.5A lanes 10, 12 and 14). However, in the case of 
the vIRF4-NTAP lysates, the pSTAT2 bands cannot be distinguished from the 
degradation products (Figure 5.5B lanes 15 and 16). Therefore, levels of STAT2 
and pSTAT2 in vIRF4-NTAP cells cannot be measured in this manner 
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Figure 5.5: The degradation products from vIRF4-NTAP lysates obscure the 
pSTAT2 bands.  
EV-NTAP, vIRF2-NTAP or vIRF4-NTAP cell lines were treated as in Figure 5.4. 
293 cells were also stimulated with rIFN (300IU/ml), or left un-stimulated. Cells 
were harvested 16 hours later. Lysates (40μg) were analysed by western blotting. 
(A) Probing with anti-rabbit HRP-conjugated secondary antibody only. The 140kDa 
and 130kDa bands in lanes 5-8 correspond to the vIRF2-NTAP or vIRF4-NTAP 
proteins respectively. Smaller bands in these lanes are degradation products of 
these proteins. The asterisk to the right of the degradation bands in the vIRF4-
NTAP sample indicates the position of degradation products from vIRF4-NTAP 
which mask the pSTAT2 bands seen in B.  The absence of the NTAP protein in 
the EV-NTAP samples is due to this protein being too small to be visualised on 
this percentage gel (7% acrylamide). (B) The same membrane as in A was probed 
with a pSTAT2 antibody, followed by incubation with the anti-rabbit HRP-
conjugated secondary antibody only and development. The bands in lanes 10, 12 
and 14 are of pSTAT2. The bands in lanes 15 and 16 cannot be distinguished 
from pSTAT2 or degradation products of vIRF4. 293 cells were used in this 
experiment to provide a negative control for degradation products, as these cells 
do not contain any NTAP protein.  
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5.5.1. Examining the levels of STAT2 and pSTAT2 in vIRF2-NTAP cells  
Since the detection of pSTAT2 in the vIRF2-NTAP cell lysates was possible, it was 
investigated in comparison to EV-NTAP cell lysates. In the same way as described 
in section 5.4, EV-NTAP and vIRF2-NTAP lysates were analysed by western blot, 
this time for STAT2 and pSTAT2. The presence of vIRF2 did not result in a 
change in levels of STAT2 or pSTAT2 (Figure 5.6, row 1 and 2, compare lanes 2 
and 4).  
 
 
Figure 5.6: vIRF2 does not affect levels of STAT2 and pSTAT2.  
EV-NTAP or vIRF2-NTAP cell lysates were produced as in Figure 5.4. Lysates 
(40μg) were analysed by western blot to detect STAT2 and pSTAT2. For primary 
antibody concentrations and conditions see Table 9.3. Probing for β-actin 
indicated equal loading, and the NTAP and vIRF2-NTAP proteins were detected 
using anti-mouse HRP-conjugated secondary antibody. This experiment was 
repeated once more and the resultant blot is shown in Figure 9.22 
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5.5.2. Examining the levels of STAT2 and pSTAT2 in vIRF4-NTAP cells 
The NTAP tag contains two protein G domains, and these can be bound by any 
antibody. As shown in Figure 5.5, one of the vIRF4-NTAP degradation products is 
the same size as STAT2 and pSTAT2 which means their detection is obscured by 
this degradation product. It was therefore necessary to find a different way to 
measure levels of STAT2 and its phosphorylated derivative. 
 
The NTAP-tag is comprised of two protein G domains and a streptavidin binding 
domain (SBD) separated by a tobacco etch virus cleavage site (TEV) (Figure 5.7). 
Since obscuring of the STAT2 and pSTAT2 proteins during western blot analysis 
is due to the presence of the protein G, its removal was necessary. Lysates from 
293 cells, EV-NTAP or vIRF4-NTAP cells were incubated with TEV protease, in 
order to cleave the protein G domains from the EV-NTAP and vIRF4-NTAP 
(resulting in EV-SBD and vIRF4-SBP proteins), and their degradation products. 
These resultant proteins will not be detected non-specifically through incubation 
with any antibody, as they do not contain the protein G domains. The digested 
lysates were analysed by western blot to detect the STAT2 and pSTAT2 proteins. 
It was found that there is no change in levels of either STAT2 (Figure 5.8 row 2, 
compare lanes 4 and 5 with lanes 6 and 7) or pSTAT2 (Figure 5.8 row 1, compare 
lane 5 lane 7) between the EV-NTAP and vIRF4-NTAP samples, indicating that 
vIRF4 does not decrease levels of STAT2 or pSTAT2. 
 
The vIRF4-NTAP samples which were untreated with the TEV protease showed 
bands at 130kDa. The lack of bands at the size of the full length vIRF4-NTAP in 
CHAPTER 5               The biological significance and investigation of the mechanism…  
  
~ 175 ~ 
 
the TEV protease treated vIRF4-NTAP samples, when probed with anti-STAT2 or 
anti-pSTAT2 antibodies confirms that the NTAP protein has been digested from 
these lysates (Figure 5.8 rows 1 and 2, compare lanes 6 and 7 with lanes 8 and 
9). To confirm that vIRF4-SBP was present in the digested vIRF4-NTAP samples 
an antibody against SBP was used and this detected EV-SBP, vIRF4-SBP (Figure 
5.8 rows 3 and 4, lanes 4-7) and also vIRF4-NTAP (Figure 5.8 rows 3 and 4, lanes 
8 and 9). The vIRF4-SBP was shown to be about 15kDa smaller than the vIRF4-
NTAP, a difference that corresponds to the size of the protein G domains (Figure 
5.8 row 3, compare lanes 6 and 7 with lanes 8 and 9). Analysis of the 293 cell 
lysates confirmed that any bands were due to STAT2 or pSTAT2 and not from 
degradation products.  One sample of 293 cell lysates, treated with rIFNα, was not 
digested with the TEV protease in order to show that digestion has no effect on 
either STAT2 or pSTAT2 levels (Figure 5.8 rows 1 and 2, lane 1).    
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Figure 5.7: The NTAP tag.  
The NTAP tag is comprised of two protein G domains and a streptavidin binding 
domain (SBD) separated by a Tobacco etch virus (TEV) cleavage site. The vIRF2 
or vIRF4 proteins are contiguous with the SBD. The approximate molecular sizes 
of the domains are shown, but the figure is not dawn to scale.  
 
 
Figure 5.8: vIRF4 does not affect levels of STAT2 and pSTAT2. 
293, EV-NTAP or vIRF4-NTAP cell lysates were produced as in Figure 5.4. 
Lysates were digested with AcTEV Protease (TEV protease) overnight on a 
rotating wheel at 4˚C. The digested lysates (40μg) were analysed by western blot 
to detect STAT2 and pSTAT2 as described in Figure 5.7. Probing for β-actin 
indicated equal loading and the vIRF4-NTAP protein was detected using anti-
mouse HRP-conjugated secondary antibody. The vIRF4-SBP and SBP proteins 
resulting from TEV protease vIRF4-NTAP and EV-NTAP samples respectively 
were detected using an ant-streptavidin binding protein antibody. This experiment 
was repeated and the result is shown in Figure 9.23.  
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5.6. Discussion 
Both vIRF2 and vIRF4 have been shown to negatively regulate the JAK-STAT 
signalling pathway (chapters 3 and 4), but the mechanisms behind their action are 
currently unknown. The aim of the work in this chapter was to assess the extent 
and the mechanisms of these viral proteins upon the antiviral response. 
 
To provide a biological readout of the extent of the vIRF2 and vIRF4 anti-IFN 
effect, the rescue of the IFN sensitive EMCV titre was assessed. vIRF2 rescued 
EMCV titre following rIFNα treatment, whereas vIRF4 was unable to do so (Figure 
5.1). This effect of vIRF2 is consistent with previously published findings from our 
laboratory (Mutocheluh et al., 2011). Since the vIRF2 mediated blockade on the 
JAK-STAT signalling pathway is strong enough to rescue EMCV from the effect of 
rIFN, it could be hypothesised that vIRF2 may play a role in allowing more 
efficient infection by KSHV during primary infection or lytic reactivation. The lytic 
vIRF2 protein could suppress the IFN response resulting in increased infection. 
This hypothesis could be tested by infecting the stable cell lines with KSHV, and 
quantifying levels of the virus. The stable cell lines could be infected with rKSHV 
which constitutively expressed the GFP protein. The presence of GFP means that 
the levels of this virus could be quantified using flow cytometry. If the presence of 
vIRF2 increased the levels of KSHV it would provide evidence that vIRF2 is 
playing a role in increasing KSHV infection. 
 
Contrastingly, vIRF4 was unable to rescue EMCV titre from IFN. There are some 
possibilities why this was the case. Firstly, vIRF2 can downregulate IFNβ promoter 
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activation (Fuld et al., 2006, Areste et al., 2009), whereas vIRF4 cannot. Since 
vIRF2 inhibits IFNβ promoter activation, and therefore IFN production, the vIRF2-
NTAP cells would theoretically produce less endogenous IFN in response to 
EMCV infection than cells lacking vIRF2. However, in the vIRF4-NTAP cells the 
infection with EMCV would result in endogenous IFN production, in addition to the 
exogenous recombinant rIFNα added to the culture as part of the experiment. IFN 
can also positively regulate the production of more IFN by activating the IFN 
production pathway (Sato et al., 1998), so in vIRF2 expressing cells, this positive 
regulation would be inhibited, while in vIRF4 expressing cells this would not be 
inhibited. Overall, this additional endogenous IFN would increase the IFN 
concentration in the local cell environment. The increased IFN around the infected 
cells may activate the antiviral response to a level which vIRF4 could not inhibit, 
thus confounding the effect of vIRF4. 
 
Secondly, the experiment used 300IU/ml of rIFNα which may have been an 
excessive amount of IFN to use for this readout. At lower IFN concentrations 
vIRF4 may rescue EMCV titre.  
 
Thirdly, vIRF2 can interact with and inhibit PKR kinase activity reducing the 
inhibition of viral mRNA translation (Burysek and Pitha, 2001). PKR can detect 
dsRNA and lead to an inhibition of viral mRNA translation (see section 1.4.10.1). 
The EMCV titre in vIRF2 expressing cells may be increased as viral mRNA 
translation is not inhibited. Since vIRF4 has not been shown to interact with PKR, 
it is unlikely to prevent the activation of this kinase, and thus, mRNA translation is 
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halted, leading to reduced EMCV titre. Overall, the contrasting results observed 
between the effect of vIRF2 and vIRF4 on EMCV titre may reflect mechanistic 
differences in their mode of action. 
 
The EMSA experiments aimed to examine the binding of ISGF3 to the ISRE 
sequence in the stable cell lines. It was found that in both vIRF2-NTAP and vIRF4-
NTAP cells the binding of ISGF3 to the ISRE consensus sequence was 
significantly inhibited when compared to the EV-NTAP cell line (Figure 5.3). Since 
ISGF3 drives expression of ISGs, these results confirm the luciferase reporter 
studies (chapter 3 and 4) that vIRF2 and vIRF4 downregulate JAK-STAT 
signalling and repressing the host cell anti-viral response.  
 
There are numerous steps in the JAK-STAT pathway, and thus numerous steps 
for viral proteins to target, in order to inhibit the antiviral response. A common way 
for viruses to attenuate JAK-STAT signalling is to reduce the levels of the 
components of the ISGF3 complex. For example, the Dengue virus NS5 protein 
binds to STAT2 and targets it for degradation, inhibiting JAK-STAT signalling 
(Ashour et al., 2009). Alternatively, the V Protein encoded by Simian Virus 5 
inhibits interferon signalling by targeting STAT1 for proteasome-mediated 
degradation (Didcock et al., 1999). 
 
To investigate if either vIRF2 or vIRF4 cause reduced levels of the ISGF3 
components or their precursors, the levels of STAT1, pSTAT1, STAT2, pSTAT2 
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and IRF9 were compared in the stable cell lines. pSTAT1 levels reduced in the 
vIRF2-NTAP cell lines compared to the EV-NTAP cell lines (Figure 5.4). This 
result confirms the previous studies from our laboratory (Mutocheluh et al., 2011). 
Further experiments would aim to identify how pSTAT1 levels are reduced by 
vIRF2. Interestingly, the levels of STAT1 are not decreased in the vIRF2 
expressing cells, suggesting that the reduction of pSTAT1 levels is not due to 
degradation of STAT1 or a reduction in STAT1 transcription. To confirm this 
theory, the stable cell lines could be treated with the proteasome inhibitor, MG132, 
and STAT1 and pSTAT1 levels re-assessed. If levels of pSTAT1 are not reduced 
in the vIRF2-NTAP cell lines, it indicates that proteasomal degradation is involved 
and vice versa. qPCR could be used to compare levels of STAT1 mRNA amongst 
the stable cell lines to rule out any effects from differences in transcription of 
STAT1.  
 
Kumthip et al, (2012) found that the HCV NS5A protein decreases levels of 
pSTAT1, without affecting levels of STAT1. NS5A was shown to bind to STAT1 
and it was proposed that this binding was responsible for the reduction of pSTAT1 
and inhibition of the JAK-STAT signalling pathway (Kumthip et al., 2012). It can be 
hypothesised that, like NS5A, vIRF2 can also bind to STAT1, leading to a 
decrease in levels of pSTAT1. To determine if vIRF2 could bind to STAT1 and to 
identify any other vIRF2 binding partners, pull down experiments were analysed 
by mass spectrometry (see results chapter 6).  
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In the vIRF4-NTAP cells, none of the components of the ISGF3 complex were 
found to be reduced compared to the EV-NTAP cells. This result reveals that 
vIRF4 does not downregulate ISRE promoter activity by decreasing levels of the 
ISGF3 components. Because levels of ISGF3 components are not reduced in 
vIRF4-NTAP cells, vIRF4 is unlikely to be targeting protein levels of components 
upstream of the ISGF3 in the JAK-STAT signalling pathway. For example if levels 
of the IFNAR1 were reduced, it would be expected to reduce ISGF3 components.  
 
Since vIRF4 is not down regulating ISRE promoter activity by reducing levels of 
the ISGF3 components, the mechanism behind its action remains to be found. The 
translocation of ISGF3 components from the cytoplasm to the nucleus is a vital 
step in activation of the ISRE promoter. The P protein encoded by Rabies virus 
attenuates JAK-STAT signalling by inhibiting the translocation of STAT1 into the 
nucleus (Vidy et al., 2005). Immunofluorescence staining of the ISGF3 
components in vIRF4 expressing cells could determine whether vIRF4 is causing 
the sequestration of these signalling components in the cytoplasm, and restricting 
their translocation to the nucleus. 
 
Collectively, the western blot analysis on ISGF3 components implies that vIRF2 
and vIRF4 exert their anti-IFN effect in different manners. It is not surprising that 
vIRF2 and vIRF4 have different mechanisms to achieve the same overall result.  
KSHV encodes many proteins which inhibit IFN signalling, which points to the 
importance of innate immune evasion by the virus. KSHV would not have so many 
proteins which all work in the same way as they would be unnecessary and 
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selective pressure would result in loss of these genes over time. Additionally, if 
these proteins employed the same mechanism to achieve inhibition of IFN 
signalling, the host would only require one mechanism to overcome the effects of 
the viral proteins. Therefore, it makes sense that vIRF2 and vIRF4 have different 
mechanisms to inhibit IFN signalling. These proteins may also act at slightly 
different stages of the viral life cycle, or act in different cell types. Another 
possibility for the difference of results seen by western blot is simply that vIRF2 
and vIRF4 may be expressed ectopically at different levels, making one 
mechanism more obvious, by western blotting, than the other.  
 
Overall, this chapter has shown that ectopic expression of vIRF2, but not vIRF4, 
can rescue the IFN sensitive EMCV virus. EMSA experiments revealed that both 
vIRF2 and vIRF4 inhibit binding of the ISGF3 to the ISRE promoter. Finally, 
western blot analysis revealed that vIRF2 decreases the levels of pSTAT1 
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One of the aims of chapter 5 was to determine whether vIRF2 or vIRF4 exert their 
interferon inhibitory activities by down regulating levels of the ISGF3 components. 
It was found that vIRF2 caused a selective decrease in pSTAT1 levels, but did not 
affect levels of STAT1. This decrease in pSTAT1 is expected to lead to inhibition 
of JAK-STAT signalling, and is proposed to be one way in which vIRF2 inhibits the 
host antiviral effect. vIRF4 was not found to downregulate any of the ISGF3 
components.  
 
This chapter aims to build on these results by gaining further knowledge of how 
vIRF2 is decreasing levels of pSTAT1 and to identify how vIRF4 may be exerting 
its anti-IFN effect. Instead of testing each possible mechanism of inhibition 
separately, which is both time consuming and costly, it was decided that protein 
binding partners of both vIRF2 and vIRF4 should be identified, based on the 
hypothesis that this would reveal biologically significant interactions in terms of 
IFN signalling. This approach was therefore expected to narrow down the possible 
mechanism of action of vIRF4, and lead to understanding of how vIRF2 is 
decreasing pSTAT1.   
 
The aims of this chapter are to: 
1) Perform pull down experiments on lysates from the stable cell lines in order 
to purify NTAP-tagged KSHV proteins and their cellular binding partners 
2) Identify these cellular protein binding partners of vIRF2 and vIRF4 by mass 
spectrometry 




3) Select some of these binding partners for examination in more detail in the 
Chapter 7. 
 
Some interaction partners of the KSHV vIRF2 or vIRF4 proteins have already 
been identified by other groups. For example, interactions have been found 
between vIRF2 and CBP (Burysek et al., 1999b) and vIRF2 and PKR (Burysek 
and Pitha, 2001). In the case of vIRF4, interactions have been confirmed between 
USP7 (Lee et al., 2011) and MDM2 (Lee et al., 2009) amongst others.  
 
Since the work in this thesis focuses on the negative regulation of ISRE-containing 
promoter transactivation by the vIRF2 and vIRF4 proteins, the cellular interactions 
of these proteins following rIFNα treatment was examined. The aim was to 
determine any binding partners which contribute to the observed downregulation 
of JAK-STAT signalling.   
 
As described previously, both the vIRF2 and the vIRF4 genes were cloned 
separately into an NTAP expression vector. This vector expresses an NTAP-tag, 
which allows for tandem affinity purification of the contiguous vIRF2 or vIRF4 
proteins along with any binding partners. Tandem affinity purification (TAP) can be 
performed using a variety of vectors, with a variety of tags. The TAP-tag portion of 
the NTAP vector used in this study consisted of two IgG binding units of protein G 
from Streptococcus sp, linked to the SBP by a TEV cleavage site (Figure 5.7). The 
two-step purification therefore required the use of IgG agarose beads, which bind 




to the protein G domains, followed by elution through TEV protease cleavage, and 
then a second purification step using Streptavadin beads to bind SBP and eluting 
with biotin. Following purification, the identity of any binding partners can be 
determined through mass spectrometry analysis. The advantage of tandem 
purification over single purification is that the final eluate often contains far fewer 
contaminants, and thus the results are more specific. However, the tandem step 
process can result in a lower yield of final product which is a disadvantage as the 
mass spectrometry analysis may not pick up weak or low abundance binding 
partners. Through preliminary experiments, it became clear that the yield of final 
proteins generated through the tandem affinity purification was very low. To rectify 
this, the method was changed to a single purification protocol by removing the IgG 
incubation and TEV protease cleavage steps in the protocol, and using the 
streptavidin beads only. This method resulted in a much higher yield of protein 
following initial experiments, and was thus used in the large scale protein 
purification. Because single purifications may result in more contaminants, SILAC 
was used in combination with the pull down to help to differentiate between 
specific and non-specific binding proteins.  
  




6.2. TAP resulted in very little purified protein, therefore a single purification 
step was used instead 
TAP is a two-step protocol that enables the affinity purification of proteins and their 
binding partners. The identity of these binding partners is determined by mass 
spectrometry. One major advantage of tandem purification compared to single 
affinity purification procedures is that the level of non-specific contaminants is 
greatly reduced.  
 
Prior to full scale protein purification, a scaled down version of the TAP protocol 
(see Burckstummer et al (2006), for this method) was performed in order to 
confirm that the procedure worked. Briefly, lysates from the stable cell lines were 
incubated with IgG-coated beads, so that the protein G domains of the NTAP 
tagged proteins bound to the beads. Following washing, the tagged proteins are 
eluted using TEV protease, which cleaves the NTAP tag, leaving the Protein G 
domains bound to the beads and releasing the protein of interest attached to the 
SBP. The second purification step involves incubation with Streptavidin beads, 
followed by washing and elution with biotin. 
 
Unfortunately, despite numerous attempts, either no or very little protein could be 
detected in the final eluate (data not shown). To increase the yield of final protein 
with binding partners, the first purification step with IgG beads was not performed 
and only the streptavadin bead step was implemented (see materials and method 
section 2.5.3 for details). However, because this procedure was a single 
purification process, the chance of non-specific proteins being identified was 




increased considerably. One way to overcome this problem would be to use a 
higher salt concentration to wash the streptavidin beads, which would result in 
more stringent interactions. This solution has the disadvantage of also erroneously 
removing low abundance and/or low affinity binding partners, which may be 
important in the function of vIRF2 and vIRF4. Therefore, it was decided that 
proteins would be purified from differentially labelled samples, in order to quantify 
and compare levels of purified proteins in the vIRF2-NTAP and vIRF4-NTAP 
sample with the EV-NTAP control. By quantifying the protein partners, anything 
which increase in binding compared to the EV-NTAP samples could be thought of 
a possible interaction partners, whereas proteins which bound the same amount 
could be classed as background. The labelling of samples was achieved using 
isotope labelling of amino acids, more commonly known as SILAC.  
 
6.3. Combining SILAC, mass spectrometry and pull down experiments 
The stable cell lines were labelled by SILAC, followed by purification on 
streptavidin beads. The purified samples were then analysed by mass 
spectrometry to identify binding partners and to detect differences in protein 
abundance.  
 
6.3.1. Labelling of the stable cell lines 
In this thesis, the three cell lines to be analysed (EV-NTAP, vIRF2-NTAP and 
vIRF4-NTAP) were cultured in identical media except one contained ‘light’ amino 
acids, one contained ‘medium’ amino acids and the other contained ’heavy’ amino 




acids. For details of how cells were labelled, see sections 2.5.1 and 2.5.2. These 
amino acids were incorporated into all newly synthesized proteins, so that after at 
least 5 passages all un-labelled amino acids were expected to have been 
replaced by the labelled amino acids.  
 
6.3.2. Pull down of the NTAP-tagged proteins and their binding partners 
under SILAC conditions 
The pull down strategy employed to purify the NTAP tagged proteins and binding 
partners is shown in Figure 6.1 and described in detail in sections 2.5.2 and 2.5.3. 
This experiment was performed three times. For experiments 1 and 3, the EV-
NTAP cell lines were labelled with the light media, the vIRF2-NTAP cells were 
labelled with medium media and the vIRF4-NTAP cells were labelled with heavy 
media. For experiment 2, the vIRF2-NTAP cells were instead labelled with heavy 
media and the vIRF4-NTAP cells with the medium media. This switch in labelling 
media was to insure any proteins identified were not due to the differences in the 
labelling media.  
 
Throughout this purification procedure, samples were collected as indicated in 
Figure 6.1A, B and C. These samples were later analysed by western blot (Figure 
6.2A). Enrichment of all three proteins (NTAP, vIRF2-NTAP and vIRF4-NTAP) is 
evident (Figure 6.2A, lanes 7-9, compared with the other lanes). There was 
detection of NTAP and vIRF2-NTAP in the flow through samples (Figure 6.2A, 
lanes 4 and 5), indicating that not all of these bound to the streptavidin beads.  




To show the presence of the NTAP-tagged proteins in the final eluates of all three 
separate experiments, a portion of these samples were analysed by western blot 
(Figure 6.2B). The presence of the NTAP, vIRF2-NTAP and vIRF4-NTAP proteins 
is clear in all three experiments. To ensure that proteins, other than the NTAP-
tagged proteins, were present in the final eluate samples, these samples were run 
on a SDS gel and proteins were visualised by silver staining. Hence the samples 
could be analysed by mass spectrometry.  
 
6.3.3. Mass spectrometric analysis of the eluted samples 
Equal volumes of the R0K0 and R6K4 and R10K8-labelled samples 
(corresponding to the eluates from the NTAP, vIRF2-NTAP and vIRF4-NTAP  
samples) were mixed together, resulting in three final samples (corresponding to 
the three separate experiments). The combined samples were submitted to the 
Proteomics Facility at the University of Bristol for analysis. Details of how samples 
were analysed are found in 2.5.4  
 





Figure 6.1: Strategy for identifying cellular interaction partners of vIRF2 and 
vIRF4. 
  





Figure 6.2: A. Samples collected at various stages of the pull down process. 
B. Final eluates from all three pull down experiments show the presence of 
the NTAP, vIRF2-NTAP and vIRF4-NTAP proteins. 
A. Samples were put aside as described in sections 0 and 2.5.3. The lysate 
samples were collected following lysis of the cells (Figure 6.1A). The flow-through 
samples contained proteins which had not bound to the streptavidin beads (Figure 
6.1B). The eluate samples were the final purified proteins (Figure 6.1C). 20µg of 
each sample was loaded on an SDS-PAGE gel and analysed by western blot to 
detect the NTAP tagged proteins and β-actin.’white*'s’ represent the proteins of 
interest (NTAP, vIRF2-NTAP, vIRF4-NTAP) Primary antibody: anti-β-actin. 
Secondary antibody: anti-mouse HRP-conjugated secondary antibody (for β-actin 
detection). The use of the anti-mouse HRP-conjugated secondary antibody was 
sufficient to detect the NTAP-tag in all the cell lines as this tag contains protein G. 
Probing for β-actin confirmed equal loading between the lysate and flow through 
samples. This blot shows the result of one pull down experiment. This was 
repeated twice and the resultant blots can be seen in Figure 9.24 B.Final eluate 
samples from all 3 experiments were collected. 10ul of each sample was analysed 
by western blot to detect the NTAP, vIRF2-NTAP and vIRF4-NTAP proteins. The 
use of the anti-rabbit HRP-conjugated secondary antibody was sufficient to detect 
the NTAP-tag in all the samples as this tag contains protein G.   





Figure 6.3: Silver-stained SDS-PAGE gel showing the pull downs from three 
separate experiments.  
The final samples as shown in Figure 6.2 were run on a a precast NuPage 
(Invitrogen) 10% Bis-Tris gel. Silver staining was carried out as described in 
section 2.5.5.  
  




6.4. Results of Mass Spectrometry: 
Since the cells used to make the stable cell lines were 293 derived (a human cell 
line), proteins were identified by comparison to human sequences. In total 963 
proteins were quantified in three experiments by SILAC LC-MS/MS (experiment 1 
= 290 proteins, experiment 2 = 352 proteins, experiment 3 = 321 proteins). The 
results were ‘cleaned’, by removing any peptide sequences which appeared only 
once per experiment, as these proteins cannot be classed as ‘real’ results. 291 
proteins were brought forward from the three experiments following this procedure 
(experiment 1 = 86 proteins, experiment 2 = 108 proteins, experiment 3 = 97 
proteins). Of the 291 proteins 153 were unique. The Venn diagram (Figure 6.4) 
presents these results graphically.  
 
6.4.1. Distinguishing between significant and non-significant results 
One problem with SILAC mass spectrometry is deciding which identified proteins 
to class as significant and which to discard. Since mass spectrometry is so 
sensitive many identified proteins are in fact contaminants. Deciding on a cuttoff 
point for specific proteins and contaminants is therefore a key step in identifying 
real interactions. Two ways to separate significant and non-significant interactions 
will be discussed in this thesis.  
 
1) Less stringent: This method is commonly used in the literature (Boulon et 
al., 2010), and is based on the principle that a protein showing a 1.5 fold 
increase in its abundance in the pull down compared to the control is a 
specific interaction. 




2) Very stringent: This method ensures only the top 5% of hits are classed as 
specific interactions. 
 
The less stringent approach uses the ratios of the proteins of interest compared to 
the control. The mass spectrometry results were presented as SILAC ratios for 
each identified protein. For example, each identified protein was given a 
medium/light ratio (which would be vIRF2/EV in experiments 1 and 2, and 
vIRF4/EV in experiment 2) and a heavy/light ratio (which would be vIRF4/EV in 
experiments 1 and 2, and vIRF2/EV in experiment 2). A higher ratio for a binding 
protein means that it is more likely to have bound specifically to the protein of 
interest. This approach means that proteins with low ratios, which are more likely 
to be background contamination or proteins which bound non-specifically to the 
beads, can be distinguished from proteins with higher ratios, which represent more 
significant interactions. A ratio of 1.5-fold is a commonly used cutoff when Orbitrap 
instruments are used (Boulon et al., 2010). When using arbitrary cutoff values, it is 
clear that a high threshold yields more ‘real’ results. However, some genuine 
interactions may also be lost. Conversely, using a low threshold, will include more 
contaminants, but may include some low abundance/low affinity interactions 
(Boulon et al., 2010). 
 
As a conservative cutoff, a 2-fold ratio was used in this thesis to identify cellular 
proteins likely to be binding to vIRF2 or vIRF4 specifically. Usually, the average 
SILAC ratio for each identified binding protein would be calculated from the values 
from each experiment. However, in these results, experiment 2 yielded much 




higher SILAC ratios than the other two, and averaging results from all three 
experiments would mean that peptides from experiment 2 could become un-
significant. While these interactions may indeed be false, a search of the literature 
has shown some of these interactions to be real (the case of vIRF4 binding to 
USP7 is one example). Therefore, the number of peptides with a SILAC ratio over 
2-fold in any experiment was determined. In the case of vIRF2/EV, 56/153 (37%) 
proteins had a ratio of greater than or equal to 2 (Table 6.1). In the case of 
vIRF4/EV, 23/153 (15%) proteins had a ratio of greater than or equal to 2 (Table 
6.2).  
 
The very stringent approach identifies the top 5% of proteins which bind to the 
vIRF2 or vIRF4 proteins, compared to the EV-NTAP control. To identify this 
category of interacting cellular proteins, firstly the SILAC ratios were converted to 
log2, so that the data were normally distributed. The average log2 ratios and 
standard deviation of the log2 ratios were determined for all for medium/heavy and 
light/heavy ratios. The log2 ratio for each protein was then converted into a Z-
score so that protein ratios could be normalized to the mean and standard 
deviation of each experiment. The formula to calculate the z score was: 
 
Z score = log2 ratio (of peptide) – mean log2 ratio of all ratios for that experiment 
         SD of all log2ratios for that experiment 
 




A Z-score of ≥1.95, giving the top 5% of hits for each experiment, was then used 




Figure 6.4: Triplicate experiments showing the extent of overlap of proteins 
identified in each of the 3 independent experiments.  
Venn diagram of all proteins identified by SILAC.  
  




Table 6.1: Potential vIRF2 binding partners based on a less stringent 
approach.   
Proteins which showed an  2-fold change in abundance compared to the control 
were included in this table.  * indicates proteins also identified in the very stringent 
approach. 




ratio of 2 
Number of 
expts below 
ratio of 2 
CREB-binding protein* Q92793 2 0 
HAT p300* Q09472 2 0 
Ras GTPase-activating-like 
protein* 
P46940 3 0 
Ubiquitin carboxyl-terminal 
hydrolase* 
F5H8E5 2 1 
Protein Njmu-R1* Q9HAS0 1 0 
Nucleoside diphosphate kinase A* P15531 2 0 
Nucleoside diphosphate kinase* Q32Q12 3 0 
Protein RCC2 Q9P258 3 0 
Trim3* E7EUK0 1 1 
40S ribosomal protein S6 P62753 1 0 
60S acidic ribosomal protein P2 P05387 1 0 
Ribosomal protein L18 E7EW92 1 0 
6-phosphofructokinase type C Q01813 2 1 
Guanine nucleotide-binding 
protein subunit beta-2-like 1 
P63244 1 0 
60S acidic ribosomal protein P2 Q02878 1 0 
60S acidic ribosomal protein P2 P05387 1 0 
Ribosomal protein L15 E7EQV9 1 0 
40S ribosomal protein S8 P62241 1 0 
DHX9 F5GXA5 1 0 
RPL4 E7EWF1 1 0 
RPLP0 protein Q3B7A4 1 0 
Ribosomal protein L5 Q5T7N0 1 0 
60S ribosomal protein L7a P62424 1 0 
60S ribosomal protein L12 P30050 1 0 
RPSA C9J9K3 1 0 
RPS2 E9PQD7 1 0 
PABPC1 E7EQV3 1 0 
40S ribosomal protein S23 P62266 1 0 
Ribosomal protein L28 C9JB50 1 0 
60S ribosomal protein L19 P84098 1 0 
LIM domain and actin-binding 
protein 
Q9UHB6 1 0 




40S ribosomal protein S3 P23396 1 0 
RPL27A E9PJD9 1 0 
60S ribosomal protein L13 P26373 1 1 
40S ribosomal protein S5 P46782 1 1 
HNRNPU B3KX72 1 2 
Ribosomal protein S9 B5MCT8 1 0 
Myosin light polypeptide 6 P60660 1 0 
40S ribosomal protein S18 P62269 1 2 
Actin, cytoplasmic 1 P60709 1 2 
Heterogeneous nuclear 
ribonucleoprotein K  
Q5T6W5 1 1 
40S ribosomal protein S19 P39019 1 1 
40S ribosomal protein S14 P62263 1 2 
60S ribosomal protein L23a P62750 1 0 
60S ribosomal protein L11 P62913 1 2 
60S ribosomal protein L38 P63173 1 1 
40S ribosomal protein S13 P62277 1 2 
Polypyrimidine tract-binding 
protein 1 
P26599 1 0 
1PL24 C9JXB8 1 2 
DDX3X  B4E3E8 1 2 
HMMR E3W978 1 1 
THO complex subunit 4 Q86V81 1 0 
Splicing factor SFPQ P23246 1 0 
Histone H2B type 1 O60814 1 0 
TFAM A8MRB2 1 0 
 
Table 6.2: Potential vIRF4 binding partners based on a less stringent 
approach.   
Proteins which showed an  2-fold change in abundance compared to the control 
were included in this table * indicates proteins also identified in the very stringent 
approach. 
Protein name Accession 
number 
Number of 
expts over ratio 
of 2 
Number of expts 
below ratio of 2 
CREB-binding protein* Q92793 1 0 
Ubiquitin carboxyl-terminal 
hydrolase* 
F5H8E5 1 2 
Heat shock protein HSP 
90-ALPHA* 
P07900 1 2 
RCC2 Q9P258 1 2 
40S ribosomal protein S6 P62753 1 0 




Vimentin P08670 1 2 
60S acidic ribosomal 
protein P2 
B3KX72 1 2 
40S ribosomal protein 
S20* 
P60866 1 2 
40S ribosomal protein S3 P23396 1 1 
40S ribosomal protein S18 P46782 1 2 
40S ribosomal protein S17 P62269 1 0 
Splicing factor, proline- and 
glutamine-rich  
P23246 1 0 
Splicing factor SFPQ P0CW22 1 0 
LIMA1 B4DN52 1 0 
40S ribosomal protein S19 P39019 1 2 
Myosin-9  P35579 1 0 
40S ribosomal protein S14 P62263 1 2 
40S ribosomal protein S11 P62280 1 0 
RPL35 F2Z388 1 1 
40S ribosomal protein S10 P46783 1 2 
40S ribosomal protein S7 P62081 1 2 
40S ribosomal protein S13 P62277 1 2 
Actin, cytoplasmic 1 P60709 1 2 
 
  




Table 6.3: Potential vIRF2 binding partners based on a very stringent 
approach 
Protein name Accession 
number 
Number of 
expts in top 5% 
Number of expts 
below top 5% 
CREB-binding protein Q92793 2 0 
HAT p300 Q09472 2 0 
Ras GTPase-activating-
like protein 
P46940 2 1 
Ubiquitin carboxyl-
terminal hydrolase 
F5H8E5 2 0 
Protein Njmu-R1 P15531 1 0 
Nucleoside diphosphate 
kinase A 
Q32Q12 1 0 
Nucleoside diphosphate 
kinase 
Q32Q12 1 0 
Trim3 E7EUK0 1 1 
 
 
Table 6.4: Potential vIRF4 binding partners based on a very stringent 
approach 
Protein name Accession 
number 
Number of 
expts in top 5% 
Number of expts 
below top 5% 
CREB-binding protein Q92793 1 0 
Ubiquitin carboxyl-
terminal hydrolase 
F5H8E5 1 0 
Heat shock protein HSP 
90-ALPHA 
P07900 1 2 
40S ribosomal protein 
S20 
P60866 1 0 
RBPJ B4DY22 1 0 
 
  




6.5. Selecting proteins to analyse further: 
The results in Table 6.1-Table 6.4 show possible binding partners for vIRF2 and 
vIRF4. To verify that these proteins are real interactors and not contaminants of 
the method, further experiments needed to be performed. Due to time constraints, 
it was not feasible to examine all possible binding partners, and therefore selected 
proteins were identified for further study. They were 1) CREB-binding protein 
(Q92793), 2) HAT p300 (Q09472), 3) Ubiquitin carboxyl-terminal hydrolase 
(F5H8E5) 4) 40S ribosomal protein S3 (P23396), 5) 40S ribosomal protein S6 
(P62753). All these proteins were predicted to bind to both vIRF2 and vIRF4 in the 
less stringent approach and some of them were identified in the very stringent 
approach.  The rationale for these selections is outlined in the discussion to this 
chapter.   
  





This chapter has described how pull down experiments were performed on lysates 
from the stable cell lines and how proteins were identified from these samples. 
The results from the mass spectrometry have been analysed in two ways to 
provide either less or very stringent predictions of the vIRF2 or vIRF4 interactome. 
As described in this chapter, identification of protein binding partners by mass 
spectrometry is very sensitive. This is very useful, as it may identify low 
abundance or weak interactions between proteins. However, it also means that 
contaminants may be misinterpreted as real interactions. Therefore to confirm if 
the predicted interactions are real, further experiments must be performed such as 
immunofluorescence experiments to examine co-localisation of proteins and 
immunoprecipitation. Based on the results in this chapter, five proteins have been 
chosen to confirm whether their interactions with vIRF2 and vIRF4 are genuine, 
thus justifying their examination in more detail in the context of IFN signalling. 
These 5 proteins are discussed in the following paragraphs.  
 
6.6.1. CBP and p300 
CBP was identified by Chrivia et al 1993 to bind to cAMP response element-
binding protein (CREB) while p300 was found to associate with the adenovirus 
E1A protein (Eckner et al., 1994). These two proteins share a high degree of 
sequence homology (Figure 7.12). Both the CBP and p300 co-activator proteins 
are involved in binding to transcription factors and RNA polymerase II to stabilize 
the transcription complex and transcribe genes. They also exhibit HAT activity, 
which is involved in gene transcription (see section 7.9.3 for further details). As 




well as being able to acetylate histones, these proteins can also acetylate other 
proteins (reviewed in Kalkhoven, (2004)).  
 
Previous studies have found that vIRF2 can bind to the CBP/p300 protein 
(Burysek et al., 1999b). However no reports have identified CBP as an interacting 
partner for vIRF4. The results from this chapter found CBP as a possible binding 
partner for both vIRF2 and vIRF4 in both the less stringent (Table 6.1 and Table 
6.2 respectively) and very stringent approaches (Table 6.3 and Table 6.4 
respectively). p300 was identified as a potential binding protein for vIRF2 in both 
the less stringent (Table 6.1) and very stringent (Table 6.3) approaches. However 
it was not predicted to be a binding partner for vIRF4 in any approach to examine 
to data. The other KSHV-encoded vIRF proteins (vIRF1 and vIRF3), have also 
been shown to bind CBP/P300. vIRF1 inhibits IFN signalling by blocking the 
cellular IRF3 recruitment of the CBP/p300 coactivator (Lin et al., 2001). vIRF3 
directly interacts with cellular IRF3, IRF7, and the transcriptional coactivator 
CBP/p300 (Lubyova et al., 2004). 
 
Therefore, because CBP has been shown to associate with vIRF1, vIRF2 and 
vIRF3 and because vIRF4 has been predicted to bind CBP based on the results of 
this chapter, the interactions between CBP and either vIRF2 or vIRF4 were 
selected for further study. The yield of vIRF4 obtained from the pull down, prior to 
mass spectrometric analysis was low, and thus, possible interactions between 
vIRF4 and p300 may not have been present. Since CBP and p300 are very similar 




proteins, it was decided that, even though vIRF4 was not predicted to bind to 
p300, immunoprecipitation should be used to confirm this prediction.  
 
6.6.2. Ubiquitin carboxyl-terminal hydrolase  
USP7, also known HAUSP is a de-ubiquitylating enzyme, which cleaves ubiquitin 
from specific proteins. USP7 was first identified by its interaction with the herpes 
simplex virus type I immediate early protein, ICP0 (Everett et al., 1997, Meredith et 
al., 1994). The EBV encoded EBNA1 protein is also a target of USP7 (Holowaty et 
al., 2003).   
  
Lee et al, (2011) have shown that vIRF4 can bind to USP7. This interaction is 
believed to be important in the MDM2 and p53 signalling cascade, as expression  
of USP7 regulates levels of MDM2 and p53 and expression of vIRF4 decreases 
levels of p53 (see introduction section 1.5.4). There have been no reports of any 
interaction between vIRF2 and USP7.  
 
Yu and Hayward, (2010) have shown that USP7 may be involved in inhibiting type 
I IFN production. USP7 stabilises the RTA-Associated Ubiquitin Ligase (RAUL) 
protein, which is a negative regulator of the IFN production pathway. This 
stabilisation leads to increased IRF7 and IRF3 degradation, in turn suppressing 
type I IFN production. They also showed that the KSHV lytic switch protein, RTA, 
enhanced this mechanism to inhibit the antiviral response.  
 




In the present study, it was hypothesised that vIRF2 or vIRF4 may be using the 
de-ubiquitination activity of USP7 to inhibit the JAK-STAT signalling pathway in 
some manner. Hence, it was decided that the binding of vIRF2 and vIRF4 to USP7 
should be confirmed by other methods, and if proven correct, studies should 
investigate USP7 in the context of IFN signalling.  
 
6.6.3. Ribosomal proteins 
23/56 of the proteins identified as binding to vIRF2, and 12/23 of the proteins 
identified as binding to vIRF4 were ribosomal proteins, based on the less stringent 
approach (Table 6.1 and Table 6.2 respectively). One hypothesis to explain the 
number of these putatively interacting ribosomal proteins is that it reflected their 
abundance in cells, i.e. ribosomal proteins may be so abundant that they can 
contaminate even SILAC based assays. To investigate if their abundance could 
be leading to contamination of SILAC, the data in Table 6.1 and Table 6.2 was 
compared with the ‘PaxDb: Protein Abundance Across Organisms’ (see http://pax-
db.org/#!species/9606). This database ranks proteins based on their abundance in 
different species. At the time of analysis, the 8 most abundant proteins in human 
cells were APOA2, RBP4, APOC2, TTR, ALB, APOA1, ORM1 and TMSB4X in 
order of abundance. None of these proteins were found to be possible interaction 
partners with vIRF2 or vIRF4. CBP, which was found to bind to vIRF2 and vIRF4 
in both the less and more stringent approaches ranked 17371 out of 19860 
proteins. Therefore, there is no correlation between the abundance of a protein in 
a cell and its association with the vIRF2 and vIRF4 proteins. Hence, these 
ribosomal proteins were considered for further investigation 




The ribosomal proteins which were common between vIRF2 and vIRF4 were 40S 
ribosomal protein S6, 60S acidic ribosomal protein P2, 40S ribosomal protein S3, 
40S ribosomal protein S18, 40S ribosomal protein S19, 40S ribosomal protein 
S14, 40S ribosomal protein S13 (Table 6.1 and Table 6.2). It could be 
hypothesised that at least some of these ribosomal proteins are necessary for 
directing the expression of IFN-responsive genes. The idea that the ribosomal 
proteins provide regulatory transcript-specific translational control is not 
unprecedented. Kondrashov et al, (2011) have shown that the RPL38 ribosomal 
protein is involved in transcript-specific translational control, and suggest a role for 
ribosomal proteins in control of gene expression. Perhaps one of the ribosomal 
proteins identified in this chapter may select for translation of interferon-inducible 
proteins. Due to time constraints, not all ribosomal proteins could be examined 
individually, so it was necessary to pick two, to study in further detail. They were 
the 40S ribosomal protein S3 and the 40S ribosomal protein S6. These proteins 
are discussed briefly below including the justification for their choice in further 
studies.  
 
6.6.3.1. 40S ribosomal protein S3  
Ribosomal protein S3 (RPS3) is a component of the 40S ribosomal small subunit. 
This protein was investigated further because it was found to bind to heat shock 
protein 90 (HSP90). This interaction prevented the ubiquitination and degradation 
of RPS3, thereby retaining the integrity of the ribosome (Kim et al., 2006). The 
mass spectrometry results in this chapter found that vIRF4 also associated with 
HSP90 (Table 6.2 and Table 6.4). Therefore, the hypothesis that vIRF4 interacts 




with RPS3 and HSP90 in order to regulate the stability of RPS3 and control 
translation was proposed. 
 
6.6.3.2. 40S ribosomal protein S6  
Ribosomal protein S6 (RPS6) is a component of the 40S ribosomal subunit. 
Interestingly, there is evidence suggesting that this protein is involved in regulating 
translation of ISGs. As well as the JAK-STAT signalling pathway, several other 
pathways are also activated by type I IFNs. These pathways have roles in 
transcription and translation of ISGs (reviewed in Platanias et al 2005). The PI3-
kinase pathway is activated by type I IFNs, and results in activation of the target of 
rapamycin (mTOR)/ S6 kinase (S6K) pathway, causing phosphorylation of RPS6, 
which can then induce protein synthesis (Lekmine  et al 2003, Kaur et al 2008, 
Kaur et al 2012). Due to the link with ISG translation, RPS6 was chosen as the 
second ribosomal protein to investigate further.  
 
6.6.4. ISGF3 components 
No ISGF3 components were identified as being binding partners of vIRF2 or 
vIRF4. This finding may represent a real lack of binding, or the interactions may 
not have been strong enough to be detected by the methods used here.  
 
6.6.5. Summary 
This chapter has described how immunoprecipitation experiments were performed 
on SILAC labelled stable cell lines. The immunoprecipitates were analysed by 




mass spectrometry, and the interactomes of vIRF2 and vIRF4 were identified by 
both less stringent and very stringent analyses. Based on these results, five 
proteins were chosen for further study in the context of IFN signalling. The next 
chapter will confirm the interactions of these proteins with the vIRF2 and vIRF4 
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7.1. Introduction 
Chapter 6 identified a number of possible binding partners for vIRF2 and vIRF4. It 
was decided that the binding of five of these proteins could be significant 
interactions in the context of IFN signalling (see chapter 6 discussions) and should 
be validated. If confirmed, these interactions could then be analysed more 
specifically relating them to IFN signalling.  
 
The aims of this chapter are to: 
1) Identify if either the vIRF2 or vIRF4 proteins can interact with RPS3, RPS6, 
USP7, p300 or CBP. 
2) Examine whether validated interactions are associated with the vIRF2- or 
vIRF4-mediated down-regulation of JAK-STAT signalling.   
 
To verify the interaction partners of vIRF2 or vIRF4, identified by SILAC-MS, co-
immunoprecipitation studies were performed on cells which were transfected to 
express either vIRF2 or vIRF4 transiently. Instead of using the pCDNA4TO-NTAP, 
pvIRF2-NTAP and pvIRF4-NTAP vectors to transfect cells, alternative expression 
vectors were used, so that the NTAP-tag, expressed from pCDNA4TO-NTAP-
based vectors, would not interfere with the identification of specific proteins in the 
immunoprecipitates. vIRF2 was already cloned and expressed from the pvIRF2-
His/Max vector (Areste et al., 2009). Therefore vIRF4 was cloned into the  
pcDNA4His/Max backbone, to produce the pvIRF4-His/Max expression vector. 
Both vIRF2-His/Max and pvIRF4-His/Max express the viral proteins with 
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contiguous Xpress and Histidine (His) epitope tags, and can therefore be 
immunoprecipitated/identified through use of the anti-Xpress or anti-His 
antibodies. This approach would express the vIRF2 and vIRF4 proteins with 
Xpress and His tags, meaning that they are different forms of the viral proteins to 
those expressed from the pvIRF2-NTAP and pvIRF4-NTAP vectors used in the 
mass spectrometry studies. Therefore this provides additional validation in the 
accurate identification of cellular partners.  
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7.2. Cloning vIRF4 into the pcDNA4/HisMax vector 
vIRF2 had been previously cloned into the pcDNA4/HisMax vector, to produce 
vIRF2-His/Max, and chapters 3 and 4 have shown that the vIRF2 protein 
expressed from this plasmid functions the same as the vIRF2-NTAP protein in 
ISRE-luciferase assays. The vIRF2-His/Max vector has been used many times in 
experiments in our laboratory (Areste et al., 2009, Fuld et al., 2006) and is known 
to work well in both immunoprecipitation and immunofluorescence experiments. 
Therefore, it was decided that the vIRF4 gene should also be cloned in to the 
pcDNA4/HisMax vector.   
 
An overview of the cloning scheme is illustrated in Figure 7.1. The pCR-Blunt-
vIRF4 vector (described in section 3.3) was used as the amplification template for 
the vIRF4 gene. Specific PCR primers (Table 2.14 ‘vIRF4 Forward HisMaxA-
BamHI’ and ‘vIRF4 Reverse HisMaxA’) containing the appropriate restriction site 
(BamHI) amplified the vIRF4 gene from the pCR-Blunt-vIRF4 template (Figure 
7.1A) and the product was ligated into pCR-Blunt (Figure 7.1B). The resultant 
pCR-Blunt-vIRF4(BamHI) (Figure 7.1C) was confirmed by restriction digestion. 
The vIRF4 gene was excised, via enzymatic digestion from pCR-Blunt-
vIRF4(BamHI) with BamHI first, and then digested with EcoRI (this restriction site 
is found in the pCR-Blunt vector) (Figure 7.1D). The resultant fragment was ligated 
into the pcDNA4/HisMax vector which had been digested with BamHI and EcoRI 
(Figure 7.1E). The resultant pvIRF4-HisMax construct was confirmed by 
sequencing. The expression of vIRF4 from this plasmid, transiently transfected 
into 293 cells, was confirmed by western blot (data not shown), and vIRF4 was 
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shown to inhibit rIFNα stimulated ISRE-containing promoter activation, through 
DLAs (data not shown). 
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Figure 7.1: Cloning the vIRF4 gene into the pcDNA4/HisMax vector. 
(A) vIRF4 was amplified from pCR-Blunt-vIRF4 with primers (see Table 2.14) and 
cloned into pCR-Blunt (B), to produce pCR-blunt-vIRF4(BamHI) (C) The vIRF4 
fragment was then excised from the pCR-Blunt-vIRF4(BamHI) vector using BamHI 
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7.2.1. Ribosomal proteins 
41% of proteins identified as binding to vIRF2 and 52% for vIRF4 were ribosomal 
proteins (Table 6.1 and Table 6.2 respectively). It was therefore decided that 
ribosomal interactions with the vIRF2 or vIRF4 proteins should be confirmed. 
Sections 6.6.3.1 and 6.6.3.2 explain why interactions with two of the ribosomal 
proteins (RPS3 and RPS6) were selected to be investigated first. 
 
7.2.1.1. RPS3 immunoprecipitation 
293 cells transfected with the pcDNA4/HisMax, pvIRF2-HisMax or pvIRF4-HisMax 
vectors, were lysed and immunoprecipitation was performed using the anti-Xpress 
antibody. This antibody binds to the Xpress-epitope tag, encoded by pvIRF2-
HisMax and pvIRF4-HisMax vectors. To determine if RPS3 was binding to vIRF2 
or vIRF4 the immunoprecipitate was analysed by western blot using the anti-RPS3 
antibody. Figure 7.2A shows that RPS3 was detected in the input lysates (Figure 
7.2A input row) and the positive control (Figure 7.2A lane 9) but RPS3 was not 
detected in the output immunoprecipitates from vIRF2 or vIRF4 transfected cells 
(Figure 7.2A lane 3-6, in the RPS3 output row). Therefore, RPS3 did not 
immunoprecipitate with vIRF2 or vIRF4. 
 
7.2.1.2. RPS6 immunoprecipitation 
Immunoprecipitation was performed as in section 7.2.1.1 however, the 
immunoprecipitates were analysed by western blot using the anti-RPS6 antibody. 
Figure 7.2B shows the results of this experiment. As for RPS3, RPS6 did not 
associate with either vIRF2 or vIRF4 as there are no RPS6 positive bands in the 
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immunoprecipitate samples containing either vIRF2 or vIRF4 (Figure 7.2B lane 3-
6, in the RPS6 output row).  
 
 
Figure 7.2: vIRF2 and vIRF4 do not associate with either RPS3 or RPS6.  
Co-immunoprecipitation studies were performed with lysates of 293 cells that had 
been transiently transfected with the pcDNA4/HisMax, pvIRF2-HisMax or pvIRF4-
HisMax expression plasmids (1000ng) and treated with or without rIFN 
(300IU/ml). vIRF2 or vIRF4 were immunoprecipitate with anti-Xpress monoclonal 
antibody (IP: xpress) or the mouse IgG isotype control (IP:IC) (see section 2.4 for 
details). The isotype control antibody controlled for non specific binding to regions 
of the antibody. Immunoprecipitates were analysed by western blotting. The anti-
His antibody detected the vIRF2 and vIRF4 proteins expressed from the pvIRF2-
HisMax or pvIRF4-HisMax vectors respectively. The anti-RPS3 (A) or anti-RPS6 
(B) antibodies were used to detect the respective ribosomal proteins. As a positive 
control for these proteins, 293 cell lysates were run in parallel (+ve control). The 
inputs to the immunoprecipitation were analysed by western blot using the RPS3 
(A) or RPS6 (B) antibodies to show that RPS3 or RPS6 were present. These 
experiments were repeated, and the results are shown in Figure 9.25 
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7.2.1.3. Polysome profiling 
The results described in sections 7.2.1.1 and 7.2.1.2 show that based on 
immunoprecipitation experiments, in contrast to the SILAC-MS experiments, RPS3 
and RPS6 were not found to associate with vIRF2 or vIRF4. However, many 
ribosomal proteins were identified as potential binding partners in chapter 6. The 
RPS3 and RPS6 proteins were chosen because of reasons outlined in sections 
6.6.3.1 and 6.6.3.2. One feature of using immunoprecipitation and SILAC mass 
spectrometry to characterize the interactome of protein, is that as well as direct 
interactions, this approach enables the identification of entire complexes which 
may be interacting with the target protein. Because so many ribosomal proteins 
were identified in chapter 6, it was unlikely that vIRF2 or vIRF4 were binding 
directly with all of these. One explanation for identifying so many ribosomal 
proteins is that the viral proteins were interacting with a specific ribosomal 
protein(s) which recruited the rest of the complex. Therefore, polysome profiling 
experiments were performed to investigate if vIRF2 or vIRF4 interact with any 
ribosomal proteins at all.  
 
These polysome profiling experiments were designed to investigate whether either 
vIRF2 or vIRF4 can associate with ribosomal subunits, either actively translating 
(polysomes) or not (monosomes), and were performed by Dr. Nicolas Locker.  
Monosome and polysome fractions can be resolved by layering cytoplasmic 
extracts, from the stable cell lines, onto sucrose gradients and performing 
analytical sedimentation. The polysomes are multiple translation-competent 80S 
ribosome complexes translating a single mRNA (Masek et al., 2011). As these 
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form heavier complexes, they are found in the more dense fractions (fractions 6-
10). Conversely, single ribosomal subunits that are not translation-competent are 
found in the less dense fractions (fractions 2/3 for the 40S subunit, fractions 4/5 for 
the 60S subunit and 80S complexes) (Masek et al., 2011).  
 
Cytoplasmic extracts from the stable cell lines treated with rIFNα were separated 
on a sucrose gradient allowing the separation of the heavy actively translating 
mRNAs which contain the polysomes, from the light monosomal mRNAs that are 
inactive. If either vIRF2 or vIRF4 associate with ribosomes, they should also be 
eluted in these fractions. Each fraction was analysed by western blot for the 
presence of vIRF2-NTAP or vIRF4-NTAP and also for the ribosomal protein L5 as 
a positive control. The results show that EV-NTAP, vIRF2-NTAP and vIRF4-NTAP 
were found mainly in fractions 1-2 (Figure 7.3 A, B and C, lanes 1 and 2), which 
suggests that vIRF2 and vIRF4 are not associating with ribosomes. In the case of 
vIRF2, there are small amounts found in fractions 3, 4 and perhaps 5 (Figure 7.3B, 
lanes 3-5), however, in the EV control samples, trace amounts of the NTAP 
protein are also found in fractions 3 and 4 (Figure 7.3A, lanes 3-5). These data 
suggest that the presence of these NTAP proteins is simply due to bleed through 
due to their high levels of expression in the cell lines. The results confirm the 
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Figure 7.3: The polysome profiles of the stable cell lines suggest there is no 
interaction between either vIRF2 or vIRF4 and ribosomes.  
The EV-NTAP, vIRF2-NTAP and vIRF4-NTAP cell lines were treated with 
tetracycline (0.125μg/ml) for 24 h and then with 300IU/ml rIFNα for a further 24 
hours. Cytoplasmic extracts were collected and polysome profiling was performed 
(as described in methods section 2.12). The results show the polysome trace for 
each cell line (upper panel of each figure). The fractions collected were analysed 
by western blot for the NTAP-tagged proteins (using anti-mouse HRP secondary 
antibody) and for the L5 ribosomal protein (lower panel of each figure). These data 
were provided by Dr Nicolas Locker (University of Surrey).  
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7.3. USP7 immunoprecipitation 
USP7 was predicted as a binding partner for both vIRF2 and vIRF4 in chapter 6. 
Other groups have shown that vIRF4 can associate with USP7 (Lee et al 2011). 
There has been no published link between vIRF2 and USP7. Immunoprecipitation 
experiments were performed to validate the interactions of either vIRF2 or vIRF4 
with USP7. Immunoprecipitation was performed as in section 7.2.1.1, with the 
immunoprecipitates being analysed by western blot with the anti-USP7 antibody. 
Figure 7.4 shows the result of this experiment. USP7 was detected in the 
immunoprecipitates from pvIRF2-HisMax and pvIRF4-HisMax transfected cells, 
both with and without rIFNα treatment (Figure 7.4, lanes 3-6, see USP7 output 




Figure 7.4: vIRF2 and vIRF4 associate with USP7.  
Co-immunoprecipitation studies were performed as described in Figure 7.2. The 
immunoprecipitates were analysed by western blot using the anti-His antibody to 
detect the vIRF2 and vIRF4 proteins and the anti-USP7 antibody to detect USP7. 
As a positive control for these proteins, 293 cell lysates were run in parallel (+ve 
control). The lysates for the immunoprecipitations were analysed by western blot 
to show that USP7 was present. This experiment was repeated and the results are 
shown in Figure 9.26.  
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7.4. USP7 inhibitor studies 
Since vIRF2 and vIRF4 bind to USP7, it was hypothesised that USP7 may have a 
role in IFN signalling. Due to time constraints, this possibility could not be 
investigated fully, and so one main experiment was performed. The USP7 inhibitor 
P22077 (R&D) inhibits USP7 activity. It was hypothesised that if USP7 had a role 
in IFN signalling, then inhibition of USP7 may augment JAK-STAT signalling. 
Therefore luciferase reporter assays were performed in the presence and absence 
of the USP7 inhibitor to examine its effect on the ISRE-containing reporter activity.  
 
7.4.1. Confirming that the USP7 inhibitor works 
In order to confirm the activity of the USP7 inhibitor, the levels of RAD18 were 
examined. A decrease in USP7 activity leads to a decrease in the levels of RAD18 
(Zlatanaou and Stewart et al, unpublished data). 293 cells were treated with or 
without the USP7 inhibitor over time (0-72 hours) and the levels of RAD18 were 
analysed by western blot. The results show that RAD18 levels decreased after 48 
and 72 hours of USP7 inhibitor treatment (Figure 7.5 compare lane 1 with lanes 3 
and 4). Based on these results, DLAs were performed to examine JAK-STAT 
signalling following USP7 inhibitor treatment for 48 hours. 
 
7.4.2. Examining the effect of inhibition of USP7 on ISRE-containing 
promoter activity 
To investigate the effect of inhibiting USP7 activity on JAK-STAT signalling, ISRE-
reporter assays were performed. 293 cells were co-transfected with the ISRE-
containing promoter and the constitutively expressing Renilla pRLSV40 plasmid. 
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Five hours later the cells were treated with or without P22077. Twenty four hours 
later, the cells were treated with or without rIFNα and DLA were performed a 
further 24 hours later. The results show that following treatment with the USP7 
inhibitor, ISRE-containing promoter activity was reduced by 66% compared to 
those cells not treated with inhibitor (Figure 7.6 compare columns 4 and 2). 
However, this decrease was not found to be statically significant, due to the 
variability of values between experiments (see appendix Figure 9.28). 
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Figure 7.5: RAD18 levels are reduced after 48 hours of treatment with the 
USP7 inhibitorP22077.  
293 cells were treated with P22077 (25µM) for times indicated in the figure. The 
cells were lysed and analysed by western blot using the anti-RAD 18 antibody 
(see Table 9.3). Probing for β-actin confirmed equal loading. This experiment was 
repeated and the results are shown in Figure 9.27 
 
 
Figure 7.6: Investigating the effects of USP7 inhibitor treatment on JAK-
STAT signalling. 
293 cells were transfected with pISRE-luc (250ng) and the pRLSV40 plasmid 
(1ng) 5 hours post transfection, the cells were treated with P22077 (25µM), or 
mock treated, for 24 hours. rIFNα (300U/ml) was then added and cells were left for 
a further 24 hours. Cells were harvested and DLA performed. The pRLSV40 
plasmid was added as an internal control to which firefly luciferase levels were 
normalised. The results are shown as fold increase compared to the 293 cells 
which were un-treated with the USP7 inhibitor and untreated with rIFNα (lane 1). 
The data represent the mean ± the SEM of the four independent experiments 
(shown in Figure 9.28). 
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7.5. p300 immunoprecipitation 
In chapter 6, p300 was identified as a putative binding partner of vIRF2, but not 
vIRF4. vIRF2 has been previously identified as binding p300 (Burysek et al., 
1999b). Because vIRF4 was predicted to bind to CBP, and because of the close 
sequence similarity between p300 and CBP, it was hypothesised that vIRF4 may 
bind to p300, even though the mass spectrometry did not detect this. 
Immunoprecipitation was therefore performed to confirm if the results in chapter 6 
were correct. Immunoprecipitation was performed as in section 7.2.1.1, but the 
immunoprecipitates were analysed by western blot with the anti-p300 antibody. 
The results show that p300 immunoprecipitated with vIRF2 in the presence and 
absence of rIFNα (Figure 7.7 lanes 3 and 4, see output p300), but did not 
immunoprecipitate with vIRF4 (Figure 7.7 lanes 5 and 6, see output p300). These 
findings confirm the predictions made by mass spectrometry.  
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Figure 7.7: vIRF2 but not vIRF4 associates with p300.  
Co-immunoprecipitation studies were performed as described in Figure 7.2. The 
immunoprecipitates were analysed by western blot using the anti-His antibody to 
detect the vIRF2 and vIRF4 proteins and the anti-p300 antibody to detect p300. 
As a positive control for these proteins, 293 cell lysates were run in parallel (+ve 
control). The inputs to the immunoprecipitation were analysed by western blot 
using the p300 antibody to show that p300 was present. This experiment was 
repeated and the results are shown in Figure 9.29 
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7.6. CBP immunoprecipitation 
Chapter 6 identified CBP as a potential binding partner for vIRF2 and vIRF4. Other 
groups have shown this to be true for vIRF2 (Burysek et al., 1999b). There have 
been no reports on the association of vIRF4 with CBP. Therefore, to verify the 
mass spectrometry studies, co-immunoprecipitation experiments were performed 
for CBP and vIRF4. It was not possible to detect endogenous CBP in 293 cells by 
western blotting (data not shown). Therefore, a CBP expression plasmid was 
transfected into 293 cells along with the pcDNA4/HisMax, pvIRF2-His/Max or 
pvIRF4-His/Max vectors and immunoprecipitation was performed as described in 
section 7.2.1.1. The immunoprecipitates were analysed by western blot using the 
anti-CBP antibody. The results show that CBP immunoprecipitated with vIRF2 and 
vIRF4 in the presence or absence of rIFNα (Figure 7.8 lanes 3-6, see output CBP 
row). The same results were observed in each of the three repeat experiments 
(see appendix Figure 9.30). These data confirm the predictions made from the 
mass spectrometry studies.  
 
7.7. CBP immunofluorescence 
Section 7.6 confirmed the mass spectrometry data concerning binding of either 
vIRF2 or vIRF4 to CBP. Next, colocalisation experiments were performed to 
determine if the physical association of the proteins could be visualised by 
immunofluorescence and confocal microscopy.   
 
293 cells were transfected with the pcDNA4/HisMax, pvIRF2-His/Max or pvIRF4-
His/Max vectors and the CBP-GFP vector. Immunofluorescence staining was then 
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performed to identify the vIRF2 and vIRF4 proteins using the anti-Xpress antibody, 
while the GFP-epitope tag expressed contiguously with CBP served to identify this 
protein.  
 
The results show that both vIRF2 and vIRF4 co-localise with CBP (Figure 7.9). In 
pvIRF2-His/Max transfected cells, the vIRF2 protein was found in both a 
cytoplasmic and nuclear location (Figure 7.9, see the ‘Xpress tag column’ of row 
‘pvIRF2-HisMax’). When in the nucleus, vIRF2 co-localised with CBP-GFP (Figure 
7.9, see row ‘pvIRF2-HisMax’). In pvIRF4-HisMax transfected cells, vIRF4 was 
found predominantly in the nucleus, where it also co-localised with the CBP-GFP 
protein (Figure 7.9, see row ‘pvIRF4-HisMax’). The staining for the Xpress-tag was 
shown to be specific, since as expected there is no staining in the 
pcDNA4/HisMax transfected cells, which do not express the tag (Figure 7.9, row 
labelled pcDNA4/HisMax). 
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Figure 7.8: vIRF2 and vIRF4 associate with CBP.  
Co-immunoprecipitation studies were performed as described in Figure 7.2, 
except that the CBP-GFP plasmid (see Table 2.12) was transfected into each 
samples also. The immunoprecipitate extracts were analysed by western blot 
using the anti-His antibody to detect the vIRF2 and vIRF4 proteins and the anti-
CBP antibody to detect CBP. As a positive control for these proteins, 293 cell 
lysates, transfected with CBP-GFP, were run in parallel (+ve control). The inputs 
to the immunoprecipitation were analysed by western blot using the anti-CBP 
antibody to show that CBP was present. This experiment was repeated and the 
results are shown in Figure 9.30. 
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Figure 7.9: Immunofluorescence staining demonstrate that the vIRF2 and 
vIRF4 proteins bind to CBP.  
293 cells were plated on coverslips in 24-well plate and left to adhere 
overnight. They were then co-transfected with the pcDNA4/HisMax, pvIRF2-
HisMax or pvIRF4-HisMax expression plasmids and the CBP-GFP plasmid. 
After 48 hours, cells were fixed in 4% paraformaldehyde and permeabilized 
with ice cold methanol (10 minutes). Staining was achieved using the anti-
Xpress primary antibody and anti mouse (594) secondary antibody (see  
Table 9.4). The CBP protein was expressed contiguous to a GFP-tag, and 
therefore no staining was necessary to visualise this protein. Nuclear staining was 
achieved with Bisbenzamide. Results were visualised by confocal microscopy. As 
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a negative control for the staining of the Xpress-tag, pcDNA4/HisMax transfected 
cells were used. Cells lacking the CBP-GFP plasmid were used as a negative 
control (not shown). The cross over of the GFP fluorescence into the red channel, 
and vice-verse was also assessed to ensure that the staining was not due to 
photo-leaching between channels (data not shown).A, experiment 1. B, 
experiment 2.  
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7.8. Inhibition of de-acetylation does not inhibit the effect of either vIRF2 or 
vIRF4 on JAK-STAT signalling 
An explanation to account for the association of vIRF2 and vIRF4 with CBP was 
that these viral proteins were inhibiting the activity of CBP. CBP has a number of 
domains which perform different functions. As CBP exhibits HAT activity, one 
important function is its ability to acetylate proteins. Therefore, the hypothesis that 
vIRF2 or vIRF4 were inhibiting CBP acetylation, and thereby inhibiting JAK-STAT 
signalling was investigated. Histone de-acetylases (HDAC) de-acetylate 
acetylated lysines and are responsible for reversing the effect of HATs. Sodium 
Butyrate (NaB) is an inhibitor of HDACs, and therefore inhibits the removal of 
acetyl groups from lysine residues, resulting in an increase in acetylated proteins. 
To investigate if an increase in acetylated proteins would inhibit the negative effect 
of vIRF2 or vIRF4 upon JAK-STAT signalling, luciferase reporter assays were 
performed in the presence and absence of NaB. Cells were transfected with the 
ISRE-luc containing promoter and one of the pCDNA4TO-NTAP, pvIRF2-NTAP or 
pvIRF4-NTAP vectors. They were then treated with or without NaB (1mM, or 5mM 
for 24 hours) followed by stimulation with rIFNα (24 hours) and dual luciferase 
measurements were made. The results show that without NaB, vIRF2 inhibited 
ISRE-containing promoter activity by 53% (Figure 7.10 compare columns 1 and 2), 
with 1mM NaB, it caused a 63% inhibition (Figure 7.10 compare columns 4 and 5), 
and with 5mM NaB it led to a 66% reduction (Figure 7.10 compare columns 7 and 
8). Whilst there does seem to be a small increase in the level of inhibition with 
increasing amounts of NaB, it was not significant and therefore it can be 
concluded that NaB does not affect the level of inhibition of ISRE-containing 
promoter activity caused by vIRF2. In the case of vIRF4, the level of inhibition of 
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ISRE-containing promoter activity without NaB was 32% (Figure 7.10 compare 
columns 1 and 3), with 1mM NaB, it caused a 37% inhibition (Figure 7.10 compare 
columns 4 and 6), and with 5mM NaB a 31% reduction was observed (Figure 7.10 
compare lanes 7 and 9). Again, these effects are not statistically different, leading 
to the same conclusion as for vIRF2, therefore it can be concluded that NaB does 
not affect the inhibition of ISRE-containing promoter activity caused by vIRF4.  
 
To confirm that NaB was inhibiting HDAC activity, 293 cells were treated with NaB 
(1mM, or 5mM) or left untreated. These lysates were analysed by western blot for 
acetylated lysines and the results show there is an increase in lysine acetylation 
with 1mM NaB, and a further increase following 5mM NaB treatment (Figure 7.11 
compare lanes 1, 2 and 3). This indicates that NaB is inhibiting HDAC activity, and 
thus increasing the amount of acetylated proteins.  
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Figure 7.10: NaB does not rescue inhibition of ISRE-reporter activity by 
vIRF2 and vIRF4 proteins.   
293 cells were transfected with pISRE-luc (250ng) and the pRLSV40 plasmid 
(1ng) and one of the pCDNA4TO-NTAP, pvIRF2-NTAP or pvIRF4-NTAP vectors. 
5 hours post transfection, the cells were cultures in DMEM complete medium. 24 
hours later, the cells were treated with rIFNα (300U/ml) and with NaB and 
harvested 24 hours later. The pRLSV40 plasmid was added as an internal control 
to which firefly luciferase levels were normalised. For each condition (No NaB, 
1mM NaB and 5mM NaB) the results shown have been normalised to the EV-
NTAP transfected cells in order to identify if the reduction in ISRE-containing 
promoter activity by vIRF2 of vIRF4 changes. The data represent the mean ± the 
SEM of three independent experiments. The level of inhibition caused by either 
vIRF2 or vIRF4 was compared without NaB and with the two concentrations of 
NaB, and the differences were not found to be significantly different. The three 
individual experiments are shown in Figure 9.31.  
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Figure 7.11: Treatment of 293 cells with NaB increases the level of acetylated 
proteins.  
293 cells were treated with NaB (as indicated in figure) for 24 hours. Lysates were 
then analysed by western blot using the anti-acetylated-lysine antibody (see Table 
9.3). Probing for β-actin indicated equal loading.  
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7.9. Discussion 
In chapter 6, the putative interactomes of vIRF2 and vIRF4 were described. Five 
of these proteins were selected for further study in the present chapter (RPS3, 
RPS6, USP7, p300 and CBP). One aim of the present chapter was to 
independently validate the SILAC results, in respect of those five selected cellular 
proteins, by either immunoprecipitation or immunofluorescence assays. If 
interactions were confirmed by these techniques, these proteins were studied 
more closely, with the aim of identifying the significance of any interactions in the 
context of either the vIRF2 or vIRF4 mediated inhibition of JAK-STAT signalling. In 
this discussion, the results for each of the five cellular proteins selected for further 
study in will be considered. 
  
7.9.1. Investigating the interaction of vIRF2 and vIRF4 with ribosomal 
proteins 
As outlined in section 6.6.3, many of the predicted interacting partners for vIRF2 
and vIRF4 were ribosomal proteins, and therefore, they were identified for further 
study. Since investigation of each ribosomal protein identified was not possible in 
the time frame available, two ribosomal proteins were chosen for further study. 
Based on their reported links to type I IFN signalling, these were RPS3 and RPS6 
(see sections 6.6.3.1 and 6.6.3.2 for explanations of why these were chosen).  
 
To validate the SILAC results for these proteins, immunoprecipitation experiments 
were performed on cells transfected with vIRF2 or vIRF4 expression vectors. The 
results show that neither RPS3 nor RPS6 were present in vIRF2 or vIRF4 
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immunoprecipitates, suggesting that RPS3 and RPS6 do not interact with the viral 
proteins (Figure 7.2).  
 
As so many ribosomal proteins were identified as interactome components in 
chapter 6, it was hypothesised that the vIRF2 and vIRF4 proteins were interacting 
with a specific ribosomal protein(s) which then recruited the rest of the ribosomal 
complex. The results in chapter 6 therefore may have revealed both direct and 
indirect interactions. One way in which to distinguish between such interactions 
would be to perform immunoprecipitations under varying salt concentrations. 
Higher salt concentrations result in more stringent conditions, and thus only direct 
interactions would be identified, whereas lower salt concentrations would reveal 
indirect interactions. However, this solution is not practical when so many 
ribosomal proteins need to be assessed. Therefore, polysome profiling 
experiments were performed to validate if vIRF2 or vIRF4 were interacting with 
ribosomes.  
 
The results of the polysome profiling showed that neither vIRF2 nor vIRF4 
associated with ribosomes (Figure 7.3). These results support the 
immunoprecipitation studies performed in this chapter, which did not identify RPS3 
or RPS6 as binding partners for vIRF2 of vIRF4 (Figure 7.2); it does not support 
the SILAC pull down results from chapter 6. Two possible explanations to account 
these conflicting results are discussed below.  
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1) There are no interactions between either vIRF2 and vIRF4 and ribosomal 
proteins: This conclusion supports the results performed in the present chapter, 
but would mean that the SILAC pull down results were incorrect. The SILAC 
predictions for ribosomal proteins were based on these proteins having a ≥ 2 fold 
SILAC ratio in the vIRF2-NTAP or vIRF4-NTAP cells compared to the NTAP 
expressing cells. However, this 2 fold SILAC ratio was generally the case in only 1 
experiment out of the 3 performed (see Table 6.1 and Table 6.2). Therefore, it 
could be proposed that since the predictions were based on just 1 out of 3 
experiments, the SILAC data concerning ribosomal proteins are not very reliable. 
Thus, rather than these cellular proteins being specific partners of the viral 
proteins, they were eluted from the vIRF2 of vIRF4 pull down through non-specific 
interactions. However, it should be noted in this regard that these ribosomal 
proteins are not overly abundant cellular proteins (see section 6.6.3). 
 
2) There are interactions between either vIRF2 and vIRF4 and ribosomal proteins: 
The statement would support the SILAC results but would mean that the results 
obtained in this chapter were incorrect. This conclusion is unlikely to be true, 
because, as discussed above the conclusions made from the SILAC results were 
based on only 1 out of 3 replicates. The immunoprecipitation and western blotting 
for RPS3 and RPS6 were performed twice for each protein (Figure 7.2 and Figure 
9.25), and show the same result. As a further positive control, a protein which 
bound to either RPS3 or RPS6 could be included if this experiment was performed 
again. The polysome profiling was only performed once. Ideally, to ensure the 
validity of these data, the polysome profiling should be repeated, but due to time 
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constraints, and the fact that it was performed by a collaborator, it was not 
possible.  
 
In summary, it seems unlikely that either vIRF2 or vIRF4 bind to or interact with 
ribosomal proteins. This result highlights the need to confirm SILAC pull down 
data by additional methods, to verify the validity of interaction partners. The 
ribosomal proteins were chosen for validation because of the exciting possibilities 
that their binding could lead to new mechanisms of virus control of gene 
expression post-transcriptionally. However since, taken together, the results 
suggest that no interactions are taking place between vIRF2 and vIRF4, ribosomal 
interactions will not be investigated further.  
 
7.9.2. Investigating the interaction of vIRF2 and vIRF4 with USP7 
The mass spectrometry results in chapter 6 predicted that USP7 is an interaction 
partner for both vIRF2 and vIRF4. In the case of vIRF4, this association has been 
described previously (Lee et al., 2011) (see sections 1.5.4 and 6.6.2). Thus these 
findings validate the SILAC pull down results for vIRF4 and USP7. This chapter 
has shown that both vIRF2 and vIRF4 can bind to USP7 (Figure 7.4), and in the 
case of vIRF2 this has not been reported previously. These experiments were 
performed independently a total of three times (see Figure 9.26 for replicates).  
 
Since both vIRF2 and vIRF4 bind to USP7, and because vIRF2 and vIRF4 share 
the function of inhibiting JAK-STAT signalling, it was hypothesised that USP7 
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could have played a role in JAK-STAT signalling. The KSHV-encoded RTA protein 
has been shown to bind to USP7 (Yu and Hayward, 2010), and these authors 
suggested USP7 may be involved in inhibiting type I IFN through its stabilisation of 
RAUL (see section 6.6.2 for more details). These studies concern the effect of 
USP7 on the IFN production pathway, which is an earlier stage in type I IFN 
signalling than the JAK-STAT signalling pathway, the pathway which was the 
focux of this thesis is mainly interested. The effect of USP7 on the JAK-STAT 
signalling pathway therefore remains to be discovered.  
 
ISRE-containing luciferase reporter assays were performed in the presence or 
absence of the USP7 inhibitor, P22077. The data in Figure 7.6 show that 
treatment with P22077 resulted in inhibition of ISRE-containing promoter activity, 
but this reduction was not found to be significant. However, this non-significance is 
thought to be due to variations between replicates. Nevertheless, the suggestion 
of inhibition of JAK-STAT signalling was un-expected, since active USP7 is 
thought to inhibit the IFN production pathway (Yu and Hayward, 2010). The results 
in this chapter show that inhibiting USP7 activity may downregulate the JAK-STAT 
signalling pathway, indicating that USP7 activity regulates type I IFN signalling in 
different ways. The results also suggest that active USP7 may have some role in 
JAK-STAT signalling. Due to time constraints, no further experiments could be 
performed to follow up on this result, but a number of future studies can be 
proposed: 
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1) siRNA knockdown of USP7: This approach would provide an alternative to 
reducing USP7 function, and thereby provide further evidence for the 
conclusion that inhibition of USP7 causes a reduction in JAK-STAT 
signalling.  
 
2) Overexpression of USP7 could be performed to determine if it would lead to 
increased JAK-STAT signalling.  
 
3) If USP7 was confirmed to be important in JAK-STAT signalling, it should be 
identified if vIRF2 or vIRF4 can inhibit USP7 function. Possible mechanisms 
for this include the degradation of USP7, inhibition of its activity or out-
competing other substrates binding to it.  
 
4) USP7 is responsible for the de-ubiquitination of p53 (Li et al., 2002) and of 
MDM2 (Cummins and Vogelstein, 2004). This alters the stability of these 
proteins, which in turn could have numerous downstream effects. It is 
necessary to assess the possibility that the inhibitory effect on JAK-STAT 
signalling, with P22077, is due to changes in either MDM2 or p53 levels, or 
down-stream components. This would identify more specifically where in 
the MDM2/p53 pathway the inhibitory effect on JAK-STAT signalling is 
resulting from. To achieve this, siRNAs could be used to specifically knock 
down MDM2/p53, or an excess of MDM2/p53 could be transfected into 
cells, followed by ISRE-luc based luciferase reporter assays.  
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Overall, the effect of inhibiting USP7 activity on JAK-STAT signalling needs further 
work to explain the molecular mechanism. However, the possibility remains that 
vIRF2 or vIRF4 could be acting through USP7 to modulate JAK-STAT signalling.  
 
7.9.3. CBP and p300 
The CBP and p300 proteins were chosen to be validated as interaction partners of 
vIRF2 and vIRF4, and these results will be discussed in the following sections.  
 
CBP and p300 contain a high level of sequence homology and share a number of 
functional domains. Both the N- and the C-terminal regions of p300/CBP can 
activate transcription, while the central regions have HAT activity. The cystidine-
histidine rich domains (CH1, CH2, CH3), KIX domains, and the SRC1 interaction 
domain (SID) domains are important in mediating protein-protein interactions. The 
bromodomain (BD) is important for recognising acetylated residues (reviewed in 
Chan and La Thangue., (2001)).  These domains and the percentage homology 
between the CBP and p300 proteins are illustrated in Figure 7.12.  
 
Both CBP and p300 are important regulators of RNA pol II mediated transcription. 
They have HAT activity, and acetylate histones H2A, H3B, H3 and H4. This 
activity neutralises positively charged lysine residues, modifying the interactions 
between DNA and histone to enable the DNA to be accessible to activators of 
transcription (reviewed in Kalkhoven (2004)). CBP and p300 can interact with the 
basal transcription complexes (TBP and Transcription factor IIB (TFIIB)) and RNA 
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polymerase II through their activation domains (Figure 7.12) and to other 
transcription factors, through their CH1, CH2, CH3, KIX and SID domains (Figure 
7.12). These interactions stabilise the transcription complex, enabling successful 
gene transcription (reviewed in Kalkhoven (2004)).  
 
7.9.3.1. Investigating the interaction of vIRF2 and vIRF4 with P300 
The results in chapter 6 identified p300 as a predicted binding partner for vIRF2. 
This interaction has been reported in the literature previously (Burysek et al., 
1999b). vIRF4 was not predicted by SILAC-MS pulldown to associate with p300, 
but it was predicted to associate with CBP, which has a high level of homology to 
p300 (Figure 7.12). Therefore, the hypothesis that vIRF4 may also bind to p300 
was investigated. This work was to complement experiments examining the 
association of vIRF4 and CBP, thereby identifying if the interaction of vIRF4 was 
specific to only CBP, or could be extended to p300. The results of 
immunoprecipitation experiments revealed that as expected vIRF2 interacted with 
p300. However, vIRF4 was not found to associate with p300 (Figure 7.7). This 
result confirms the SILAC pull down analysis. It is interesting that vIRF4 does not 
associate with p300, but does associate with CBP, as these proteins have very 
similar functions and are highly homologous. However, one explanation for these 
negative results, is that vIRF4 could be causing degradation of p300, and thus 
even if there was an association between vIRF4 and p300, pull downs and 
immunoprecipitations could not detect p300. To test this theory, levels of p300 
could be quantified, by western blot, in cells expressing vIRF4 and compared to 
those lacking it. Nevertheless, because vIRF4 was not found to associate at all 
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with p300 in the SILAC pull down in chapter 6, or in the immunoprecipitation 
experiments performed in the present chapter, it seems unlikely that vIRF4 
interacts with p300.  
 
 
Figure 7.12: Homologous regions of CBP and p300.  
The regions of homology are indicated and the percentage similarity between CBP 
and p300 within these regions is shown. Figure redrawn, but based on (Giles et 
al., 1998). 
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7.9.4. Investigating the interaction of vIRF2 and vIRF4 with CBP 
CBP was identified as a predicted interaction partner for both vIRF2 and vIRF4 in 
chapter 6. The interaction between vIRF2 and CBP has been previously reported 
in the literature (Burysek et al., 1999b). CBP has also been reported to interact 
with vIRF1, leading to inhibition of the formation of IRF3-CBP-DNA complexes, 
and therefore inhibiting the activation of IFN promoters (Lin et al., 2001). 
Additionally, vIRF3 interacts with CBP, but its role in IFN signalling is unclear 
(Lubyova et al., 2004, Joo et al., 2007). Since vIRF4 was predicted to interact with 
CBP, and because vIRF1, vIRF2 and vIRF3 have all been shown to interact with 
this cellular protein, the interaction of vIRF4 with CBP was validated.  
 
Immunoprecipitation experiments showed that CBP was identified in vIRF4 
immunoprecipitates (Figure 7.8). Since the interaction of vIRF2 with CBP has 
previously been reported (Lin et al., 2001), it provided a positive control for the 
experiment, and as expected, was found to associate with CBP (Figure 7.8). This 
experiment was performed a total of three times, to ensure reliability of the results 
(Figure 9.30).  Additionally, immunofluorescence assays revealed that both vIRF2 
and vIRF4 co-localised with CBP (Figure 7.9). The immunofluorescence 
experiments were important as they showed that vIRF2 and vIRF4 associate with 
CBP in whole cells and that their association in immunoprecipitation experiments 
is not an artefact of mixing of proteins from different cellular compartments during 
cell lysis.  
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Since the association of the vIRF2 and vIRF4 proteins with CBP has been 
confirmed by three different means (SILAC-MS, immunoprecipitation and 
immunofluorescence), these interactions are considered genuine. The effect of 
these associations on JAK-STAT signalling was next investigated. Based on the 
information in the literature, a number of hypotheses were proposed which link the 
vIRF2/vIRF4-CBP interactions with downregulation in JAK-STAT signalling.  
These will be discussed sequentially.  
 
7.9.4.1. vIRF2 or vIRF4 compete with STAT2 to bind CBP, which reduces 
the ability of STAT2 to transactivate ISGs. 
Bhattacharya et al (1996) showed that CBP/p300 interacts with STAT2 through 
the C-terminal 83 amino acids of STAT2 at and the CH1 domain of CBP. This 
domain of STAT2 is vital for transcriptional activation by ISGF3 (Qureshi et al., 
1996). Since STAT2 provides the essential transcriptional activation domain of 
ISGF3 (Bluyssen and Levy, 1997) the STAT2-CBP/p300 interaction is thought to 
be important in the transactivation of ISGs.  The Adenovirus E1A protein, which 
inhibits JAK-STAT signalling and binds to CBP/p300 (Kalvakolanu et al., 1991), 
exerts this inhibition through its association with CBP/p300 by inhibiting STAT2 
transactivation (Bhattacharya et al., 1996). Similarly, Zhang et al., (2008) found 
that the Human T-cell leukaemia virus type 1 (HTLV-1) Tax protein could inhibit 
the transactivation of STAT2 by binding to CBP. The binding of Tax to CBP/p300 
was necessary for its inhibition of JAK-STAT signalling, and increasing amounts of 
Tax decreased the STAT2-p300 interactions. They therefore concluded that Tax 
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inhibits IFNα stimulated JAK-STAT signalling through competing with STAT2 for 
binding to CBP/p300 and inhibiting the transactivation of STAT2.  
 
 
Since there is precedence for the inhibition of JAK-STAT signalling by competing 
with STAT2 to bind CBP, this hypothesis was investigated in the context of vIRF2 
and vIRF4. To assess this theory, ISRE-luciferases assays were performed in the 
presence or absence of excess CBP, and the inhibitory effect of vIRF2 and vIRF4 
on JAK-STAT signalling was measured. However, the results of these 
experiments proved inconclusive. The experiments performed lacked a negative 
control plasmid for the CBP-GFP, and thus no real conclusions could be drawn 
from the results. No further experiments could be performed due to time 
constraints. Additional experiments to assess the importance of CBP in the 
inhibition of JAK-STAT signalling by vIRF2 or vIRF4 or to investigate the theory 
that vIRF2 or vIRF4 disrupts CBP-STAT2 interactions are discussed below. 
 
1) Appropriate negative control plasmids for CBP should be obtained, and the 
luciferase experiments described above would be performed to generate 
consistent data. 
 
2) The effect of excess CBP on ISG mRNA could be analysed in the presence of 
either vIRF2 or vIRF4. If excess CBP increased the levels of ISG mRNA, it 
would suggest that the interaction between the viral proteins and CBP is 
necessary for inhibition of ISG transcription. 
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3) Identify if binding to CBP is necessary for inhibition of JAK-STAT signalling. 
The region of vIRF2, and if possible vIRF4 which binds to CBP should be 
identified. The vIRF2 truncated mutants (described in chapter 3, section 3.8) 
could be used in immunoprecipitation experiments to identify which regions of 
vIRF2 can bind to CBP. Fragments of vIRF4 could be produced and the same 
experiments performed. These results could then be related back to ISRE-
luciferase assays involving the mutants (Figure 3.14 in the case of vIRF2, not 
performed for vIRF4). If there was a correlation between ability to bind CBP 
and ability to inhibit ISRE-containing promoter activation, then the importance 
of the interaction of these viral proteins with CBP could be appreciated. Note: 
since vIRF4 does not bind to p300, but does bind to CBP, it is hypothesised 
that vIRF4 is binds to CBP at a region which is not found in p300. 
 
4) Identify if the presence of vIRF2 or vIRF4 reduces the binding of STAT2 to 
CBP/p300. Lysates from vIRF2 or vIRF4 expressing cells could be 
immunoprecipitated with CBP and the amount of STAT2 pulled down with 
CBP could be quantified. If reduced in the presence of vIRF2 or vIRF4, then 
this finding will suggest that interaction of the viral proteins with CBP reduces 
the CBP/p300-STAT2 complex formation, and may explain a mechanism of 
action. 
 
5) Identify the region of CBP which binds to vIRF2 and vIRF4. CBP truncated 
mutants could be used to identify the region which is binding to vIRF2 and 
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vIRF4, to provide information on how this interaction may lead to a reduction 
on IFN signalling. For example, if either vIRF2 or vIRF4 bound to the CH1 
domain of CBP, it could be proposed that the viral protein inhibits the 
interaction of CBP with STAT2, since STAT2 also bind CBP at the CH1 
domain. Burysek et al., (1999b) have shown that vIRF2 binds to the C-terminal 
half of CBP/p300, however the specific location within this has not been 
determined.   
 
6) Perform immunofluorescence assays to identify if the presence of vIRF2 or 
vIRF4 inhibits binding of CBP to STAT2. 
 
7.9.4.2. vIRF2 or vIRF4 inhibit CBP HAT activity and thus inhibit IFN 
signalling. 
Another possibility for the association of vIRF2 and vIRF4 with CBP is that these 
viral proteins inhibit the acetylating activity of CBP. The role of acetylation in STAT 
signalling has become increasingly appreciated. Tang et al., (2007) showed that 
IFNαR2 recruits CBP, which then acetylates the receptor. This recruits IRF9, 
leading to the formation of the ISGF3 complex. STAT1 and STAT2 are also 
acetylated by CBP, and in the case of IRF9 and STAT2, this acetylation has been 
shown to be critical for activation of ISGs (Tang et al., 2007). Therefore, the 
hypothesis that vIRF2 or vIRF4 were inhibiting CBP acetylation, and thereby 
inhibiting JAK-STAT signalling was investigated. 
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HDACs deacetylate acetylated lysines, conversely, HDAC inhibitors reverse this 
leading to an accumulation of acetylated lysines. In Tang et al., (2007), a HDAC 
inhibitor increased CBP mediated acetylation of IFNαR2. Therefore the effect of 
the HDAC-inhibitor, NaB on the inhibition of JAK-STAT signalling by vIRF2 or 
vIRF4 was assessed. The results showed that NaB could not counteract the 
inhibition of JAK-STAT signalling caused by vIRF2 or vIRF4 (Figure 7.10), 
suggesting that vIRF2 or vIRF4 do not inhibit the acetylation function of CBP. In 
these results, addition of HDAC actually led to a decrease in ISRE activity (Figure 
9.31). This result is not unprecedented, in Nusinzon et al, (2003) it was shown that 
inhibition of HDAC activity decreased the IFNα stimulated innate antiviral 
response. They found that deacetylase activity led to positive transcriptional 
regulation of IFN responsive genes. These results seem to contradict the general 
correlation of HDAC activity with transcriptional repression. Overall, it seems that 
the dynamic relationship between deacetylases and acetylases in JAK-STAT 
signalling is complex and requires more study. 
 
7.9.4.3. vIRF2 or vIRF4 cause a reduction in the levels of CBP, which leads 
to a reduction in ISRE activity 
Sections 7.9.4.1 and 7.9.4.2 have described how CBP is an important component 
of JAK-STAT signalling. Therefore, vIRF2 and vIRF4 could simply be reducing 
levels of CBP to bring about an inhibition of JAK-STAT signalling. To identify if 
vIRF2 or vIRF4 caused a reduction in CBP levels, western blot quantification of 
this cellular protein could be performed. However, as reported in the results 
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section 7.6, endogenous CBP could not be detected in 293 cells. Due to time, 
constraints an alternative solution to this problem was not possible.  
 
7.9.4.4. Summary of CBP investigations 
In summary the results of this chapter have validated the interaction between 
vIRF2 and CBP, and provided the novel finding that vIRF4 also associates with 
CBP. This means that all the KSHV-encoded vIRF proteins associate to CBP, 
suggesting that the interactions between the viral proteins and CBP are of 
functional importance.  Indeed, in the case of vIRF1, this interaction has been 
shown to be in part responsible for the inhibition of the IFN production pathway 
(Lin et al., 2001). The future experiments detailed in this discussion provide ways 
in which to determine the importance of CBP interactions with either the vIRF2 or 
vIRF4 proteins in the context of JAK-STAT signalling.  
 
7.9.5. Summary of chapter 
Overall this chapter has shown that interactions between either vIRF2 or vIRF4 
and ribosomal proteins are unlikely. However, this chapter has also validated the 
interactions between USP7 and vIRF2 or vIRF4. This result led to the discovery 
that a USP7 inhibitor reduces JAK-STAT signalling. Finally, the interactions 
between either vIRF2 or vIRF4 and CBP have been confirmed and experiments to 
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8.1. Summary of findings in relation to previous studies  
The broad aims of this thesis were to identify if and how the vIRF2 and vIRF4 
proteins mediate type I IFN signalling. Studies in the Blackbourn laboratory have 
shown that vIRF2 downregulates the IFN production pathway and the JAK-STAT 
signalling pathways (Areste et al., 2009, Fuld et al., 2006, Mutocheluh et al., 
2011). However in the case of the JAK-STAT signalling pathway, the molecular 
mechanisms remain unclear.  Prior to this thesis, only one study had examined the 
effect of vIRF4 upon type I IFN signalling. In that study, the authors assessed the 
ability of vIRF4 to inhibit SEV-mediated IFNβ promoter activation, and found no 
effect (Kanno et al., 2006). There have been no reports of the effect of vIRF4 on 
the later JAK-STAT signalling pathway. Hence, one of the aims of this thesis was 
to investigate the effect of vIRF4 on both the IFN production pathway, to verify the 
findings of Kanno et al, (2006) and the JAK-STAT signalling pathway.  
 
Chapter 3 detailed the cloning of the vIRF4 gene into the NTAP expression vector 
and its subsequent expression in 293 cells. This chapter confirmed previous 
observations made by Kanno et al, (2006) that vIRF4 could not downregulate the 
IFN production pathway, and thus it differs from vIRFs 1-3 in this respect. The 
experiments described in this thesis used the synthetic dsRNA, poly(I:C), to 
activate IRF3 signalling while the experiments performed by Kanno et al, (2006) 
used SEV infection to activate IRF3. SEV is an RNA virus, and it will therefore 
trigger RNA sensors to activate IFNβ promoter activity. However, as described in 
section 1.4.5, there exist DNA sensors which can also activate IFNβ promoter 
activity (see Figure 1.6) Since KSHV is a DNA virus, KSHV is likely to encode a 
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protein which inhibits DNA-mediated activation of type I IFN promoters and 
therefore, vIRF4 may only inhibit DNA-mediated IFNβ promoter activation. The 
synthetic DNA, Poly(dA:dT) could be used to activate DNA sensors as it is 
recognised by DAI and RNA polymerase III (Takaoka et al., 2007, Ablasser et al., 
2009, Chiu et al., 2009). Such experiments would reveal if vIRF4 can specifically 
downregulate DNA sensing pathways. It must be noted that even though KSHV is 
a DNA virus, it will most likely also result in the presence of dsRNA, and (Weber et 
al., 2006) have shown that DNA virus infection leads to dsRNA production. 
Nevertheless, this thesis clearly shows that vIRF4 has no effect on the RNA-
mediated activation of the IFN production pathway.  
 
Importantly, chapter 3 also demonstrated that vIRF4 could inhibit the IFNα-
mediated activation of ISRE-containing promoters. This is a novel result and it 
shows for the first time that like the other vIRFs, vIRF4 is able to downregulate the 
innate immune system.   
 
The effect of vIRF4 upon JAK-STAT signalling was investigated in more detail and 
in chapter 4, inducible, stable cell lines expressing either the vIRF2 or vIRF4 
proteins were produced.  These cells lines were characterised, in order to ensure 
that they expressed vIRF2 or vIRF4 and were tested for their ability to modulate 
type I IFN signalling. As expected, cells expressing vIRF2 could downregulate the 
IFN production pathway, whereas those expressing vIRF4 could not. Both vIRF2 
and vIRF4 could inhibit JAK-STAT signalling, confirming the results in chapter 3.  
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Chapter 5 utilised these stable cell lines to begin to examine mechanistically the 
function of vIRF2 and vIRF4. As a biological read-out, the ability of either vIRF2 or 
vIRF4 to rescue the titre of the IFN-sensitive EMCV virus was assessed. In line 
with previous reports from our group (Mutocheluh et al., 2011), vIRF2 could 
rescue EMCV titre following IFN treatment, indicating a biologically relevant effect 
of this KSHV protein on IFN signalling. In the case of vIRF4, no rescue of EMCV 
titre was observed. Section 5.6 provides suggestions and speculation as to why 
this could be the case. However, this result suggests that the vIRF4 protein, 
expressed in vIRF4-NTAP cells, is not having as potent an effect on IFN signalling 
as vIRF2. These results suggest that vIRF2 and vIRF4 have different mechanisms 
of action.   
 
EMSA experiments, examining the effect of the viral proteins on ISGF3:ISRE 
binding revealed that both vIRF2 and vIRF4 could significantly inhibit the formation 
of this complex. This result is novel, and shows that the viral proteins are 
specifically inhibiting the binding of the ISGF3 complex to ISREs. It suggests that 
the point in the pathway at which the viral proteins are operating is prior to ISGF3 
binding to the ISRE sequence. This result provides conformation for the reporter 
genes assays showing the inhibitory effect of vIRF2 or vIRF4 on JAK-STAT 
signalling. 
 
Since experiments performed in our laboratory showed that vIRF2 could reduce 
levels of pSTAT1 (Mutocheluh et al., 2011) we sought to verify this finding, while 
at the same time assessing vIRF4 for its ability to alter levels of ISGF3 
CHAPTER 8                                                         Discussion 
 
~ 256 ~ 
 
components. Western blot analysis revealed that as expected vIRF2 decreases 
levels of pSTAT1. However expression of vIRF4 did not affect levels of any of the 
ISGF3 components. This finding suggests that vIRF4 exhibits its anti-IFN by 
activities other than modulating levels of the ISGF3 components.  
 
In chapter 6, the vIRF2 and vIRF4 interactomes were identified using SILAC-MS. 
In the case of vIRF2, it was hypothesised that this approach might identify whether 
vIRF2 interacts with ISGF3 components directly, thereby accounting for the 
reduction of pSTAT1 levels. Additionally, the SILAC-MS approach was hypothesis 
to reveal a possible further mechanism of vIRF2-mediated JAK-STAT inhibition. 
For vIRF4, this approach was undertaken to identify any cellular partners which 
might explain the inhibition of JAK-STAT signalling.  
 
Based on these results, five possible binding partners which were common to both 
vIRF2 and vIRF4 were selected for validation and further study. These proteins 
were RPS3, RPS6, USP7, p300 and CBP. Chapter 7 provided validation of these 
interactions, and showed that RPS3 and RPS6 did not interact with either of the 
viral proteins. p300 only interacted with vIRF2 whereas USP7 and CBP interacted 
with both vIRF2 and vIRF4. The interaction between vIRF4 and USP7 has been 
previously reported (Lee et al., 2011), and has been linked to a decrease in levels 
of the tumour suppressor, p53. USP7 can deubiquitinate p53, increasing its 
stability and vIRF4 may inhibit this. Thus the data verify a previously published 
observation, validating the integrity of the SILAC-MS approach.  The association 
between vIRF2 and USP7 is a novel result, and may implicate vIRF2 in the control 
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of p53. Then, like the other KSHV-encoded vIRFs, vIRF2 may have tumourigenic 
properties via its effect on p53 levels. It must be noted that this concept is 
currently speculation, and further experiments are necessary to determine this 
hypothesis.  
 
To assess the possible significance of interactions between either USP7 or CBP 
and vIRF2 or vIRF4, these proteins were taken forward for further study. The 
deubiquitylating USP7 enzyme was hypothesised to have an effect on IFN 
signalling. To examine this theory, the effect of the USP7 inhibitor, P22077, upon 
JAK-STAT signalling was assed in ISRE-containing luciferase assays. The results 
revealed that this inhibitor decreased ISRE-containing promoter activity, 
suggesting that active USP7 has a role in JAK-STAT signalling. As described in 
section 7.9.2, more experiments are necessary to confirm this hypothesis. 
However, if validated it is plausible that either vIRF2 or vIRF4 may have evolved to 
target USP7 in order to downregulate IFN signalling. For example, these viral 
proteins may inhibit USP7 activity, or prevent it binding to substrates.   
 
Due to the validation of interactions between vIRF4 and CBP, it can now be 
concluded that all the KSHV vIRFs bind to this cellular HAT. This is a novel result. 
Because acetylation of JAK-STAT signalling components has proved critical in 
successful activation of ISGs (Tang et al., 2007), it was proposed that vIRF2 or 
vIRF4 may suppress CBP HAT activity in order to inhibit JAK-STAT signalling. To 
examine this possibility, an inhibitor of HDAC activity was used to increase levels 
of acetylated proteins and investigate if this can counteract the inhibitory effect of 
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the viral proteins. This experiment revealed that inhibiting HDAC had no effect on 
the level of inhibition caused by vIRF2 or vIRF4, suggesting that these viral 
proteins do not target the HAT activity of CBP in order to downregulate JAK-STAT 
signalling. Additional work is therefore required to elucidate possible mechanisms 
of vIRF2 and vIRF4 mediated JAK-STAT signalling inhibition via CBP.  
 
Possible ways in which vIRF2 and vIRF4 could target CBP in order to inhibit JAK-
STAT signalling are covered in sections 7.9.4.1, 7.9.4.2 and 7.9.4.3. These 
include either inhibiting the ability of CBP to acetylate STAT2 or IRF9, which is 
necessary for ISG activation (Tang et al., 2007), or reducing levels of CBP in the 
cell. Due to time constraints, these possibilities were not investigated. However, 
suggestions for future experiments have been provided in the discussion to 
chapter 7, sections 7.9.4.1, 7.9.4.2 and 7.9.4.3.  
 
A summary of the conclusions of this thesis are as follows: 
1) The vIRF2 protein inhibits both IFN production and JAK-STAT signalling 
pathways.  
2) The vIRF4 protein inhibits the IFNα-mediated activation of ISRE-containing 
promoters, but does not inhibit poly(I:C)-mediated activation of the IFNβ 
promoter.  
3) Both vIRF2 and vIRF4 decrease the binding of the ISGF3 complex to ISRE 
sequences 
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4) vIRF2 reduces levels of pSTAT1, whereas vIRF4 does not affect levels of 
this or the other ISGF3 components 
5) vIRF2 and vIRF4 associate with USP7, and this interaction may have 
relevance in the inhibition of JAK-STAT signalling caused by these viral 
proteins. 
6) vIRF2 and vIRF4 associate with CBP, and this interaction may have 
relevance in the inhibition of JAK-STAT signalling caused by these viral 
proteins.  
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Figure 8.1: Proposed inhibition of the JAK-STAT signalling pathway by 
vIRF2 and vIRF4. 
Upon activation of the IFN receptors by type I IFNs, a signalling cascade is evoked 
which results in the translocation of the ISGF3 complex into the nucleus. Here, it 
binds to ISRE consensus sequences and activates the transcription of ISGs. This 
thesis confirmed that vIRF2 inhibited levels of pSTAT1, as shown in the figure. 
This thesis has also shown for the first time that vIRF2 and vIRF4 inhibit binding of 
the ISGF3 to ISRE sequences in the nucleus. Other hypothesised mechanisms of 
action involved vIRF2 and vIRF4 binding to CBP to inhibit either the association of 
CBP with ISGF3 components or activation of ISGs. Alternatively, the viral proteins 
could reduce levels of CBP in the cells. USP7 has also been linked to JAK-STAT 
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Throughout this thesis the vIRF proteins were ectopically expressed in cells in 
order to examine their effect on type I IFN signalling. This enabled the specific 
effect of the individual vIRF proteins upon type I IFN signalling to be examined. 
This strategy is common in the study of individual proteins but the limitations for 
drawing conclusions are appreciated. In KSHV infection these viral proteins could 
be working in combination, or their effects could be either amplified or diminished 
due to the effects of other viral proteins. Additionally, since KSHV genes are 
expressed in a temporal manner in lytic infection, these proteins may have varying 
effects at different time points. To assess the inhibitory effect of vIRF2 and vIRF4 
on type I IFN signalling in a more physiologically relevant system, their levels 
could be knocked down in KSHV infected cells.  
 
About a quarter of the KSHV genome encodes proteins with immunomodulatory 
functions or potential. The importance to KSHV of inhibiting ISGF3 and JAK-STAT 
signalling is highlighted by the number of proteins it encodes which suppress this 
pathway (see sections 1.5 and 1.5.5). These proteins act in different manners to 
inhibit the detection of viral components by the cells, and are hypothesised to act 
at different stages during the KSHV lifecycle. Work in this thesis confirmed and 
investigated the vIRF2-mediated inhibition of JAK-STAT signalling. It revealed that 
vIRF2 can inhibit levels of pSTAT1, but does not seem to bind directly either to 
this component, or to any ISGF3 components. How it decreases levels of pSTAT1 
therefore remains to be identified.  
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Importantly, this thesis has identified that the vIRF4 protein can target the JAK-
STAT signalling pathway to inhibit activation of ISRE-containing promoters. The 
vIRF4 protein can therefore be included as an inhibitor of type I IFN signalling. 
vIRF2 and vIRF4 both bind to CBP, as protein which has been implicated in both 
the IFN production pathway and JAK-STAT signalling. It is hypothesised that 
vIRF2 and vIRF4 may exert their anti-IFN effects thought this protein, and further 
experiments are necessary to confirm this. Finally, work for this thesis has 
suggested the possible role of the USP7 protein in regulating JAK-STAT 
signalling, something which is currently un-reported. Again, further work is 
necessary to examine this hypothesis.     
 
vIRFs have only been found in one other virus to date, namely RRV, one of the 
closest relatives to KSHV. RRV encodes 8 vIRFs. In experiments aiming to 
understand the role of these RRV encoded vIRFs, Robinson et al., (2012a) 
produced a recombinant RRV virus which lacked all 8 vIRFs. When used to infect 
a number of cell types in vitro, this vIRF knockout virus resulted in increased levels 
of both type I and type II IFN production compared to that in the WT recombinant 
virus infected cells (Robinson et al., 2012a). This result indicates that the vIRFs in 
RRV are critical to reducing the levels of IFN production in infected cells. 
Additionally, this vIRF knockout virus was also used to infect Rhesus macaques in 
vivo and resulted in decreased viral loads, earlier and more sustained production 
of proinflammatory cytokines as well as an earlier T cell response compared to the 
WT recombinant virus (Robinson et al., 2012b). Again this result highlights the 
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importance of the vIRFs and additionally examines the roles of the RRV encoded 
vIRFs in de novo infection.  
 
The KSHV encoded vIRFs downregulate IFN signalling, as shown both in this 
thesis and throughout the published literature. KSHV encoded vIRFs also share 
some homology to the RRV encoded vIRFs. It can therefore be hypothesised that 
if experiments, such as those in Robinson et al., (2012a) were performed using a 
KSHV-vIRF knockout virus in vitro, an increase in the level of type I IFNs might 
also be observed when compared to a WT recombinant virus. 
 
Although other viruses don’t encoded vIRFs, they can still modulate IFN signalling. 
EBV, the closest human herpesvirus to KSHV does not encode any vIRFs, 
however, it encodes other proteins which downregulate the immune response. An 
example of such proteins are the Latent membrane protein 2A (LMP2A) and 
LMP2B. These proteins promote the turnover of the IFNARs, which causes a 
decrease in JAK-STAT signalling (Shah et al., 2009). Additionally, the EBV-
encoded small nuclear RNAs (EBERs) can limit the effects of type I IFNs. EBERS 
bind to PKR and inhibit its phosphorylation leading to resistance to PKR-mediated 
apoptosis (Nanbo et al., 2002).  
 
As detailed in section 1.4.9, many other viruses also encode proteins which inhibit 
JAK-STAT signalling. Because of the number of different proteins which evade 
this the innate immune response, it is clear that it is important step in viral 
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infection. Studying how viruses, which have evolved with the human immune 
system, act will provide insights into the mechanisms of a particular virus. 
Additionally, it may also lead to a deeper understanding of how the human 
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9.1. Appendix: Supplimentary methods 
 
Table 9.1: Solutions and buffers used for Immunoblotting.  
Italics represent components added fresh to each solution immediately before use. 
Solution Composition 
Sonication buffer 
50mM Tris-HCl (pH 7.3), 9 M urea, and 150mM - 
mercaptoethanol 
Non-ionic detergent Lysis 
buffer 
 
50mM Tris HCI  pH 8.0, 50mM NaCI, 5 mM EDTA, 
1% Triton X-100, 50mM sodium fluoride, 1mM 
sodium orthorvanadate, 0.05% SDS, 10mM Sodium 
pyrophosphate, 1mM PMSF, (used at 1:100 
dilution), Protease Inhibitor cocktail set III 
calbiochem (539134) 
 (used at 1:100 dilution) 
IP lysis buffer 
50mM Tris-HCL (pH 7.5), 125mM NaCl, 5% 
Glycerol, 0.2% NP-40, Protease cocktail inhibitor set 
III calbiochem (539134) (used at 1:100 dilution) 
10x Electrophoresis 
running buffer (1L) 
Tris base (30.24 g), Glycine (142.5 g), 1L distilled 
water (dH2O), pH 8.4 
10x Electrophoresis 
running buffer (1L) 
100ml 10X electrophoresis buffer, 0.1% of 20% 
SDS, 1L dH2O 
10X Transfer buffer (1 L) Tris 30.3g, Glycine 142.5g & 1 L dH2O, pH to 8.4 
1X Transfer buffer (1 L) 
100ml 10X transfer buffer, 20% methanol, 700ml 
dH2O 
4X Tris-SDS-HCI, pH 6.8 0.5M Tris-Cl, 0.4% SDS 
4X Tris-SDS-HCI, pH 8.8 1.5M Tris-Cl, 0.4% SDS 
Tris Buffered Saline (TBS) 
(1 L) 
NaCl 90g, Tris base 60g & 1L dH2O 
TBS-Tween (TBS-T) (1 L) 100ml TBS, 0.05% Tween-20, 900ml dH2O. 
PBS 
10 xPBS tablets (DULBECCO) disolved in 1 L of 
SDW 
PBS-Tween (PBS-T) (1 L) 100ml PBS, 0.05% Tween-20, 900ml dH2O. 
2X Loading sample buffer 
(10ml) 
1M Tris-HCl, pH 6.8, 4ml 10% SDS, 2ml glycerol, 




100mM Tris-HCl pH 6.8, 2% (w/v) SDS, 50mM 2-β-
mercaptoethanol. 
5% Milk blocking buffer in 
TBS-T 
5% (w/v) powdered milk dissolved in TBS-T, stored 
at 4°C. 
5% Milk blocking buffer in 
PBS-T 
5% (w/v) powdered milk dissolved in PBS-T, stored 
at 4°C. 
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Table 9.2: Resolving gels and stacking gels used throughout this study. 
The values shown generate solution to prepare 2 gels.  
Stock solution Supplier 


















SIGMA 6.0 5.0 2.4 1.7 0.63 
4X Tris-SDS-
HCl, pH 6.8 
Lab made 
solution 
- - - - 0.83 
4X Tris-SDS-
HCl, pH 8.8 
Lab made 
solution 








5.25 6.25 5 5.7 3.20 
10% APS SIGMA 0.05 0.05 0.05 0.05 0.025 
TEMED SIGMA 0.01 0.01 0.01 0.01 0.01 
 
Table 9.3: Primary antibodies used for western blotting 
Antibody Dilution Supplier 
TBP 1:2000 Abcam (Ab818) 
PSTAT (Tyr701) 1:1000 Cell Signaling Technology (9167) 
STAT1 1:100 Santa Cruz Biotechnology (sc-346) 
STAT2 (C-20) 1:100 Santa Cruz Biotechnology (sc-476) 
pSTAT2 1:1000 Millipore Catalog  (07-224) 
p48/IRF-9 1:100 Santa Cruz Biotechnology (sc-
10793) 
ORF50/RTA 1:500 From our laboratory 
Β-actin 1:2500 Sigma (A-5441) 
RPS3 1:1000 Cell Signaling Technology (2579) 
RPS6 1:100 Santa Cruz Biotechnology (sc-
74459) 
p300 1:100 Santa Cruz Biotechnology (sc-584) 
CBP 1:100 Santa Cruz Biotechnology (sc-583) 
USP7 1:1000 Bethyl Laboratories (A300-033A) 
Poly Histidine 1:5000 SIGMA (H1029) 
Xpress 1:2000 Invitrogen (R910-25) 
RAD18 1:1000 Abcam (Ab57447) 
Acetylated lysine 1:1000 Cell signaling technology 9441 
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Table 9.4: Secondary antibodies used for western blotting 
Antibody Dilution Supplier 
anti-rabbit IRDye800LT-
conjugated 
1:10,000 LI-COR Biosciences (926-68020) 
anti-mouse IRDye680LT-
conjugated 
1:20,000 LI-COR Biosciences (926-32211) 
anti-mouse HRP-
conjugated 
1:2000 DAKO (P0447) 
anti-rabbit HRP-
conjugated 
1:2000 DAKO (P0448) 
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9.2. Appendix: Repeated experiments 
Many of the experiments shown throughout this thesis have been averaged from 
the results of 3 of more experiments or are representative of more than one 
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Figure 9.1: ISRE-luc expression peaked 16 hours post rIFNα treatment. 
Experiments performed as in Figure 3.6A. The data presents the relative 
luciferase activity (normalised to Renilla levels) of three individual experiments.  
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Figure 9.2: ISRE-luc expression following treatment with 300 IU/ml rIFNα. 
Experiment performed as in Figure 3.6B. The data presents the relative luciferase 
activity (normalised to Renilla levels) of three individual experiments.  
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Figure 9.3: vIRF2 inhibits the poly(I:C) activated IFNβ promoter. Experiment 
performed as in Figure 3.7. The data presents the relative luciferase activity 
(normalised to Renilla levels) of three individual experiments.  
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Figure 9.4: vIRF2 inhibits the rIFNα activated ISRE-containing promoter. 
Experiment performed as in Figure 3.8. The data presents the relative luciferase 
activity (normalised to Renilla levels) of three individual experiments.  
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Figure 9.5: vIRF2 decreases the activity or IRF3. Experiment performed as in 
Figure 3.9. The data presents the relative IRF3-activity (normalised to Renilla 
levels) of three individual experiments.  
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Figure 9.6: vIRF4 does not inhibit poly(I:C)-driven activation of the IFNβ 
promoter. Experiment performed as in Figure 3.10. The data presents the relative 
luciferase activity (normalised to Renilla levels) of three individual experiments.   
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Figure 9.7: vIRF4 inhibits rIFNα-driven expression of pISRE-luc. Experiment 
performed as in Figure 3.11. The data presents the relative luciferase activity  
(normalised to Renilla levels) of three individual experiments  
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Figure 9.8: The effect of the vIRF2 truncated mutants on poly(I:C)-driven 
activation of the IFNβ promoter. Experiment performed as in Figure 3.13. The 
data presents the relative luciferase activity (normalised to Renilla levels) of three 
individual experiments  
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Figure 9.9: The effect of the vIRF2 truncated mutants on rIFNα activation of 
an ISRE-containing promoter. . Experiment performed as in Figure 3.14. The 
data presents the relative luciferase activity (normalised to Renilla levels) of three 
individual experiments.   
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Figure 9.10: vIRF2 expresses in 293 cells transfected with the vIRF2-NTAP 
vector. Replicate experiment performed as in Figure 4.2.  
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Figure 9.11: vIRF2 inhibits poly(I:C)-driven activation of the IFNβ promoter. 
Experiments performed as in Figure 4.3. The data represent the relative luciferase 
activity (normalised to Renilla levels) of three individual experiments each assayed 
in duplicate. The range between duplicates is shown.  
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Figure 9.12: vIRF2, expressed from the pvIRF2-NTAP vector, inhibits rIFNα-
driven expression of pISRE-luc Experiments performed as in Figure 4.4. The 
represent show the relative luciferase activity (normalised to Renilla levels) of 
three individual experiments each assayed in duplicate. The range between 
duplicates is shown.  
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Figure 9.13: 24 hours of tetracycline treatment is necessary for expression 
of the NTAP-tagged proteins. Replicate experiments performed as in Figure 4.6. 
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Figure 9.14: vIRF2 inhibits IFNβ promoter activation, while vIRF4 has no 
effect on IFNβ promoter activation Experiments performed as Figure 4.8. The 
data represent the relative luciferase activity (normalised to Renilla levels) of three 
individual experiments assayed in duplicate. The range between duplicates is 
shown.   
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Figure 9.15: vIRF2 and vIRF4 inhibit ISRE-containing promoter activation 
Experiment performed as in Figure 4.9. The data represent the relative luciferase 
activity (normalised to Renilla levels) of three individual experiments each assayed 
in duplicate. The range between duplicates is shown. 
  
APPENDICES                                                                                                                Repeated experiments                                                     
~ 297 ~ 
 
 
Figure 9.16: qPCR amplification plots for spiked pvIRF2-NTAP or pvIRF4-
NTAP plasmids.  
(A) Known amounts (from 102–106 copies, shown on graph) of the pvIRF2-NTAP 
plasmid were spiked into the PCR assay. The primers (see Table 2.20, vIRF2) 
were used at 3µM and the FAM-labelled probe (see Table 2.19, vIRF2) was used 
at 5µM. Samples were analysed in duplicate. (B) Performed as in A, but with the 
pvIRF4-NTAP plasmid spiked in. vIRF4 primers (see Table 2.20) were used at 
3µM and the FAM-labelled probe (see Table 2.19, vIRF4) was used at 10µM.  
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Figure 9.17: Time course of RTA expression in BCBL1 cells following reactivation. Experiment performed as in Figure 
4.10 
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Figure 9.18: Optimum expression of vIRF2 and vIRF4 mRNA in BCBL1 cells, 
following lytic reactivation of KSHV. Experiment performed as in Figure 4.11. 
The data were normalized to cellular GAPDH levels and results were expressed 
relative to 0 hours (lane 1). The data represent the mean from one representative 
experiment which was assayed in duplicate; the range between duplicate values is 
indicated. 
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Figure 9.19: vIRF2 and vIRF4 inhibit binding of ISGF3 to an ISRE probe. 
Experiments performed as in Figure 5.2. Band intensities were quantified from 3 
ISGF3 EMSA assays. The band intensities (A) are shown from the EMSA assays 
(B). Western blotting for TBP confirmed equal loading (C). 
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Figure 9.20: vIRF2, but not vIRF4 is able to rescue EMCV titre from the 
effects of rIFN. Experiments performed as in Figure 5.1.  
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Figure 9.21: pSTAT1 is reduced in the vIRF2-NTAP cell line compared to the 
EV-NTAP cell line. Experiments performed as in Figure 5.4 
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Figure 9.22: vIRF2 does not effect levels of STAT2 and pSTAT2. Experiments 
performed as in Figure 5.6 
 
 
Figure 9.23: vIRF4 does not effect levels of STAT2 and pSTAT2. Experiments 
performed as in Figure 5.8. 
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Figure 9.24: Pull down samples collected at various stages of the process 
Experiment performed as in Figure 6.2 
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Figure 9.25: vIRF2 and vIRF4 do not associate with RPS3 or RPS6. 
Experiments performed as in Figure 7.2 
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Figure 9.26: vIRF2 and vIRF4 associate with USP7. Experiments performed as 
in Figure 7.4 
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Figure 9.27: RAD18 levels are reduced after 28 hours of treatment with the 




Figure 9.28: Inhibition of USP7 causes an inhibition in JAK-STAT signalling. 
Experiments performed as in Figure 7.6 
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Figure 9.29: vIRF2 but not vIRF4 associates with p300. Experiments performed 
as in Figure 7.7 
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Figure 9.30: vIRF2 and vIRF4 associate with CBP. Experiments performed as in  
Figure 7.8 
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Figure 9.31: NaB does not rescue the inhibition of ISRE-reporter activity by 
the vIRF2 and vIRF4 proteins. Raw data Experiments performed as in Figure 
7.10. The data presents the relative luciferase activity (normalised to Renilla 
levels) of three individual experiments.   
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9.3. Publication arising from this work 
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